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SUMMARY 
 
Cancer is a genetic disease caused by the gradual accumulation of somatic mutations 
in key driver genes. Next generation sequencing (NGS) technologies enable 
comprehensive characterization mutational landscapes of tumor genomes, lead to the 
discovery of cancer drivers and eventually contributing to a better understanding of 
tumorigenesis.  
In this thesis, we have used various NGS technologies to decipher T-cell acute 
lymphoblastic leukemia (T-ALL) genomes. T-ALL is a type of leukemia originating 
from malignant transformation of developing T-cells as a result of chromosomal 
translocations and cooperating point mutations.  
We have identified novel T-ALL drivers using three NGS experiments, namely 
targeted sequencing, exome sequencing and transcriptome sequencing. We assessed 
available tools and methods and constructed bioinformatics pipelines for each 
experiment. We further validated and optimized these pipelines to obtain the most 
accurate and specific predictions sets. We evaluated our findings in the view of 
existing knowledge and put forward novel driver processes and genes taking part in 
T-ALL pathogenesis.  
In our first project we followed a targeted sequencing approach and sequenced 97 
genes across 15 primary samples and 18 T-ALL cell lines. By conducting a 
benchmark study we identified the most optimal bioinformatics pipeline for this 
experimental setup and obtained high quality mutation prediction. We have found 
mutations in the known T-ALL drivers as well as in promising candidates such as 
TET1, JAK3 and sprouty family members SPRY3 and SPRY4.  
In our second project, we have sequenced all coding exons of 67 primary, 39 matched 
remission samples and 17 cell lines. We have implemented somatic mutation calling 
methods and rigorous filtering to characterize the mutational profile of these T-ALL 
exomes. We observed marked differences between the adult and pediatric samples 
both in terms of mutation rate and mutation pattern. Eventually, we identified 15 
driver genes affected by somatic mutations, including 7 novel drivers. From this list, 
we discovered the involvement of the ribosome in tumorigenesis via mutations in 
RPL10 and RPL5, and also identified a novel tumor-suppressor, CNOT3.  
In our third project, we focused on the transcriptome and applied RNA-seq 
technology on 31 primary samples and 18 cell lines. We have assembled, optimized 
and validated bioinformatics pipelines for the measurement of gene expression levels 
and the discovery of mutations, fusion genes and alternative transcript events. This 
approach enabled a complete characterization of the T-ALL transcriptome, revealing 
novel drivers and events including the oncogenic fusions SSBP2-FER and TPM3-
JAK2; an exon skipping event in SUZ12 and mutations in candidate T-ALL drivers 
including STAT5B, PTK2B and H3F3A.  
In this thesis, we discovered novel T-ALL drivers, assessed and implemented state of 
  
the art bioinformatics approaches and demonstrated the power of NGS technologies 
in the context of cancer genomics. Ongoing and future sequencing projects are 
expected to offer further insights into human cancers and eventually lead to 
advancements in personalized cancer treatment.  
  
SAMENVATTING 
 
Kanker is een genetische aandoening veroorzaakt door somatische mutaties die zich 
accumuleren in potentiële oncogenen. Next generation sequencing (NGS) 
technologieën maken het mogelijk om mutationele landschappen binnenin een 
kankergenoom te karakteriseren, om genen met oncogene drijfkracht te ontdekken, 
en om een dieper inzicht te verwerven in het proces van oncogenese.  
In deze thesis hebben we gebruik gemaakt van NGS technologieën om het genoom 
van T-cell acute lymphoblastische leukemie (T-ALL) te ontcijferen. T-ALL is een 
klasse van leukemie die ontstaat door de kwaadaardige transformatie van 
ontwikkelende T-cellen ten gevolge van chromosomale translocaties en punt 
mutaties. Door toepassing van drie specifieke NGS-gebaseerde projecten hebben we 
nieuwe kandidaat kankergenen geïdentificeerd die het proces van T-ALL kunnen 
aandrijven. Hierbij hebben we bioinformatica methodes vergeleken en voor elk van de 
NGS experimenten vervolgens een bioinformatica protocol opgesteld. We hebben 
vervolgens deze protocols gevalideerd en geoptimaliseerd om zo de meest accurate en 
specifieke voorspellingen te bekomen. We hebben onze bevindingen vervolgens 
geëvalueerd in de context van de huidige kennis over T-ALL en schuiven aan de 
hand daarvan nieuwe kandidaat genen en processen naar voor die een oncogeen 
aandrijvend potentieel hebben in de context van T-ALL. 
In het eerste project hebben we een doelgerichte sequencing-aanpak gehanteerd 
waarbij we 97 genen in 15 primaire stalen en 18 T-ALL cel lijnen gesequenced 
hebben. Aan de hand van een referentiestudie hebben we het meest optimale 
bioinformatica protocol opgesteld passende bij deze experimentele opstelling. Dit 
leverde ons mutationele voorspellingen op van hoge kwaliteit zoals mutaties in 
gekende T-ALL oncogenen alsook in veelbelovende nieuwe kandidaat genen zoals 
TET1, JAK3 en de sprouty familie leden SPRY en SPRY4.  
In het tweede project hebben we het ganse coderende genoom, of exoom, 
gesequenced van 67 primaire kankerstalen, 39 overeenkomstige stalen in remissie en 
17 cellijnen. Hierbij hebben we methodes geimplementeerd die in staat zijn om 
mutaties te identificeren gevolgd door een zeer nauwgezette filtering om zo het 
mutationele profiel van de T-ALL exomen te karakteriseren. We hebben opvallende 
verschillen geobserveerd tussen volwassen en pediatrische stalen, zowel op gebied van 
de mutatie snelheid en het mutationele patroon. Finaal hebben we een lijst met 15 
potentiele oncogenen geïdentificeerd met een somatische mutatie, waarvan 7 nieuwe 
kandidaten. Zo hebben we mutaties ontdekt in de genen RPL10 en RPL5, wat wijst 
op een belangrijke rol voor ribosomen in het oncogene proces. Daarnaast hebben we 
ook een nieuwe potentieel tumor-suppressieve functie blootgelegd voor het gen 
CNOT3.  
In het derde project hebben we ons voornamelijk gefocust op het transcriptoom van 
T-ALL. Hiervoor hebben we de RNA-sequencing technologie gebruikt op 31 primaire 
  
stalen en 18 cellijnen. Ook hier hebben we een analytisch protocol opgesteld, 
geoptimaliseerd en gevalideerd op basis van de bioinformatica methodes die nodig 
zijn om genexpressie te meten en om mutaties, fusie-genen en alternatieve 
transcripten aan het licht te brengen. Met deze aanpak waren we in staat om een 
volledige karakterisatie te bekomen van het transcriptoom van T-ALL wat 
uiteindelijk geleid heeft tot de identificatie van nieuwe kandidaat genen met 
oncogene drijfkracht. Daarnaast hebben we ook nieuwe oncogene fusies zoals SSBP2-
FER en TPM3-JAK2, exon-overslaande events in SUZ12 en mutaties in STAT5B, 
PTK2B en H3F3A geïdentificeerd.  
In deze scriptie hebben we nieuwe kandidaat genen ontdekt met het potentieel om 
het oncogene proces in T-ALL in gang te zetten. Daarnaast hebben we een 
grensverleggend bioinformatica protocol opgesteld, beoordeeld en toegepast en 
daarbij de kracht van NGS technologieen in de context van kankergenomica 
aangetoond. Verwacht wordt dat huidige en toekomstige sequencing-projecten ons 
alsnog een diepgaander inzicht zullen geven in het humane kankerproces en een 
immense vooruitgang zullen betekenen in het gevecht tegen kanker.  
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CHAPTER I: INTRODUCTION 
CANCER PROCESSES 
 
Hanahan and Weinberg defined the “hallmarks of cancer” that constitute the 
essential changes in cell physiology necessary for tumor development and growth 1,2. 
These principles are useful for simplifying the dauntingly complex disease of cancer. 
We can evaluate the NGS findings from the viewpoint of this framework and 
understand the contribution of NGS in cancer genomics. In the original paper, the 
authors have defined six hallmarks that are shared essentially by all human cancers: 
“self-sufficiency in growth signals, insensitivity to growth-inhibitory (antigrowth) 
signals, evasion of programmed cell death (apoptosis), limitless replicative potential, 
sustained angiogenesis, and tissue invasion and metastasis” 1. Progress in the cancer 
research field resulted in the addition of two hallmarks in 2011 “reprogramming of 
energy metabolism and evasion of immune destruction” 2. The authors also 
elaborate on “enabling characteristics” that facilitate cancer cells to acquire hallmark 
capabilities, namely genome instability and mutation, and tumor promoting 
inflammation. Collectively these hallmarks dictate tumor formation and 
proliferation.  
Genome instability 
The DNA repair and maintenance mechanism of the cell is almost immaculate and 
allows very low rates of mistakes during each cell division (10-9 for somatic cells 3, 
and 10-11 for stem cells 4), thus tumor cells may need to circumvent these 
mechanisms to obtain favorable genotypes. Although next generation sequencing 
studies revealed that some pediatric cancers and liquid tumors might achieve 
neoplastic transformation with low mutation loads 5, many tumors increase 
mutation capacity to facilitate the acquisition of hallmark capabilities and promote 
tumor growth 6. Increased mutation capacity of the tumors facilitates acquisition of 
the hallmark capabilities and promotes tumor growth. Genomic instability can be 
achieved by several mechanisms such as exposure to mutagens, inactivation of the 
“caretaker” genes 7, which are DNA repair, DNA damage response and mitotic 
checkpoint genes; as well as oncogene induced DNA damage and telomere disruption 
1,2,8,9. NGS studies confirmed the existence of various types of genomic instability 
inherent in cancer genomes, and in some cases elucidated the mechanisms governing 
it.  
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Chromosomal instability (CIN) is the major form of genomic instability in human 
cancers 10,consisting of alterations in chromosome numbers (aneuploidy), 
chromosome translocations, and gene amplifications. One of the contributions of 
NGS technologies in detection of CIN is the high-resolution it provides. We can now 
observe chromosomal alterations that were not detectable with previous methods. 
For instance, NGS analysis revealed a large number of intra-chromosomal 
rearrangements and tandem duplications in breast cancer genomes, which would not 
have been detected with low resolution cytogenic methods 11. Furthermore, a new 
CIN phenomenon termed “chromothripsis” was identified through NGS 12. It 
involves up to thousand chromosomal rearrangements in a single event localized in 
one or few chromosomes, and it is observed in around 3% of cancer genomes across 
all subtypes, with a higher prevalence in bone cancers (25%) 13.  
Moreover, comparative evaluation of CIN trends across cancers is now possible with 
the results of NGS studies spanning many human cancers. In the pre-NGS era, 
epithelial tumors were thought to be more genomically unstable with higher 
proportion of chromosomal rearrangements compared to the hematological and 
mesenchymal cancers 14. Analysis of NGS studies across 18 cancer types confirmed 
this observation 15. It was also revealed that CIN profiles could be shared across 
different cancers and show dramatic changes between individuals of the same cancer 
type. For instance, BRCA-associated breast and ovarian cancers have genomic 
instability due to defects in homology directed repair and have high levels of CIN 
and a similar spectrum of mutations 16, while lung cancer in smokers and never 
smokers display extensive differences in the number of alterations due to mutagens 
in tobacco 17. 
Another form of genomic instability involves alterations spanning single nucleotides 
or short fragments, thus termed “mutational instability” 10. Mutational instability 
can manifest itself with an abnormal rate of somatic mutation. NGS analysis 
revealed that melanoma and lung cancer genomes harbor around 200 non-
synonymous mutations per tumor, 3-fold higher than in solid tumors 5. These 
cancers are associated with ultraviolet light and tobacco exposure, respectively, both 
of which cause DNA damage with different mechanisms 18,19. Germline defects in 
caretaker genes have been associated with hypermutation profile in hereditary 8 and 
sporadic cancers. For instance in colon cancers, the high mutational load is caused 
by alterations in the caretaker genes, including hypermethylation of the MLH1 gene 
and mutations in the components of DNA mismatch repair pathway (MLH1, 
MLH3, MSH2, MSH3, MSH6 and PMS2) together with mutations in POLE 
(proofreading domain of polymerase) 20. These tumors harbor a 7-fold higher 
number of non-synonymous mutations than the mutagen induced lung and 
melanoma tumors 5. Furthermore, localized hypermutation patterns, termed 
“kataegis”, were identified and observed in breast cancer with NGS analysis. This 
phenomenon is attributed to the AID/APOBEC family of proteins, which originally 
function as RNA editing enzymes (C-to-U) with recent findings proposing a DNA 
mutator role 21,22.  
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Tumor promoting inflammation 
The presence of immune cells around tumor tissues has been observed in ranging 
quantities across almost all tumor types 2. Although the presence of these cells 
might indicate the efforts of the immune system to fight with tumors, there is 
growing evidence that the presence of these cells is protumorigenic and contribute to 
the acquisition of the hallmark capabilities by providing bioactive molecules such as 
growth or survival factors 23. Inflammation related programs in the tumor cells are 
predominantly orchestrated by the activated oncogenes NFKB and STAT3 24. In 
this context, activating mutations in NFKB across many cancers 24 and constitutive 
phosphorylation of STAT3 downstream of EGFR mutations in lung cancers 25 can 
exemplify genomic aberrations associated with inflammation. In addition to 
providing a favorable environment for tumor growth, it has been suggested that 
activated inflammatory cells can increase mutation rates of tumor cells either 
through the release of DNA damaging agents such as reactive oxygen species (ROS) 
and reactive nitrogen intermediates (RIN); or by stimulating ROS accumulation in 
the neighboring epithelial cells 26. In fact, mutation rates are found to be 4-fold 
higher in the inflamed microenvironment compared to the normal tissues 27, thus 
linking these two enabling characteristics of cancer together.  
Self-sufficiency in growth signals 
Self-sufficiency in growth signaling was the first hallmark defined by the authors. 
Normal cells are tightly regulated by external signaling mechanisms for proliferation 
and growth. Cancer cells circumvent the necessity of these external signals by 
producing their own growth factors, stimulating nearby cells to supply growth 
factors, increasing the number of receptor proteins in the cell surface to become 
hypersensitive to ambient levels of growth factors, and finally by deregulating 
signaling pathways to be constitutively active without the presence of ligand 2.  
NGS studies provided ample evidence in regards to the deregulation of growth 
signaling pathways. Mutations in the members of the mitogen activated protein 
kinase (MAPK) signaling cascade have been observed in a wide variety of cancer 
types. Oncogenic mutations in the RAS family of genes (HRAS, KRAS, NRAS) are 
observed in 16% of all human cancers, with highly variable frequencies for specific 
cancer types (for instance KRAS mutations are observed in 33% and 61% of large 
intestine and pancreas cancers, respectively, while mutations in NRAS and HRAS 
have prevalence of at most 3% in these cancers) 28. Mutations in the RAF family 
members are mostly observed in BRAF with 20% of cancer samples suffering an 
alteration, while mutations in RAF1 (CRAF) are less common at about 2% across 
cancers. Melanoma genomes harbor BRAF mutations in 45% of the cases mostly 
being in a specific residue V600E 29.  
Another deregulated signaling pathway is the PI3K/PTEN signaling pathway, and 
activation of PI3K via mutations and inactivation of PTEN via mutations or 
methylation are observed frequently in many tumors 30. This pathway is especially 
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the most frequently mutated pathway in breast cancer, with mutations observed in 
more than 70% of the cases 31.  
Insensitivity to antigrowth signals  
Similar to growth factors, extracellular antigrowth factors ensure homeostasis in 
normal cells. Two mechanisms act in a complementary role one governed by the RB 
pathway and the other by the TP53 pathway. RB evaluates the external signals and 
decides whether or not to proceed with the proliferation cycle, whereas TP53 
evaluates internal signals and halts the cell cycle or initiates apoptosis or senescence 
2. Thus, a cancer cell must inactivate these two tumor suppressor mechanisms in 
order to proliferate. As expected, alterations are observed in the members of both 
these pathways with large-scale NGS studies. For instance, RB pathway members 
are altered in 77% of primary glioblastomas tumors, and deletions in the CDKN2A 
and CDKN2B genes are the most frequently observed aberrations with 55% and in 
53%, respectively 32. Another mechanism deregulating RB signaling occurs through 
disrupting TGF-β signaling. In normal cells TGF-β prevents phosphorylation of RB 
thus suppresses cell proliferation, whereas cancer cells may inactivate TGF-β 
signaling through several genomic alterations. The TGF-β signaling pathway is 
known to be mutated in colorectal and pancreatic cancers 33, with mutation 
frequencies of 87%-27% (correlating with the hypermutation status) in colon cancers 
20 and 100% in pancreatic cancers 34. 
TP53 has a lot of critical roles in maintaining a healthy genome, and its inactivation 
is essential for most cancers not only for evading antigrowth signals but also for 
evading apoptosis. The genomic alterations observed in TP53 will be discussed in 
the next section.  
Evasion of apoptosis  
Cellular stresses including genomic instability and cellular hypoxia triggers 
programmed cell death by apoptosis in normal cells. Apoptosis is a defense 
mechanism for the organism to eliminate unhealthy cells from the system. However, 
cancer cells, despite being under cellular stress, evade from apoptosis and continue 
proliferation. Apoptotic pathways mainly have two components: “sensors” of cellular 
stress that receive signals either from extracellular or intracellular environment, and 
“effectors” that execute apoptosis upon receiving the signal from censors 2. Cancer 
cells operate by deactivating these pathways either via over-expressing anti-
apoptotic regulators, or by inactivating pro-apoptotic factors. The most common 
mechanism of apoptosis evasion is the loss of TP53. Somatic TP53 mutations are 
observed in colorectal, head and neck, ovarian and pancreatic cancers at rates from 
35% to 43%, while in leukemias the prevalence of TP53 mutations is around 10%. 
The majority of the somatic TP53 mutations are missense (73%), nonsense (8%) 
and frameshift mutations (9%), mostly clustered in the DNA binding domains 
(Data from IARC TP53 Database 35, R16 November 2012). It is also reported that 
in tumors with low mutation rates, alternative mechanisms take place for 
inactivating TP53, such as degradation of TP53 by viral oncoprotein E in cervical 
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cancers 36, by nuclear exclusion of p53 in inflammatory breast cancer and 
neuroblastomas; and by amplification of YEATS4 and MDM2 genes in sarcomas 37. 
Overall, NGS studies reinforced the role of TP53 as the “guardian of the genome” 38, 
as it is one of the few genes that is altered at high frequencies across different 
cancers as its inactivation is required for the cancer cell to prosper 8. Besides TP53, 
genes involved directly in apoptosis such as CDKN2A, BCL2 and MYC are often 
mutated in cancers 5.  
Limitless replication potential 
Intrinsic mechanisms in normal cells limit the number of times a cell can replicate to 
60-70 divisions, termed the “Hayflick limit” 39. After this limit is reached, the cell 
enters irreversibly to a non-proliferative but viable state called “senescence”. 
Knockdown of p53 and Rb in human fibroblast cells enable cells to replicate until 
they reach a state called “crisis” which is characterized by end to end fusions of 
chromosomes and massive cell death and a very rare occurrence (10-7) of an 
immortalized cell without a replication limit 1. The limiting factor of replication is 
found to be shortening of the telomeres, tandem hexanucleotide repeats located at 
the ends of chromosomes, protecting chromosome ends. These sequence repeats are 
shortened in each cell division, and the normal replication stops when the telomere 
sequences are critically short. In the majority of human cancers (85%) this limitation 
is overcome by expressing telomerase, the enzyme that extends the telomeres 40. 
Alternatively, homologous recombination-mediated replication of telomeric DNA is 
also observed in a minority of cancers and is termed Alternative Lengthening of 
Telomeres (ALT) 41,42. Recently, whole genome sequencing approaches have been 
used for assessing telomeric DNA content across 235 cases of pediatric cancers and 
marked differences in the telomere content were reported between tumor types 43. 
Moreover, telomere gain had a significant association with high frequency of genomic 
rearrangements and somatic non-silent mutations, corroborating earlier remarks of 
telomerase being responsible for genomic integrity.  
Sustained angiogenesis 
Normal cells and cancer cells need to be close to blood vessels for obtaining nutrients 
and oxygen, and exerting metabolic waste and carbon dioxide. Sprouting new blood 
vessels, termed “angiogenesis,” is not an intrinsic mechanism for normal cells and it 
is turned on only transiently in specific physiological processes such as wound 
healing and female reproductive cycling 2. Thus angiogenesis is a hallmark that a 
cancer must achieve in order to grow. Angiogenesis is predominantly governed by 
the protein coded by the gene VEGF. Upregulation of VEGF by mutations in ras 
oncogenes 44 and VHL suppression are known mechanisms 45, and with pan-cancer 
NGS projects we also observe frequent mutations in VEGFR and FGFR family 
members. For instance in lung cancer VEGFR alterations (mutations and copy 
number aberrations) are found in 9% of the cases while FGFR mutations are 
observed in 19% 46.  
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Tissue invasion and metastasis 
Cancer cells from the primary tumor site can invade and form tumors in other 
tissues of the organism in a process called “metastasis”. This mechanism allows 
cancer cells to proliferate in a new environment that have more resources and 
nutrients than the primary site. The metastasis can be broken down into two 
phases: detachment from the primary tumor site and attachment to a new host site.  
Detachment in carcinomas involves the epithelial mesenchymal transition (EMT) 
program, which is observed in numerous processes in normal tissue development 2. 
This process starts with the loss of E-cadherin, a cell-to-cell adhesion molecule, and 
a detached cancer cell, now with mesenchymal properties, may enter the 
bloodstream. EMT is a well-studied developmental program with known 
involvement of several transcription factors. Causal importance of these 
transcription factors are shown in experimental models, although the initiating 
event for EMT in cancer is largely unknown 2.  
Attachment to a new host, or colonization, poses even a bigger enigma than 
detachment, as we still do not know what the genetic makeup allowing colonization 
is; or whether the cells require new genetic alterations to enable it. Multiple 
sequencing studies were performed to analyze the differences and similarities in the 
genetic makeup of primary and metastatic tumor cells in various cancers including 
pancreatic 47,48, breast 49, lung 50, renal 51 and colon 52. For instance in pancreatic 
cancer, 64% of identified somatic mutations were identified as “founder” mutations; 
present in all metastasis sites as well as the primary site while 36% were 
“progressor” mutations, present in one or more metastases but absent in the 
primary site 47. Several genes were identified with recurrent progressor mutations, 
however, the majority of them were altered in the primary site as well. Although 
there are indications for metastasis associated aberrations as exemplified by re-
arrangements and mutations exclusive to the metastatic site in breast 49 and 
pancreatic cancers 53, no consistent genetic alterations were found to cause 
metastasis. Vogelstein et al proposes the possibility of explaining the lack of causal 
genetic alterations for metastasis simply by stochasticity of the cancer genome 
evolution: the bigger and more advanced the tumor, the more probable that a 
cancer cell would find a hospitable environment fitting to its genotype 5. Thus the 
clonal diversity of the tumor enabled by the genomic instability, may allow the 
invading cells to thrive in a new environment.  
Reprogramming energy metabolism  
Cancer cells can change their energy metabolisms from mitochondrial oxidative 
phosphorylation to glycolisation even in the presence of oxygen, thus leading to a 
state called “aeorobic glycolisis”. This process is 18-fold less efficient than oxidative 
phosphorylation however it has the added benefit of biosynthesis of macromolecules 
that is used for formation of new cells; necessary for the actively proliferating cancer 
cells 2.  
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Many of the genes that are altered for enabling the above-mentioned hallmarks also 
take roles in regulating energy metabolism of the cell such as MYC, NFKB, AKT, 
EGFR and TP53 2,54. However, mutations targeting the genes encoding 
mitochondrial enzymes have also been found. Rare mutations in the genes SDHB 
and FH, which encode tricarboxylic acid (TCA) cycle enzymes, have been found in 
familial paraganalioma and papillary renal cell cancer 54. The TCA cycle is used less 
by cancer cells, and the aforementioned mutations force a switch to aerobic glycolisis 
54. More frequently, mutations in IDH1 and IDH2 genes have been reported first in 
gliomas 55 and then in acute myeloid leukemias56 and chondrosarcomas 57. These 
mutations have been selected for altering the energy metabolism, however their roles 
in tumorigenesis remain unclear 58.  
Evading immune destruction 
The immune system defends the organism against a plethora of threats including 
bacteria, viruses, and as recent research indicates, against tumor formation and 
progression 2. Thus overriding the immune system is actually a hallmark achieved by 
every full-blown tumor. In prevention of the cancer, immune system has mainly 
three operational duties: suppression of viral infections (to reduce incidence of 
cancers with viral origin), elimination of pathogens (prevent or shorten the 
inflammation, which benefits tumorigenesis) and immunosurvellience (identification 
and destruction of transformed cells before they establish malignancy) 59. Tumor 
cells evade the immune system either by avoiding recognition or by developing 
mechanisms to escape immune-mediated killing 59. Studies in cell culture and mouse 
models have showed that loss of interferon mediated signaling due to disruptions in 
the JAK-STAT signaling cascade or loss of interferon regulated genes such as MHC 
molecules, TAP1, PSMB9 have been shown to contribute to evasion from immune 
recognition 60. To this end, mutations in the HLA-A gene in lung cancers have been 
observed with a possible contribution to achievement of this hallmark 61. HLA-A 
encodes the alpha chain of the MHC molecule, which is expressed at the cell surface 
and mediates interaction with immune cells. Loss of MHC surface expression might 
lead to evasion of the tumor cell from the immune system and inactivating 
mutations in HLA-A, observed in 3% of lung cancers, might underlie this 
phenomenon.  
 
Gene regulation in cancer 
Another view on the cancer processes can be provided through molecular functions 
governing them. All the above-mentioned processes are mediated through cascades 
of events in the intricately woven molecular networks in the cell and transcriptional 
regulation is at the heart of it. Deregulated transcriptional control results in changes 
in the gene expression levels that in turn affect various cancer processes such as 
apoptosis and cell cycle. Indeed many of the classical cancer genes are transcription 
factor or signaling molecule-encoding genes, whose misregulation propagate through 
their downstream effectors and disrupt the biological processes they perform under 
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normal conditions. For instance, the TAL1 transcription factor is over-expressed in 
almost half of the T cell acute lymphoblastic leukemia (T-ALL) cases and it drives 
aberrant proliferation, differentiation and survival 62. Mutations in signaling 
molecules affect the downstream activity of transcription factors. For instance 
alterations in the MAPK signaling cascade (as mentioned in “self sufficiency in 
growth signals”) results in activation of the transcription factors such as MYC, 
CREB and FOS, which in turn alter the cell cycle process.  
In addition to genes with specific roles in cancer processes, NGS studies identified 
driver genes that have broad functions such as chromatin modification, DNA 
methylation and RNA splicing. Indeed, 25% of the true cancer drivers identified by 
Vogelstein et al are chromatin modifiers 5. Initially it was unclear if these changes 
had a causal relationship with cancer, however their recurrence across a wide range 
of tumors ensured their driver status 63. These genes are involved in transcriptional 
regulation in an indirect manner by changing the accessibility of the genome (for 
transcription) through chromatin modifications and DNA methylation, or by 
disrupting the splicing machinery, which regulates the amount and type of the 
mature mRNAs. For instance, mutations in several nucleosome remodeling genes 
such as ARID1A, SMARCA1 and SMARCA4 are found in several cancers including 
colorectal 20, ovarian 64, and renal cell 65 carcinomas as well as lymphomas 66. These 
mutations result in inactivation of the gene, implying the genes that are actively 
transcribed in these cancers as candidate genes that are affected by the misregulated 
nucleosome remodeling program 67. Indeed, ARID1A containing complexes have been 
shown to repress c-Myc during differentiation 68, pointing to another way of 
activating c-Myc in tumorigenesis with loss-of-function mutations in ARID1A . 
Similarly, mutations in splicing factors have been identified in chromic myeloid 
leukemias with SF3B1 mutations in 10-15% of the cases, then in solid tumors with 
mutations in U2AF1, SF3B1, U2AF2 and PRPF40B 63, however the specific targets 
of spliceosome defects in tumorigenesis remain to be elucidated.  
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MOLECULAR PATHOGENESIS OF T-CELL ACUTE 
LYMPHOBLASTIC LEUKEMIA  
 
In this thesis, T-cell acute lymphoblastic leukemia (T-ALL) genomes and 
transcriptomes will be explored using next generation sequencing technologies in 
order to detect driver mutations and gain insight into pathogenesis of these 
malignancies. This chapter provides an overview on the current status of known 
genomic aberrations and molecular mechanisms in operation in these tumors.  
 
T-ALL is a hematological cancer arising from malignant transformation of lymphoid 
progenitors. Chromosomal translocations and cooperating point mutations equip the 
progenitor T-cell with diverse hallmark capabilities. At the core of genetic alterations 
underlying T-ALL are aberrations resulting in a differentiation block and disrupted 
NOTCH signaling (Figure 1). Additional mutations contribute to tumorigenesis by 
altering cell cycle, growth and proliferation mechanisms (Table 1).  
 
Figure 1. Schematic overview of T-ALL genetic subgroups 69 
 
Differentiation block 
A block in differentiation is a hallmark of T-ALL and is usually achieved by 
chromosomal translocations resulting in the activation of differentiation specific 
transcription factor (TF) genes. These translocations typically involve juxtaposition 
of regulatory elements of T-cell receptor (TCR) genes that are located on 
chromosome 7q34 (TCRB and TCRG) and chromosome 14q11 (TCRA and TCRD) 
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to TFs most of which are not expressed in normal T-cell development with the 
exceptions being TAL1 and LYL1. In addition, alternative genetic rearrangements 
can activate these TFs such as deletions in chromosome 1p32 and 11p13 leading to 
TAL1 70 and LMO2 overexpression 71, respectively and gene duplication leading to 
MYB overexpression 72. Aberrant expression of these TFs results in the 
accumulation of immature cells in defined differentiation blocks and this is also 
reflected in the transcriptional profile of the tumor cells. Indeed, distinct molecular 
subtypes caused by these alterations can be identified by gene expression signatures 
73.  
NOTCH signaling 
Apart from translocations, constitutively active NOTCH signaling is at the core of 
T-ALL pathogenesis. During normal T-cell development, NOTCH1 participates in 
cell fate specification and NOTCH signaling is required throughout different 
developmental stages. Mutations in NOTCH1 are observed in more than 60% of T-
ALL cases 74 throughout all distinct subtypes causing hyperactive NOTCH 
signaling. Interestingly, activation of the NOTCH signaling pathway is not only due 
to NOTCH1 mutations but also due to loss function mutations in FBXW7, which 
takes part in NOTCH1 degradation 75. Oncogenic NOTCH1 is involved in plethora 
of activities such as cell growth, proliferation and survival with interaction partners 
including MYC and NFKB.  
Cell cycle defects  
Deregulation of cell cycle in T-ALL occurs through inactivation of CDKN2A and 
CDKN2B genes 76. These genes are located in chromosome 9p21, and this region is 
deleted in 70% of the cases 77. CDKN2A encodes two tumor suppressor proteins p16 
and p14, whereas CDKN2B encodes for p15. P16 and p15 block cyclin D–CDK4/6 
complexes that positively regulate cell cycle through phosphorylation of RB1, and 
p14 inhibits MDM2 which induces the activation of TP53. Thus aberrations in 
CDKN2A and CDKN2B implicate not only deregulation of RB1 but also TP53.  
Cell growth and survival defects 
Another class of altered TFs affect cell growth and survival pathways. Although a 
lot of recurrent aberrations are observed in this class of genes, their contribution to 
T-ALL tumorigenesis is still an active research area 76. MYC is among these genes 
and it is a prominent oncogene not only in T-ALL but across many other human 
cancers taking part in cell growth and proliferation 78. In T-ALL, the MYC 
oncogene is activated directly by NOTCH1, however in 1% of the cases MYC 
activation can be realized by a t(8;14)(q24;q11) translocation 79. The remaining 
alterations in this class are loss of function events affecting tumor suppressor genes 
either through inactivating mutations or deletions. The majority of these genes are 
important regulators in hematopoiesis and alterations are observed in other 
hematological malignancies exemplified by ETV6 alterations found in B-ALLs, and 
RUNX1 inactivating mutations in AML 76.  
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Alterations in signaling pathways 
In addition to the above-mentioned direct regulators of cell cycle, growth, 
proliferation and differentiation, the signaling pathways regulating these processes 
are frequently mutated in T-ALL. Primarily AKT, RAS and JAK-STAT pathways 
are deregulated through genetic alterations. PTEN acts as a negative regulator of 
the AKT pathway, and inactivating mutations and deletions lead to uncontrolled 
proliferation in the tumor cells 80. RAS signaling, on the other hand, is disrupted 
through mutations in NRAS and NF1, which encodes a negative regulator of RAS 
signaling pathway. And finally, the JAK-STAT pathway is deregulated due to 
mutations in JAK1 and JAK3, or translocation involving JAK2. Additionally, a gain 
of function mutation in IL7R leads to constitutive JAK/STAT signaling 76.  
Mutations in chromatin remodelers 
Polycomb repressive complex 2 (PRC2) is responsible for repressive marking of the 
chromatin and is composed of four proteins encoded by SUZ12, EZH2, EED and 
RBBP4. Two of these genes, SUZ12 and EZH2, have been reported to be mutated in 
T-ALL up to 25% of the cases and functional evidence points to a tumor suppressor 
role for these mutations 81,82. Another chromatin modifier, PHF6 is mutated in 16% 
of pediatric and 38% of adult T-ALL cases. Notably, mutations are observed almost 
exclusively in male patients, resulting in a hemizygous mutation/deletion 83.  
 
Table 1. Recurrent genetic alterations in T-ALL. Adapted from 76 
Category Gene target Genetic rearrangement Frequency 
TAL1 
t(1;14)(p32;q11) 
t(1;7)(p32;q34) 
1p32 deletion 
3% 
3% 
16-30% 
TAL2 t(7;9)(q34;q32) 1% 
LYL1 t(7;19)(q34;p13) 1% 
BHLHB1 t(14;21)(q11.2;q22) 1% 
LMO1 t(11;14)(p15;q11) t(7;11)(q34;p15) 
1% 
1% 
LMO2 
t(11;14)(p13;q11) 
t(7;11)(q34;p13) 
11p13 deletion 
6% 
6% 
3% 
LMO3 t(7;12)(q34;p12) <1% 
TLX1 t(11;14)(p15;q11) 5%-10% & 30% 
TLX3 t(11;14)(p15;q11) 20% & 5% 
HOXA Inv(7)(p15q34) t(7;7)(p15;q34) 
3% 
3% 
HOXA (CALM-AF10) t(10;11)(p13;q14) 5%-10% 
HOXA (MLL-ENL) t(11;19)(q23;p13) 1% 
HOXA (SET-NUP214) 9q34 deletion 3% 
Differentiation impairment 
(through TF aberrations) 
NKX2.1 inv(14)(q13q32.33) t(7;14)(q34;q13) 5% 
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NKX2.2 t(14;20)(q11;p11) 1%  
MYB t(6;7)(q23;q34) Gene duplication 
3% 
8% 
t(7;9)(q34;p13) <1 %  NOTCH1 pathway NOTCH1 
Activating mutation >60% 
FBXW7 Inactivating mutation 8%-30% 
CDKN2A/2B 9p21 deletion methylation 70% 
CCND2 t(7;12)(q34;p13) t(12;14)(p13;q11) 1% 
RB1 13q14 deletion 4%  
Cell cycle defects 
CDKN1B 12p13 deletion 2% 
MYC t(8;14)(q24;q11) 1% 
WT1 Inactivating mutation/deletion 10% 
LEF1 Inactivating mutation/deletion 10%-15% 
ETV6 Inactivating mutation/deletion 13% 
BCL11B Inactivating mutation/deletion 10% 
RUNX1 Inactivating mutation/deletion 10%-20% 
Cell growth and survival defects 
(through TF aberrations) 
GATA3 Inactivating mutation/deletion 5% 
PTEN Inactivating mutation 10q23 deletion 
10% 
10% 
NUP214-ABL1 Episomal 9q34 amplification 4% 
EML1-ABL1 t(9;14)(q34;q32) <1% 
ETV6-ABL1 t(9;12)(q34;p13) <1% 
BCR-ABL1 t(9;22)(q34;q11) <1% 
NRAS Activating mutation 5%-10% 
NF1 Inactivating mutation/deletion 3% 
JAK1 Activating mutation 4%-18% 
ETV6-JAK2 t(9;12)(p24;p13) <1% 
JAK3 Activating mutation 5% 
FLT3 Activating mutation 2%-4% 
Signal transduction 
IL7R Activating mutation 10% 
EZH2 Inactivating mutation/deletion 10%-15% 
SUZ12 Inactivating mutation/deletion 10% 
EED Inactivating mutation/deletion 10% 
Chromatin remodeling 
PHF6 Inactivating mutation/deletion 20%-40% 
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UNDERSTANDING CANCER GENOMES THROUGH 
NEXT GENERATION SEQUENCING  
 
Cancer is a disease of mutations. The first indication that cancer was a genomic 
disease came from Boveri 84 and von Hansemann 85 in the beginning of the twentieth 
century. They observed unusual chromosomal aberrations in cancer cells and 
postulated that cancers are abnormal clones of normal cells caused by abnormalities 
in the hereditary material. In 1973, the Philadelphia chromosome (the translocation 
between chromosomes 9 and 22) was identified as a first example of a genomic 
abnormality associated with a particular cancer type 86. A decade later, the first 
somatic mutation in a human cancer was found: a point mutation in the HRAS 
gene87,88. The completion of the human genome sequencing project further fueled the 
cancer genomics field both by providing the technology for sequencing DNA in an 
automated fashion and by supplying the backbone in the form of the annotated 
human genome reference sequence. Despite the high cost and low throughput of 
sequencing technology, a number of studies took the task of identifying disease 
causing mutations in cancer either by sequencing a limited set of selected exons in a 
large cohort 6,7 or all known coding exons on a limited number of samples 8,9. 
However, it were the next generation sequencing (NGS) technologies that shifted the 
focus from targeted small-scale approaches to comprehensive genome-wide 
approaches. The availability of NGS platforms for research groups worldwide has 
resulted in a remarkable advancement in our understanding of the mutational 
landscapes of many human cancers. Studies examining genomic aberrations in 
targeted genomic regions and whole genomes have been reported for a large number 
of tumor samples (Table 2). Moreover, systematic cancer genome sequencing 
projects have emerged: first the Cancer Genome Project (CGP) 92 in the United 
Kingdom and then The Cancer Genome Atlas (TCGA) 93 in the USA; both aiming 
to sequence several major cancer types. The International Cancer Genome 
Consortium (ICGC) was then founded to coordinate data generation and analysis, 
and currently 52 cancer types are being sequenced and analyzed under the ICGC 
umbrella 94. Comprehensive genomic analysis have been released for various cancer 
types by these consortia as well as individual research groups, and Table 2 lists a 
few examples. Today, more than 1% of all human genes are implicated in cancer via 
mutations and overall, more than 290 000 somatic mutations in 41 main cancer 
types have been identified (data extracted from COSMIC v66) 95. 
 
Converting genomic data into biological knowledge  
The massive amounts of data produced by next generation sequencing (NGS) 
platforms enable comprehensive characterization of mutational landscapes of cancer 
genomes, however this becomes possible only after addressing the computational and 
statistical challenges in the data analysis. This section will lay out the technical 
CHAPTER I: INTRODUCTION 
14 
aspects of cancer genome sequencing and provides the state of the art for the 
analysis approaches. 
 
Table 2. Overview of cancer genomics studies that appeared during this PhD 
Tumor type Cases Sequencing type Reference 
Acute Myeloid Leukemia  200  Whole genome & exome TCGA 96 
Breast cancer 507 Exome TCGA97 
Breast cancer 100 Exome 98 
Breast Cancers  65 Whole genome & exome 99 
Burkitt Lymphoma 60 Whole genome & exome 66 
Chronic Lymphocytic Leukemia  105 Exome 100 
Colorectal Cancer  224 Exome TCGA 20 
Colorectal Cancer  74 Whole genome & exome 101 
Diffuse large B-cell lymphoma  94 Exome 102 
Diffuse large B-cell lymphoma  55 Exome 103 
Endometrial cancer 248 Exome TCGA 104 
Head and Neck squamous cell carcinoma 74 Exome  105 
Kidney renal clear cell carcinoma 417 Exome sequencing TCGA 65 
Lung Adenocarcinoma 183 Whole genome & exome 106 
Lung squamous cell carcinoma 178 Exome TCGA 61 
Melanoma 147 Exome 107 
Melanoma 121 Exome 108 
Ovarian Carcinoma 316 Exome TCGA 109 
Pancreatic Adenocarcinoma 99 Exome 110 
Pediatric Medulloblastoma 60 Whole genome & exome 111 
Pediatric Neuroblastoma 87 Whole genome 112 
Prostate Cancer 112 Exome 113 
T-cell acute lymphoblastic leukemia 67 Exome 114 
 
 
The genomic alterations that can be identified by NGS technologies consist of 
differences in the sequence or in the arrangement of sequence blocks compared to the 
reference genome. These include single nucleotide variations (SNV), small insertions 
and deletions (INDEL), copy number aberration (CNA) and structural variations 
(SV) (Figure 2). SNVs involve changes in single bases, while INDELs span multiple 
base pairs up to 1 kilobase 115. When they occur in the protein coding regions, they 
might change the encoded amino sequence (missense mutation), introduce stop 
codons (nonsense mutations) or, in the case of INDELs, change the reading frame 
(frameshift mutations). These alterations could influence the activity of the encoded 
protein or result in loss of the protein product altogether. On the other hand, when 
they occur in the non-coding genome they can disrupt the splicing patterns of the 
gene via splice site mutations (causing intron retention or exon skipping events) 116 
or alter gene transcription via mutations in the regulatory regions 117,118.  
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Figure 2. Schematic representation of genomic variations detected by NGS 
 
 
CNAs include amplifications and deletions of large chromosomal regions as well as 
focal gains and losses. These alterations could result in gene duplications or 
deletions, thus influencing gene dosage or may lead to the complete loss of genes 
located within them. SVs disrupt the composition of the genome via rearrangement 
of genomic material and could be observed in the forms of inversions or 
translocations. Inversions are rearrangements in which DNA segments are re-
inserted in to the genome in a reverse orientation. Translocations, on the other 
hand, involve the interchange of genetic material between two distinct genomic 
regions either within the same chromosome (intrachromosomal) or between different 
chromosomes (interchromosomal). Both inversions and translocations could result in 
effects such as disrupting the regulatory sequences that control gene expression or 
creating genetic rearrangements like gene fusions. 
The range of genomic aberrations that can be identified in an NGS study depends 
on the sequencing approach used (Figure 3). Whole genome sequencing (WGS) 
provides the most comprehensive view on the genome allowing identification of all 
mutations, rearrangements and copy number changes effectively and simultaneously. 
Variations of this approach can allow sequencing defined regions in a genome, 
termed ‘targeted sequencing’. This targeted approach involves enrichment of a 
library for the desired target regions using PCR or hybridization based approaches, 
and subsequent sequencing of this library. Targeted sequencing strategies could be 
used for sequencing a set of interesting genes or the entire coding sequences of the 
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genome (exome sequencing) for a complete characterization of the mutational profile 
of the samples, as demonstrated in Chapter 3 of this thesis. In addition, these 
approaches can be valuable to confirm mutations found by other NGS approaches 
or for uncovering the clonal architecture of a tumor by deep sequencing the 
potential driver genes or mutations 119.  
 
Figure 3. Different types genomic aberrations can be identified with different NGS approaches. 
Adapted from 120 
 
NGS approaches can also be used for characterizing cancer transcriptomes. 
Transcriptome sequencing, which is also called RNA-seq, focuses on sequencing the 
cDNA, obtained from the mRNA, total RNA or other RNAs such as micro-RNAs. 
RNA-seq provides an efficient way of measuring gene expression across whole 
transcriptome since the number of RNA-seq reads that map to a particular region 
can be used as an abundance measure. This feature also allows measuring expression 
at the level of transcripts and permits discovery of alternative transcript events 
(ATEs). In addition, RNA-seq can be used to inquire mutations in the expressed 
genes and identify fusions.  
Another application of NGS includes epigenome sequencing, which is not discussed 
in this thesis. Briefly, these approaches are used for characterizing the genome-wide 
DNA methylation and histone modification profiles as well as assessing chromatin 
accessibility and include techniques such as ChIP-seq, DNase-seq, and MeDIP-seq 121.  
Bioinformatics pipelines for NGS analysis in cancer genomics 
NGS data analysis is executed through ‘pipelines’ that include data processing steps 
performed with algorithms and methods specific for the biological question and the 
sequencing experiment at hand. A typical NGS analysis pipeline includes 
preprocessing of the sequence reads to remove adapter sequences and low quality 
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reads, alignment of the reads to a reference sequence, post-alignment modifications, 
detection of the genomic variants and identification of the driver aberrations 
(Figure 4).  
 
Alignment of the reads to the reference sequence 
After adapter trimming and ensuring the overall base quality of the sequence reads 
is acceptable (Table 3.A-B), the reads are aligned to the reference genome sequence. 
Tens to hundreds of millions of reads need to be mapped to the reference sequence, 
typically the genome or transcriptome. Due to the read lengths and the repetitive 
nature of the human genome, some reads might map to several places in the 
reference sequence. Furthermore, the presence of sequence mistakes along with 
genuine mutations makes it harder to find the most likely source of origin in the 
reference sequence. Several mapping algorithms have been developed specifically 
addressing these challenges (Table 3.C). The general strategy of these algorithms 
is to follow a two-step mapping procedure starting with the detection of the most 
probable location of the read in the reference sequence with fast heuristic 
approaches (such as hash-table based or Burrows Wheeler transform methods), 
followed by slow and accurate mapping of the read to the reference sequence (such 
as Smith-Waterman) 122.  
 
Figure 4. A high level overview of NGS analysis 
 
To further increase the accuracy of the alignment, a number of post-alignment 
modifications might be performed consisting of three steps: removal of duplicate 
reads from the alignment, local re-alignment around INDEL sites and base quality 
score re-calibration 123 (Table 3.D). The first post-alignment modification is the 
removal of duplicate reads that originate from the PCR amplification step in NGS 
library preparation protocols. The PCR amplification step might be biased towards 
short fragments or fragments with lower GC composition, and this might lead to 
artificial differences between coverage levels. Moreover, if this biased amplification 
occurs for a genomic material with an early PCR mistake, it might cause a false 
positive variant prediction in the downstream analysis. To prevent this systematic 
bias, pre or post alignment duplicate removal is often implemented. A pre-alignment 
duplicate removal strategy involves removing sequence reads that are identical in the 
raw fastq file. A post-alignment procedure incorporates the location of the read in 
the genome and removes the reads that have identical beginning and end 
coordinates.  
The second step in this framework is the local re-alignment of the sequences around 
INDEL sites. Presence of small insertions and deletions in the sequence might pose 
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problems in the mapping step as the aligners might introduce mismatches instead of 
gaps or insertions. Since the aligners handle each sequence read individually, a 
consensus variant sequence is hard to generate at true INDEL sites. These sites are 
often mapped with multiple mismatches instead of the INDEL, or even if the 
INDEL is mapped correctly the read harbors mismatches in the vicinity of the 
INDEL 123. To tackle this problem, GATK Indel Realigner evaluates the sequences 
around known or predicted INDELs, or sites with a cluster of mismatching bases 
with a multiple sequence alignment approach. This step cleans the regions with such 
mapping artifacts, improves INDEL calling in the downstream analysis and 
decreases the false positive prediction rate of SNVs.  
The last step of the post-alignment modifications is the recalibration of the base 
quality scores. The sequencer assigns a quality score indicating the accuracy of a 
base call. However, it has been shown that the quality scores are actually not 
accurate and affected by a number of factors such as sequencer chemistry, machine 
cycle (the position within the read), and di-nucleotide context (preceding and the 
current base) 123-125. The recalibration ensures that the base quality score reflects the 
probability of a sequencing error and not co-vary with other factors. The GATK 
implementation calculates correction factors for each class of covariates, however 
other implementations exist based on logistic regression 124 or Hidden Markov 
Models 126.  
Genome Variation Discovery 
 
SNV discovery  
The post-alignment modifications, described above, provide well-mapped, realigned 
and re-calibrated reads ready for the identification of variants. Variant calling can 
then be performed using a variety of tools as listed in Table 3.E. The challenge is to 
distinguish true variants from alignment and/or sequencing mistakes. In its most 
simple form, variant calling can be done by counting alleles at each site and using 
simple cut-offs for deciding if a base is variant or reference. Such an approach was 
followed by VarScan in which genotype calls are done in positions above certain 
coverage and quality, then a SNV prediction is made if there is a variant base above 
a certain variant allele frequency (additionally, a p-value is calculated based on 
Fisher’s exact test for the read counts supporting the reference and variant alleles 
versus the expected distribution of alleles based on sequencing error) 127. These 
simple methods work well with high coverage sequencing depths, however with low 
sequencing depths (e.g., <20X) the fixed cut-offs on variant allele frequency 
thresholds leads to under-calling of heterozygous variants 128. Furthermore, the use 
of fixed cut-offs on the sequencing metrics (depth of coverage, variant allele 
frequency, quality scores) leads to information loss. Probabilistic methods, on the 
other hand, incorporate the quality scores along with other metrics from the 
sequencing, and contain uncertainty in the prediction. Most algorithms converge on 
a Bayesian approach for this task. Briefly, these methods calculate the posterior 
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probability of each genotype given the read data for a particular site, using the 
Bayesian formulation:  
€ 
p(G |D) = p(G)p(D |G)p(D)  
 
where D represent the data (the pileup of reads and qualities in a given base) and G 
represent the genotype. The genotype likelihood can be calculated as follows for a 
diploid genome, assuming the reads are independent:  
€ 
p(D |G) = p(b |G)∏  where 
€ 
p(b |G) = p(b | A1,A2{ }) =
1
2 p(b | A1) +
1
2 p(b | A2) 
 
with A1 and A2 being the two alleles of a diploid genome in a given position. 
Generally the genotype with the highest probability is called and the probability 
value is reported as a measure of confidence 128,129. 
 
INDEL discovery 
Detection of INDELs is complicated due to mapping problems of the sequence reads 
containing INDELs (as mentioned in the beginning of this section). An optimal 
combination of a mapping and an INDEL detection method is essential for accurate 
and specific INDEL predictions. Dindel 130, a Bayesian approach for calling INDELs, 
is built on this premise : candidate INDELs are collected from the alignment file and 
candidate haplotypes (representing the reference sequences with the imputed 
candidate INDEL) are used for remapping the reads in the regions with candidate 
INDELs. It had the best performance when compared to three other INDEL callers 
(GATK, SAMTools mpileup, VarScan) 131 , however it is suitable only for Illumina 
analysis. Other methods range from simple heuristic filters (eg. VarScan 127,132) to 
pattern growth approaches (eg. Pindel 133) (Table 3.F), although often parameter 
optimization is required to obtain reliable INDEL predictions 131. 
 
Copy Number Aberration Discovery 
Although CNA detection is more common practice with arrays or WGS, methods 
are being developed to detect CNAs using exome sequencing as well. The discrete 
nature of the reads in Exome-seq is a challenge for CNA detection. Moreover, read 
depth is not exclusively correlated with copy number status since biases in sequence 
capture as well GC content affects the sequencing depth. A variety of methods are 
available now (Table 3.G), mostly employing Hidden Markov Models for 
identification of CNAs.  
 
Transcriptome Variation Discovery 
Gene expression changes do not actually constitute a class of genomic variation, 
however a change in gene expression may coincide with an underlying genomic 
aberration, thus this data can be used to enhance understanding the observed 
alterations. Gene expression levels can be estimated from the number of reads 
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mapping to each gene in the RNA-seq data. The first step is to count the number of 
aggregate reads in a given gene. Intuitively, counting the number of reads 
overlapping a defined gene region seems trivial, however there a number of subtleties 
to be addressed such as tackling the reads that are not uniquely assigned to a gene. 
For this reason a number of tools have been developed allowing user flexibility to 
handle these problems (Table 3.H). Next, the expression values need to be 
normalized to remove systematic biases. The sources of bias include between sample 
differences such as library size (sequencing depth) 134, and within sample effects due 
to differences in gene length 135 and GC content 136. Several normalization metrics 
and methods were developed over the last few years addressing the removal of these 
biases such as Upper Quantile (UQ) 137, DESeq normalization 138, Trimmed Mean of 
M values (TMM) 139, and Reads Per Kilobase per Million mapped reads (RPKM) 
normalization 134. Additionally, normalization methods based on the use of 
housekeeping genes 137 and GC-content bias 140 have also been proposed. Dillies et al 
conducted a comprehensive evaluation on different RNA-seq normalization 
techniques and concluded that DESeq and TMM methods provide reasonable 
normalization based on the qualitative characteristics and impact of the differential 
expression141. Both of these methods are based on the hypothesis that most of the 
genes are not differentially expressed, and they both calculate a correction factor for 
removing the bias of library size. Following the normalization, exploratory analysis 
can be conducted using clustering or classification algorithms in akin to microarray 
analysis. Additionally, differential expression tests can be performed using 
parametric or non-parametric approaches 142. Parametric approaches assume that 
each expression value is drawn from a particular distribution such as Poisson 143, 
Negative Binomial 138,139,144-147, or Beta Binomial 148 while non-parametric models 
estimate the noise from the count data.  
RNA-seq data can provide a comprehensive view on a transcriptome at hand by 
allowing identification and quantification of all expressed exons and transcripts. 
However, several factors make this analysis challenging: (1) non-uniform coverage 
across the transcriptome with some transcripts supported by a few reads and some 
with extensive coverage and (2) shared exons between different transcripts 149,150. 
Several methods have been developed addressing these challenges (Table 3.I). Two 
of these methods, Scripture 151 and Cufflinks 152,153 perform de novo transcriptome 
assembly using spliced reads. Both methods follow a similar approach of creating an 
assembly graph and parsing the graph for paths to infer possible transcripts. The 
main difference between the two methods lie in the way of parsing the graph: 
Scripture focuses on maximum sensitivity and reports all the transcripts compatible 
with the read structure while Cufflinks aims at maximum precision and reports the 
minimal number of compatible isoforms 150. These methods lay out the 
transcriptome from a given RNA-seq experiment, leading to identification of both 
known and novel isoforms. Estimation of expression levels of these entities is tackled 
by other methods developed to overcome the ‘read assignment uncertainty’ problem. 
Alexa-seq focuses on the reads that exclusively map to a single isoform and ignore 
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the ambiguous reads 154. However, other approaches like Cufflinks and MISO 
attempt to solve this problem by constructing likelihood functions that estimate the 
expression with the given read structure 152,153,155.  
Finally, RNA-seq data can be used to obtain gene fusions (Table 3.J). Methods 
that rely on the paired-end read structure of the RNA-seq data identify fusion genes 
using discordant reads, which are read pairs that have a significantly different inter 
distance compared to the rest of the read pairs; and split reads, which span the 
fusion boundary. deFuse follows such a strategy: the algorithm first finds the 
discordant reads and generates putative fusions events 156. The algorithm 
subsequently searches for split reads spanning the putative fusion boundary and 
implements a set of filters to generate final predictions. Another class of methods 
fragment the reads and map these to the reference sequence. Then the mapped 
fragments are used for generating putative fusion events. Algorithms employing this 
strategy are MapSplice 157, FusionMap 158 and FusionFinder 159. A third class of 
methods involve a combination of these two methods: discordant reads are used for 
creating putative fusion references, then the reads that do not map initially are 
fragmented and mapped to this new reference sequence. Tophat-fusion160 and 
ChimeraScan 161 follow this strategy.  
Identification of somatic mutations and driver genes  
It is the somatic mutations that eventually leads to cancer 1 either in a stepwise 
manner leading to gradual accumulation or through a crisis-driven manner (for 
example, chromothripsis, chromoplexy, kataegis) with the introduction of a high 
number of mutations in a relatively shorter time scale 6. After obtaining high quality 
genomic variants from NGS data, the next step is to identify their somatic status. 
When a matching normal sequence is available for a sequenced tumor sample, 
somatic mutation detection can be performed. Subtracting the variants that are 
called in the matched germline from the tumor sample variants can be seen as a 
simple and straightforward approach, yet it is biased towards regions that are not 
covered in the either of the samples, or for tumor variants with low allele frequencies 
162. Instead, somatic SNV detection algorithms have been developed for joint analysis 
of matched tumor and normal samples as listed in Table 3.K. These methods mostly 
rely on a Bayesian framework to model the genotypes, (as explained in the SNV 
discovery section) however simple models with heuristic filters do exist (VarScan2 
132). A comparison between Bayesian framework models and Varscan2 revealed that 
high probability candidate somatic mutations from VarScan2 were also identified 
with other methods, while the low probability predictions suffered from a high rate 
of germline false positives, and the method was unable to detect somatic variants 
with low variant allele frequencies (<0.2) 163. Assessment of different 
implementations of Bayesian framework models demonstrated that they perform 
equally well with high sensitivities (>99%) for coverage above 30X and variant allele 
frequency above 0.4, however as the variant allele fraction decreases the sensitivity 
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decreases as well, and at 0.1 allelic fraction MuTect was the most sensitive method 
with 53.2% sensitivity 162.  
In the absence of the matched germline data, common population variants can be 
used to approximate somatic variants. HapMap 164 and 1000 genomes 165 projects 
have identified over 55 million population variants. These variants are detected in 
the healthy population with minor allele frequencies of 5% and 1%, respectively. 
However, the use of these databases requires caution as a small percentage of 
pathogenic variants are infused to these databases.  
 
Pathogenesis of cancer is driven by driver genetic changes which confer selective 
growth advantage to the cancerous cell 5. However, a cancer cell does not harbor 
only driver events but also ‘passenger’ events, which do not contribute to malignant 
transformation and occur due to stochastic mutation processes amplified by the 
genomic instability.  
Methods dealing with driver mutation identification can be broadly divided into two 
categories: mutation significance based methods and functional consequence based 
methods (Table 3.L). Even though they evaluate the problem in different ways, 
the methods in these two categories are often used in combination. The mutation 
significance based methods focus on the SNV and INDEL predictions and work on 
the assumption that the driver genes harbor more (ie. frequency based methods) or 
have different mutation patterns compared to passenger mutations. Among these 
significance based methods GenomeMusic 166 and MutSigCV 167 assess the mutation 
significance based on the mutation frequency and calculate the background 
mutation rate from the matched germline samples or from the silent and non-coding 
mutations from the same sample, respectively. Sjoblom et al employ a different 
strategy for estimating background mutation rate and incorporate nucleotide type 
and context into the calculation: they divide mutations into categories according to 
the nucleotide context the mutation resides in (ie. A, C, T, G mononucleotide sites; 
CG, TC and GA dinucleotide sites) and estimate a distinct background mutation 
rate for each mutation type 90.  
Functional consequence based methods employ the impact the genomic variant has 
on the function of the gene. A variant can have a gain-of-function, loss of function 
or neutral effect on the protein. Gain-of-function events result in an aberrant or 
ectopic activity of the gene it is observed, while loss-of-function events result in loss 
of activity the gene performs. Typically, these two events are of interest in cancer 
studies, and can be collectively termed as ‘protein altering events’. Methods such as 
Variant Effect Predictor 168, SeattleSeq 169, and Annovar 170 assess the functional 
impact of the variant on the protein product and can be used for detecting protein-
altering events, while SIFT 171 and PolyPhen 172 employ additional information such 
as evolutionary conservation, the location of the variant on the 3D structure of the 
protein and chemical similarity between the known and novel (mutation imputed) 
protein. Furthermore, there are also methods that incorporate cancer specific 
information on top of the sequence information such as CHASM 173 and CanPredict 
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174. Both methods employ a random forest classifier to distinguish driver events from 
passengers using COSMIC mutations as the positive training set. CHASM trains its 
model on features such as amino acid substitution properties, evolutionary 
conservation of the nucleotide position, predicted structure of the mutated position 
and protein domain annotations, while CanPredict trains on the features such as 
effect of the mutation on the protein function and Gene Ontology annotations 
associated with the gene.  
These methods aim to detect driver events; however validating the output of these 
algorithms is very difficult as the only validation is the functional follow up of the 
event. Thus, it is often common practice to use a combination of these methods to 
reach a final candidate list of driver events.  
 
Table 3. Computational tools for NGS data analysis 
A. Pre-processing tools 
SeqTrim 175  
FastX URL1  
ea-utils URL2  
cutadapt URL3  
B. QC programs  
FastQC URL4  
NGS QC Toolkit 176  
QC-Chain 177  
C. Alignment 
MAQ 178 Hash-based short read aligner 
BWA, BWA-SW 179,180 BWT-based short and long read aligner 
ELAND 181 Illumina companion hash-based aligner 
SSAHA2 182 Hash-based short and ling read aligner 
Bowtie, Bowtie2 183,184 BWT-based short read aligner 
Novoalign URL5 Hash-based short read aligner 
SHRiMP, SHRiMP2 185 Hash-based short read aligner 
Stampy 186 Hash-based short read aligner 
LAST aligner 187 Suffix array based aligner 
SOAP2, SOAP3 188,189 Hash-based short read aligner 
mrFAST, mrsFAST 190,191 Primarily used for detecting structural variants 
SARUMAN 192 Short read aligner 
Corona Lite Unpublished Used for SOLiD 
BFAST 193 Hash-based aligner for SOLiD 
BLAT 194 Long read aligner 
GSNAP 195 RNA-seq aligner 
STAR 196 RNA-seq aligner 
MOSAIK 197 Hash-based short and long read aligner 
FANGS 198 Hash-based long read aligner 
D. Post-alignment modifications 
Picard URL6 Duplicate removal 
GATK  129 Indel Realigner 
GATK  129 Base Quality Score Recalibration 
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E. Mutation Calling 
SNVMix 199 Probabilistic binomial mixture model 
SAMTools 200 Bayesian SNP calling 
GATK Unified 
Genotyper 
129 Bayesian SNP calling 
SOAPsnp 125 Bayesian SNP calling 
VarScan/VarScan2 127,132 Heuristic variant calling 
Atlas-SNP2 201 Bayesian SNP calling 
F. Small Insertion/Deletion Calling 
Pindel 133  
DINDEL 130  
VarScan/VarScan2 127,132 Heuristic variant calling 
SAMTools mpileup 200  
G. Copy Number Aberration Detection 
exome2cnv 202  
ExomeCNV 203  
CoNVEX 204  
XHMM 205  
CoNIFER 206  
H. Gene Expression Quantification and Normalization 
htseq-count 207 Gene expression quantification tool from HTSEQ 
easyRNASeq 208 
Gene expression quantification tool from easyRNASeq R 
package 
summarizeOverlaps 209 
Gene expression quantification tool from GenomicRanges R 
package  
qCount URL7 Gene expression quantification tool from QuasR R package 
DESeq 138 DESeq normalization and Negative Binomial DE 
edgeR 139 TMM normalization and Negative Binomial DE 
EDASeq 140 GC-content normalization 
NOISeq 210 Non-parametric DE 
baySeq 145 Negative Binomial DE 
BBSeq 144 Beta Binomial DE 
QuasiSeq 211  
EBSeq 146 Negative Binomial DE 
NBPSeq 147 Negative Binomial DE 
ShrinkSeq 212 Several distributions for DE (incl. Negative Binomial) 
SAMSeq 142 Non-parametric DE 
I. Transcript Assembly and Quantification 
Scripture 151  
Cufflinks 152,153  
Alexa-seq 154  
MISO 155  
J. Fusion Detection 
deFuse 156  
FusionHunter 213  
MapSplice 157  
FusionMap 158  
FusionFinder 159  
Tophat-fusion 160  
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ChimeraScan 161  
K. Somatic Mutation Calling 
MuTect 162 Bayesian classifier 
VarScan2 132 Heuristic variant frequency thresholds 
SomaticSniper 214 Bayesian model of diploid genotypes based on MAQ 
Strelka 
215 Bayesian model of noisy diploid normal sample and tumour 
mixture 
JointSNVMix 
216 Bayesian model of diploid genotypes using binomial mixture 
model 
L. Driver Gene Selection 
GenomeMusic 166  
MutSigCV 167  
CaMP score 90  
VariantEffectPredictor 168  
SeattleSeq 169  
Annovar 170  
SIFT 171  
PolyPhen 172  
CHASM 173  
MutationAssessor 217  
CanPredict 174  
1 http://hannonlab.cshl.edu/fastx_toolkit/  
2 https://code.google.com/p/ea-utils/ 
3 https://code.google.com/p/cutadapt/ 
4 http://www.bioinformatics.babraham.ac.uk/projects/fastqc/ 
5 http://www.novocraft.com 
6 http://picard.sourceforge.net 
7 http://www.bioconductor.org/packages/release/bioc/html/QuasR.html 
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CHAPTER II: RATIONALE AND AIMS 
 
Completion of the human genome sequence and profound advancements in 
sequencing technologies have enabled fast and systematic analyses of cancer genomes 
for the identification of genomic aberrations. It is now possible to sequence targeted 
genomic regions, exomes, genomes and transcriptomes to obtain a comprehensive 
catalog of mutational profiles of human cancers. The central aim of this thesis is to 
exploit these technologies to uncover the range of genomic alterations present in the 
T-cell acute lymphoblastic leukemias (T-ALL) and identify the driver aberrations 
that contribute to tumorigenesis. A schematic depicting the datasets used in this 
thesis is presented in Figure 5. For each of the sequencing experiments we have built 
specific bioinformatics pipelines. Furthermore, we optimized and validated these 
pipelines (using orthogonal sequencing approaches) in each case individually.  
 
 
The specific aims of this thesis are:  
 
- Identification of novel driver genes and events involved in the pathogenesis of 
T-ALL  
 
- Accurate and precise detection of genomic aberrations including SNVs, 
INDELs, fusions, alternative transcript events as well gene expression levels  
 
- Use of different sequencing applications to decipher the mutational landscape 
of T-ALL  
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Figure 5. Schematic overview of the datasets and analysis pipelines used in this thesis 
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CHAPTER III: RESULTS  
 
 
PAPER I: High accuracy mutation detection in leukemia on a selected 
panel of cancer genes 
 
 
PAPER II: Exome sequencing identifies mutation in CNOT3 and 
ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic 
leukemia  
 
 
PAPER III: Comprehensive analysis of transcriptome variation 
uncovers known and novel driver events in T-cell acute lymphoblastic 
leukemia  
 
 
 
 
 
Author contributions are detailed in each paper. Overall, the computational 
experiments and bioinformatics analysis are done by me, while the sequence and 
functional validation studies are performed in the Laboratory of Molecular Biology 
of Prof. Jan Cools, Laboratory of Neurogenesis of Prof. Bassem Hassan and 
Laboratory of Molecular Genetics of Ribosome of Prof. Arlen Johnson.  
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ABSTRACT  
 
With the advent of whole-genome and whole-exome sequencing, high-quality catalogs 
of recurrently mutated cancer genes are becoming available for many cancer types. 
Increasing access to sequencing technology, including bench-top sequencers, provide 
the opportunity to re-sequence a limited set of cancer genes across a patient cohort 
with limited processing time. Here, we re-sequenced a set of cancer genes in T-cell 
acute lymphoblastic leukemia (T-ALL) using Nimblegen sequence capture coupled 
with Roche/454 technology. First, we investigated how a maximal sensitivity and 
specificity of mutation detection can be achieved through a benchmark study. We 
tested nine combinations of different mapping and variant-calling methods, varied 
the variant calling parameters, and compared the predicted mutations with a large 
independent validation set obtained by capillary re-sequencing. We found that the 
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combination of two mapping algorithms, namely BWA-SW and SSAHA2, coupled 
with the variant calling algorithm Atlas-SNP2 yields the highest sensitivity (95%) 
and the highest specificity (93%). Next, we applied this analysis pipeline to identify 
mutations in a set of 58 cancer genes, in a panel of 18 T-ALL cell lines and 15 T-
ALL patient samples. We confirmed mutations in known T-ALL drivers, including 
PHF6, NF1, FBXW7, NOTCH1, KRAS, NRAS, PIK3CA, and PTEN. 
Interestingly, we also found mutations in several cancer genes that had not been 
linked to T-ALL before, including JAK3. Finally, we re-sequenced a small set of 39 
candidate genes and identified recurrent mutations in TET1, SPRY3 and SPRY4. 
In conclusion, we established an optimized analysis pipeline for Roche/454 data that 
can be applied to accurately detect gene mutations in cancer, which led to the 
identification of several new candidate T-ALL driver mutations. 
 
INTRODUCTION 
 
Next generation sequencing (NGS) technologies have significantly improved our 
sequencing capacity in the past five years. They are now widely used for research 
purposes and are starting to find their way into clinical applications. Although 
whole genome and whole exome sequencing approaches are successfully implemented 
for mapping the genomic landscapes of many human diseases, they are not routine 
strategies for detecting molecular aberrations due to high costs, and long turnover 
times (run and analysis times). Targeted re-sequencing, on the other hand, is 
appealing in a clinical setting, given the lower sequencing costs, shorter sequencing 
time and simpler data analysis. Moreover, as the discovery of novel cancer genes by 
whole-exome sequencing will gradually saturate and converge into a set of commonly 
mutated genes in a particular cancer, the identification of these mutations can yield 
important diagnostic and prognostic information. 
Despite the requirement of several days for library preparation and target 
enrichment for all these platforms, the Roche/454 technology offers the advantages 
of short run times and data analysis time. In addition, the more restricted data 
output is also beneficial for turnaround time because fewer patient samples need to 
be collected to fill an entire sequencing run. Based on these advantages of the 454 
platform for sequencing relatively small gene sets, we invested in optimizing 
bioinformatics pipelines for read mapping and variant calling of 454 reads, with the 
aim for applying this both for research as well as for clinical purposes. We focused 
on T cell acute lymphoblastic leukemia (T-ALL), an aggressive hematopoietic cancer 
caused by malignant transformation of developing T-cells 1. A set of 97 genes was 
selected for targeted sequencing. The set consisted of 58 cancer genes 2 and 39 
candidate genes including tyrosine kinase and phosphotase coding genes, chromatin 
modifiers, and several genes belonging to the families of known cancer driver genes 
such as TET1-TET3, or PIK3CB-PIK3CD-PIK3CG. 
For accurate variant detection, we investigated several existing analysis pipelines and 
compared their performance. Although the companion software gsMapper is widely 
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used in the analysis of 454 data 3-5, various alternative mapping and variant calling 
algorithms have been developed, such as BWA-SW 6 and SSAHA2 7, BLAT 8 for 
mapping, and SAMTools 9, VarScan 10, and Atlas-SNP2 11 for variant calling. Li et 
al 6 reviewed the long read aligners, and Shen et al 11 reviewed the variant callers, 
however, to our knowledge, no comparison has been performed on the combination 
of mapping and variant calling algorithms in the context of mutation discovery.  
Here, we analyzed and compared nine different combinations of a mapping and 
variant calling algorithms and particularly investigated to what extent low coverage 
positions can be included in the variation calling process to increase the sensitivity of 
mutation detection. Next, we apply the optimized pipeline to identify mutations in a 
set of 58 cancer genes and 39 candidate genes, across 18 T-ALL cell lines and 15 T-
ALL patient samples, and identify recurrent mutations in both known and novel 
drivers. 
 
RESULTS 
 
Comparison of mapping and variation calling methods for Roche/454 
data 
The Roche companion software gsMapper is mostly used for the analysis of 
Roche/454 data. This software first aligns the reads to the reference genome and 
then lists all positions that are different from the reference genome (variant calling). 
Although gsMapper performed well in several studies 3-5, we wanted to assess its 
performance on our data set and investigate whether we could achieve better 
precision and accuracy using alternative aligners and variant callers. We tested eight 
different combinations of a long read aligner (BWA-SW, SSAHA2, BLAT) and a 
variant caller (SAMTools, VarScan, Atlas-SNP2) and compared their performance 
with gsMapper.  
Each pipeline was applied to the reads obtained from seven T-ALL cell lines and the 
performance of each pipeline was evaluated by Sanger re-sequencing of 210 candidate 
variants that were randomly taken from all predicted 8020 variants (containing 
both SNPs and mutations) from all pipelines. As a measure of the performance of 
each pipeline, we calculated the Matthews correlation coefficient (MCC), which is a 
measure of prediction accuracy that is calculated based on the number of 
successfully predicted true positives and true negatives found by Sanger sequencing 
(see Materials and Methods). When using default parameter settings (Table S1), 
the performance of the different pipelines was comparable, with an average MCC of 
0.62, with no alternative pipeline performing better than gsMapper (MCC of 0.82) 
(Table S1).  
In NGS studies, the presence of duplicate reads (caused by a PCR amplification step 
during library preparation) is a potential source of false positive single nucleotide 
variant (SNV) prediction 12. Therefore, we added an additional step to remove 
duplicate reads using Picard, resulting in a 2-24 % increase in MCC, depending on 
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the pipeline, with an average MCC of 0.73 (Table S1). This showed that duplicate 
removal is an important step for obtaining correct variant calls.  
Next, we further optimized the performance of each pipeline by varying the minimal 
required number of reads (depth of coverage, DoC) and the minimal required 
variant reads (variant allele frequency, VAF). Changes in DoC thresholds mainly 
affected the sensitivity, while varying VAF thresholds affected the predictions in 
terms of specificity (Figure 1.A, Table S2).  
 
Figure 1. Performance comparison and parameter optimization. 
(A) Different pipelines show different sensitivity and specificity. Varying DoC and VAF thresholds in the 
variant calling process has an additional affect on the predictions in terms of sensitivity and specificity, 
respectively. Each pipeline is represented with a different symbol and the performance of each pipeline (in 
terms of sensitivity and specificity) is plotted under varying DoC and VAF thresholds. Note that the X-
axis represents the false positive rate (1-specificity). In this ROC plot, the closer the point to the upper 
left point of the graph, the better the sensitivity and the specificity. Different colors of the symbols 
indicate the performance of the pipeline under changing VAF thresholds, and the two shaded boxes indicate 
the performance under changing DoC thresholds. The plot shows that (i) decreasing the DoC threshold 
increases the sensitivity of all pipelines as indicated with the blue dotted line; (ii) increasing the VAF 
threshold increases the specificity with a slight decrease in sensitivity as indicated (in the example of 
BLAT+VarScan pipeline) with the red dotted line; (iii) the BWA-SW+SSAHA2+Atlas-SNP2 pipeline has 
the best performance among all pipelines under DoC=3 & VAF=0.20 thresholds as indicated with the 
yellow arrow. The Roche pipeline is indicated with a black diamond shape since no parameter changes were 
performed on it, and SSAHA2+SAMTools and BWA-SW+SAMTools pipelines were colored grey since no 
VAF threshold changes were performed on them. (B) The Matthews correlation coefficient for each pipeline 
is shown for the most optimal performance of that pipeline (Table S1). It is interesting to note that the 
optimal performance of all the pipelines, except Roche gsMapper, was observed for a DoC threshold of 3.  
 
 
 
All the pipelines reached their best performance with a DoC threshold of 3, and 
with a minimum VAF threshold of 0.20 (when applicable) (Table S1-S2). In a 
final effort to minimize false positive predictions, we combined the two best mapping 
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algorithms in one pipeline, which further increased the sensitivity to 95% and the 
specificity to 93%. The reason for this increase in accuracy is that certain predicted 
variants that are caused by erroneous mapping (Figure S1) are now filtered out. 
Although this final pipeline (SSAHA2 + BWA-SW + Atlas-SNP2) performs better 
than gsMapper (91.2% sensitivity and 90.8% specificity), the difference is not large 
and gsMapper can be considered as a valid (and often easy to use) alternative 
(Figure 1.B). 
  
Widespread mutations in cancer genes across 18 T-ALL cell lines and 15 
T-ALL patient samples 
We applied the optimized pipeline determined above, consisting of the 
SSAHA2+BWA-SW combination for read mapping, and Atlas-SNP2 for variation 
calling, to identify mutations in a panel of 58 “cancer genes” across 18 T-ALL cell 
lines and 15 primary T-ALL patient samples. This set of genes consists of 13 T-
ALL drivers (Figure 2.A.I) and 45 other genes involved in a variety of cancers 
(Figure 2.A.II). All of these genes are present in the Census 2 database of cancer 
genes except for the recently discovered cancer genes ATOH1 and PHF6 13 14. Since 
PHF6 mutations are involved in T-ALL we added PHF6 to our list of T-ALL 
drivers.  
Sequence reads were mapped to the entire reference genome and those reads that 
map to the selected genes were retained. This resulted in 36% of reads that map to 
the target sequences on average, with an average coverage of 24.2X and 16.3X for 
cell lines and patient samples, respectively. Analysis of the sequence data revealed 
that exons with a very low coverage had a significantly higher GC-content compared 
to exons with higher coverage (p-value 2.2e-16), a finding consistent with a 
previously published study 15 (Figure S2). Of the 1565 exons targeted in this 
study, 18 exons had no coverage in the cell lines or in the patient samples 
(corresponding to 8710 bps); and 15 exons had no coverage in the patient samples 
only (corresponding to 5197 bps). On average, 94% and 86% of the targeted exons 
reached a mean coverage equal or above 3 for the cell lines and the patient samples, 
respectively.  
Variation calling resulted in 836 distinct single nucleotide variants (SNVs) in known 
cancer genes across the 33 samples. Cell lines had significantly more SNVs in cancer 
genes than patient samples (p-value <0.001); on average 153 SNVs were detected 
per cell line and 117 per patient sample. 56% of the predicted SNVs were reported in 
dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP/) or in the 1000 Genomes 
project (http://www.1000genomes.org/) and were excluded from further analysis, 
while the remaining 368 SNVs (Table S3) affected 55 of the 58 sequenced cancer 
genes, primarily in the exons (58.4%) and in untranslated regions (23.9%). 
Furthermore, there were 8 SNVs affecting splice sites. Of the exonic SNVs, 14 result 
in the gain of a stop codon (called “stop gain” SNVs), 140 are non-synonymous and 
the remaining 61 are synonymous coding variations.  
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To validate the mutations found in cell lines, we compared our results with 
mutations determined by the Cancer Cell Line project 16, which contains eleven of 
our 18 cell lines. Of the 35 oncogenic point mutations found in the Cancer Cell line 
project (determined by capillary sequencing) in the genes that are included in our 
panel, 31 were recovered by the automated re-sequencing on Roche/454 using the 
SSAHA2 + BWA-SW + Atlas-SNP2 analysis pipeline, corresponding to a recovery 
rate of 88.5% (Table S4). Note that gsMapper recovered 30 mutations out of 35, 
resulting in a recovery rate of 85.7%. The mutations that were missed by Roche/454 
sequencing are either due to low coverage at those positions (in two of the four 
missed mutations, both in NOTCH1), or to low variant quality (one TP53 
mutation), or to sequencing errors (one NOTCH1 mutation is covered by 10 reads, 
none of which contains the variant allele reported by the Cancer Cell line project).  
With regards to specificity, both pipelines performed well, for example on the 
FBXW7 gene for which we find a protein altering point mutation in exactly the 
same five cell lines as the Cancer Cell line project (out of the eleven common cell 
lines). In conclusion, the automated re-sequencing using Roche/454, with either the 
gsMapper pipeline or the SSAHA2 + BWA-SW + Atlas-SNP2 pipeline, is to a very 
large extent in agreement with mutations found by capillary sequencing.  
Thirteen of the 58 cancer genes have been linked specifically to T-ALL, and we 
identified protein altering mutations in at least one of these genes in all cell lines and 
in 10 patient samples (Figure 2.A.I). Of the other 45 cancer genes, 36 genes were 
mutated (Figure 2.A.II), of which 25 were mutated in at least two samples (cell 
line or patient). The genes with most mutations in T-ALL cell lines are NOTCH1 
(non-synonymous mutation in 9/18 cell lines), TP53 (10/18), FBXW7 (7/18), and 
NRAS (5/18). These also have mutations in patient samples, except TP53, 
suggesting that it may be easier to obtain cell lines from samples with TP53 
mutation or that TP53 mutations are acquired during cell culture 17. 
 
 
Figure 2: Mutations in the 97 genes (next page). 
Coding mutations in known cancer genes (A) and candidate genes (B) are indicated with different color 
codes. Panel A is further subdivided into (I) genes that are known to be drivers in T-ALL, and (II) the 
genes that have recurrent somatic mutations in various human cancers. The cell lines are located to the left 
of the table, and the patient samples are located to the right. Genes are ranked according to the frequency 
of protein altering mutations in the patient samples. 
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Identification of recurrent JAK3 mutations in T-ALL  
We next determined if mutations in cancer genes could be identified that were 
previously not linked to T-ALL. We found several such mutations in T-ALL cell 
lines (Figure 2.A.II), but their absence in the patient samples questions their 
relevance for the pathogenesis of T-ALL.  
We identified several mutations in JAK2 and JAK3 in both cell lines and patient 
samples. All JAK kinases, except TYK2 (see below), are known oncogenes in 
leukemia and activating mutations and translocations affecting JAK1, JAK2 and 
JAK3 were described in multiple, mainly myeloid, hematologic malignancies 18. Until 
recently, JAK1 was the only JAK family member in which point mutations have 
been described in T-ALL 19. However, in a recent article JAK3 gain-of-function 
mutations were described in T-ALL by Elliott et al. 20. In our study, we have 
identified 3 non-synonymous coding mutations in 2 patients for JAK2 (patient 
TLE37 had two mutations) and 4 non-synonymous coding mutations in 1 patient 
and 2 cell lines (SUPT1 cell line had two mutations) for JAK3. (Table S3). Sanger 
sequencing confirmed one JAK2 and all JAK3 variations (Table S5, Figure 3.A-
B). Complementary Sanger sequencing of all exons of the JAK2 and JAK3 genes in 
31 additional T-ALL patients identified 1 additional JAK2 variant and 2 additional 
JAK3 variants (Table S5, Figure 3.A-B). So, in total, we identified JAK2 
mutations in 2 of 46 (4%) T-ALL samples and in 0 of 18 T-ALL cell lines and JAK3 
mutations in 2 of 46 (4%) T-ALL samples and in 2 of 18 T-ALL cell lines (Table 
S5, Figure 3.A-B). For JAK2, both mutations were also present in a 
corresponding remission sample, whereas all JAK3 patient mutations were 
somatically acquired. Interestingly, patient TLE44 showed 2 somatic mutations in 
JAK3, namely A572T and M511I, which were detected on the same allele (data not 
shown). Moreover, the M511I mutation has been detected before in AML and over-
expression of this mutant transformed IL3 dependent 32D cells and induced T-ALL 
in mice 21. Whereas the A572T mutation was not described before, JAK3 amino acid 
A572 was found mutated into a V (A572V mutation) in T-cell leukemia, T-cell 
lymphoma, and AML, and this A572V mutant transformed cytokine dependent 
hematopoietic cells and induced leukemia in mice 21-24.  
 
Identification of new oncogenes and tumor suppressor genes in T-ALL 
Searching for novel T-ALL driver genes can be performed by whole-exome 
sequencing or other genome-wide approaches. Nevertheless, the Roche/454 platform 
combined with sequence capture could be useful in a candidate gene approach. In 
our targeted re-sequencing approach, 39 genes were included that were not causally 
linked to cancer, but were selected as candidate oncogenes or tumor suppressor 
genes, because of their function (e.g., tyrosine kinases and tyrosine phosphatases) or 
because family members had been implicated in cancer (e.g., TYK2 for the JAK 
family, TET1 because TET2 is a known cancer gene). Figure 2.B indicates the 
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exonic and splice site mutations observed in these genes and the genes were ranked 
according to the recurrence of protein altering variants across patient samples.  
 
Figure 3: JAK kinase mutations.  
(A) Sanger sequencing chromatograms corresponding to confirmed JAK2/JAK3 variants. (B) Domain 
structure of JAK2 and JAK3 proteins with indication of novel detected variants. Non-somatic variants are 
indicated with an asterisk. (C) Sanger sequences showing examples of TYK2 variants detect in T-ALL cell 
lines or in leukemia patient samples. (D) Schematic representation of TYK2 protein structure with 
indication of all novel TYK2 variants detected in this study. Non-somatic variants are indicated with an 
asterisk. 
 
 
Interestingly, 4 of the 15 sequenced patient samples contain a variation in TET1. 
The TET gene family (TET1, TET2, TET3) of epigenetic regulators is important 
for the hematology field because of the observation of TET2 mutations in 10-25% 
patients with various myeloid hematologic diseases 25-27. To better assess the 
mutation frequency of TET1 in T-ALL, we performed supplemental Sanger 
sequencing of TET1 in all cell lines and patient samples and in a panel of 22 
additional T-ALL cases. Overall, this resulted in the identification of TET1 variants 
in 5/37 (13.5%) of analyzed patients and in 1/18 T-ALL cell lines (KARPAS-45) 
(Table S6 and Figure 4). The somatic status of detected TET1 variants was 
confirmed for 1 case (H1297Y) where a remission sample was available. We also 
investigated the variants in TET2 and TET3 picked up by 454 and performed 
additional Sanger sequencing for these genes. TET2 variants were detected in 2 cell 
lines (JURKAT and KARPAS45) and one TET3 variant was detected in the 
CHAPTER III: RESULTS 
40 
C
HAPTER III: R
ESULTS 
CCRF-CEM cell line, no T-ALL patient samples (0/46) harbored acquired TET2 or 
TET3 mutations (Table S6).  
 
Figure 4: TET1 mutations in T-ALL.  
(A) Sanger sequencing chromatograms representing confimed TET1 variants. (B) Schematic representation 
of TET1 protein structure with indication of all novel TET1 variants detected in this study. Variants 
detected in cell lines are depicted above the TET1 protein, variants detected in leukemia patient samples 
are below the TET1 protein. Non-somatic variants are indicated with an asterisk. 
 
 
Mutations in tyrosine phosphatase genes, that act as negative regulators of tyrosine 
signaling, were identified in many T-ALL cell lines and also in several T-ALL 
patients. Additional mutations in SPRY genes, negative regulators of the 
RAS/MAPK pathway, were also detected. We identified a homozygous variation in 
SPRY3 in one T-ALL patient sample, and 3 mutations in SPRY4 (2 mutations in 
cell lines and 1 somatically acquired mutation in a T-ALL patient sample). Sanger 
sequencing confirmed the presence of these mutations, but did not reveal any 
additional mutations of SPRY3/SPRY4 in 22 additional T-ALL cases, bringing the 
SPRY4 mutation frequency to 1/37 T-ALL patients and 2/18 T-ALL cell lines 
(Table S7, Figure 5).  
 
Finally, we also identified several mutations in tyrosine kinases (IGF1R, TYK2, 
TNK1, and MST1R) and associated signaling proteins (IRS2, SOCS3), but the 
majority of these mutations were found in cell lines, while primary patient samples 
showed a much lower frequency of these mutations. The most frequently mutated 
gene across all cell lines and patient samples was the insulin receptor substrate 2 
(IRS2) gene, showing non-synonymous coding mutations in 6 cell lines and in one 
patient sample. Also frequently mutated was TYK2, with mutations observed in 6 
cell lines; one stop-gain variant and 5 non-synonymous coding variants. Although 
none of the 15 patient samples carried a mutation in TYK2, it could be present at 
low frequency in patients. To test this, we performed complementary sequencing of 
TYK2 in 93 T-ALL, 54 AML and 53 B-ALL patient samples. Despite the high 
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frequency of TYK2 variations in T-ALL cell lines, TYK2 variants were detected only 
in 2 of 93 T-ALL and 1 of 54 AML cases (Table S5, Figure 3.C-D).  
 
Figure 5: SPRY4 mutations  
(A) Sanger sequencing chromatograms showing confirmed SPRY4 variants. (B) Domain structure of the 
SPRY4 protein with indication of novel detected variants.  
 
 
Evidence for the accumulation of specific mutations during in vitro 
culture of the T-ALL cell lines 
The mutation frequency of TYK2 in T-ALL cell lines compared to primary T-ALL 
samples was substantially different, with a high mutation rate of TYK2 in cell lines, 
but only a low mutation rate in primary samples. To determine if this could be due 
to the accumulation of TYK2 mutations during culturing of the cells, we sequenced 
TYK2 in different clones of the same T-ALL cell line (Table 1). For the CCRF-
CEM cell line, we obtained 5 different subclones that were collected over the years. 
Interestingly, whereas the R1027H variant was present in all analyzed samples, the 
A35V variant was only present in our line and in one additional CCRF-CEM clone. 
In the KARPAS-45 cell line, the Q830* variation was present in 3 different clones. In 
contrast, only our JURKAT line contained the C192Y mutation, while this was 
absent in 2 other clones available at DSMZ (www.dsmz.de) (Table 1). These data 
suggest that at least some TYK2 mutations were acquired during extended 
cultivation of the cells, and thus are unlikely to represent an oncogenic event 
important for the development of leukemia in vivo. In addition, analysis of the 
transforming properties of these mutants in Ba/F3 cells could not identify major 
differences between wild type TYK2 and variants of TYK2 detected in cell lines or 
patient samples and we could not show any autophosphorylation of TYK2 in T-
ALL cell lines containing TYK2 variants (data not shown).  
These data confirm important differences between cell lines and primary patient 
samples, which may reflect the accumulation of mutations during in vitro cell 
culture. 
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Table 1. Analysis of TYK2 variants in cell lines over time and in different subclones.  
Presence of the TYK2 R1027 and A35V variants was tested in the CCRF-CEM cell line from our group 
(“CCRF-CEM Cools lab”) as well as in the CCRF-CEM cell line as it is currently sold by DSMZ (“CCRF-
CEM 2011 DSMZ (ACC240)) and in 5 different CCRF-CEM subclones that DSMZ collected over the years. 
Similarly, KARPAS-45 from the Cools lab and the KARPAS-45 lines obtained from DSMZ in 2011 and in 
1994 were screened for presence of the TYK2 Q830* variant. JURKAT cells from the Cools lab as well as 
JURKAT provided by DSMZ in 2011 and 1992 were tested for the TYK2 C192Y variant. 
*: This cell line has 4 copies of chromosome 19 containing TYK2. The height of the variant peak on the 
chromatogram suggests that only 1 copy of TYK2 contains the Q830* variant 
 
Cell line Tested variant Result 
CCRF-CEM Cools lab R1027H present 
CCRF-CEM 2011 DSMZ (ACC240) R1027H present 
CCRF-CEM subclone 1 DSMZ R1027H present 
CCRF-CEM subclone 2 DSMZ R1027H present 
CCRF-CEM subclone 3 DSMZ R1027H present 
CCRF-CEM subclone 4 DSMZ R1027H present 
CCRF-CEM subclone 5 DSMZ R1027H present 
CCRF-CEM Cools lab A35V present 
CCRF-CEM 2011 DSMZ (ACC 240)  A35V present 
CCRF-CEM subclone 1 DSMZ A35V absent  
CCRF-CEM subclone 2 DSMZ A35V absent  
CCRF-CEM subclone 3 DSMZ A35V absent  
CCRF-CEM subclone 4 DSMZ A35V absent  
CCRF-CEM subclone 5 DSMZ A35V absent  
KARPAS-45 Cools lab Q830* present* 
KARPAS-45 2011 DSMZ (ACC105) Q830* present* 
KARPAS-45 1994 DSMZ (ACC105) Q830* present* 
JURKAT Cools lab C192Y present 
JURKAT 2011 DSMZ (ACC 282)  C192Y absent 
JURKAT 1992 DSMZ (ACC 282)  C192Y absent 
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DISCUSSION 
 
We demonstrated that the targeted sequencing approach with an optimized analysis 
setting can be used to identify oncogenic mutations. This approach could be of 
particular interest for the detection of point mutations in a set of important 
oncogenes and tumor suppressors or other disease related genes for diagnosis, 
prognosis prediction or therapy choice. Such information could be generated in a 
relatively short timeframe and with unprecedented detail. One of the major 
advantages over classical Sanger sequencing is the higher throughput of this method 
allowing that all exons of a gene set of this size can easily be sequenced. As such, full 
information is provided and rare variants or even previously undiscovered mutations 
in a particular gene can be detected. Indeed, of the 160 exonic and splice site 
variants (excluding the 61 synonymous variations) detected in the cell lines and 
patient samples across our panel of cancer genes, only 40 are found in the COSMIC 
database 16, of which 24 are associated specifically with T-ALL. Although for some 
genes mutation hotspots exist (e.g., the KRAS G12, G13, Q61 mutations), the 
function of most cancer genes can be affected by mutations at different positions. 
Therefore, for most cancer genes the entire coding sequence needs to be re-
sequenced, and for this the Roche/454 technology is particularly suitable.  
To detect mutations using next-generation sequencing - either to replace or 
complement molecular diagnosis - standardized bioinformatics analysis pipelines with 
very high accuracy are required. Such a pipeline consists of a mapping algorithm to 
align the sequence reads to the reference genome, a variation calling algorithm to 
identify differences between the sample and the reference, and a variation filtering 
algorithm. 
We compared multiple combinations of mapping and variation calling algorithms, 
and found that combining two mappers, namely SSAHA-2 and BWA-SW, followed 
by Atlas-SNP2 yields the most accurate variation detection results. Adding two 
mapping algorithms filters out false positive variant predictions due to erronous 
mapping, and the error model of Atlas-SNP2 enables the elimination of reads that 
have multiple best matches in the reference genome. We also found that additional 
data filters on depth of coverage and on variant allele frequency further increased 
both the sensitivity and specifity of variation detection.  
We encountered several technical limitations during data analysis. First, we had to 
remove duplicate reads introduced by PCR amplification steps during sample 
preparation since we noticed these were causing false positive SNV predicitons. 
Second, we could only predict SNVs, while indels (small insertions and deletions) 
had to be ignored since our work (data not shown) and previous studies indicate 
that 454 reads are not suited for indel detection due to the large amount of false 
positive results 4. In a diagnostic setting, where 100% specificity is pursued, it is 
critical to identify genes or regions in genes that are prone to acquisition of indels 
and to design alternative assays to investigate them. Likewise, genomic 
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rearrangements are important causes of T-ALL but require complementary 
detection technologies.  
We believe that using a long read sequencing technology, such as Roche/454 or the 
more recent Pacific Bioscience, provides particular advantages with regards to both 
sensitivity and specificity of variation detection. First, long read alignment allows 
better distinction between highly similar genes in the genome. For example, one of 
the genes we re-sequenced was NOTCH1, a gene with multiple homologs (namely 
NOTCH2, NOTCH2Nl, NOTCH3 and NOTCH4). However, we observed no reads 
mapping to any of these homologs, even though we mapped the reads to the entire 
genome. This indicates that both the sequence capture and the mapping were 
specific. On the other hand, we also encountered an example where the sequence 
capture was not specific. Namely, the PMS2 gene is one of the targeted genes in our 
study, yet we observed reads mapping to the PMS2 pseudogene, PMS2CL, which 
contains the first six exons of PMS2 gene. Thanks to the use of long reads, this 
causes no problems for variation detection because for each gene the respective reads 
mapped uniquely to the correct gene, either PMS2 or PMS2CL. Note that the 
capture technology provides additional cues to achieve higher specificity because not 
only the exons are covered in the capture but also the flanking intronic regions. 
Therefore, the alignment is ‘aided’ by the intronic regions, where sequence similarity 
between homologs is lower, allowing for the reads to be correctly attributed to their 
origins in the genome.  
Second, mapping long reads to a reference genome is more robust towards extensive 
local variation, which can be present in particular genomic regions, or can be higher 
when samples are sequenced from a different ethnicity compared to the reference 
genome 28. We indeed found several regions that contain a high number of SNPs 
within a short sequence window. For example, there are 22 SNP clusters across all 
samples in a window of 200 bp with at least 3 SNPs, and 5 distinct clusters in a 
window of 100bp with at least 3 SNPs. Figure S3 shows several examples, such as 
cluster of three SNPs within 100bp in the SUMF1 gene in the ALLSIL cell line, and 
a cluster of 4 SNPs in a 200bp window in the PTPRM gene in CCRF-CEM cell line. 
Nevertheless, in both cases a high coverage is obtained (36x and 46x respectively). 
These examples show that long reads enable a correct alignment and variation 
discovery, in contrast to short read sequencing technologies for which the mapping 
algorithms usually allow for a maximum of two mismathes per read. 
We applied our analysis strategy to T-ALL by sequencing a set of 97 genes. This set 
consists of 58 known oncogenes and tumor suppressors in T-ALL and other cancers, 
and 39 genes selected via a candidate approach. Regarding the identification of 
variations in these genes using 454 sequencing and our optimal optimized analysis 
pipeline, we reached 95% sensitivity and 93% specificity on a confirmation set of 210 
variants validated by capillary sequencing. Furthermore, we detected 85.7% of the 
mutations reported in 11 cell lines that were also sequenced in the Cancer Cell Line 
project. High performance of our resequencing approach is also illustrated by the 
fact that we identified mutations in known candidate drivers in T-ALL that were 
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included in the collection of known cancer genes such as NOTCH1 29, FBXW7 30, 
PTEN 31, PHF6 14, WT1 32,33 and PIK3CA 34.  
We detected mutations in several known cancer genes where a link to T-ALL has 
not been established yet, such as JAK3. Interestingly, a recent article confirmed the 
mutation status of this gene in the context of T-ALL 20. We also identified novel 
mutations in genes that were not previously associated with T-ALL tumorigenesis 
such as TET1, SPRY3 and SPRY4.  
It is remarkable that more novel sequence variants are found per cell line sample 
than per patient, and that genes were in general more frequently mutated in cell 
lines than in patients. Excessive gene mutations can be explained by potential 
genomic instability of cells in culture, or can be caused by in vitro cell culture 
conditions. This hypothesis could be confirmed for TYK2, a very striking example 
for which 7/18 (38%) T-ALL cell lines contain novel TYK2 sequence variants as 
opposed to only 2/93 (2%) T-ALL patients. Interestingly, we could demonstrate 
that several TYK2 variants in cell lines had been acquired during culture. It remains 
to be determined what is promoting the frequent acquisition of TYK2 variants in 
these T-ALL cell lines as opposed to T-ALL patients. The most obvious explanation 
are differences between the in vitro cell culture conditions and the physiological 
environment of T-ALL cells. As several cytokine signaling pathways depend on 
TYK2, presence of different cytokines and/or different concentrations of cytokines 
that use TYK2 signaling might be critical. These observations underscore once more 
that data obtained from cell culture models should be interpreted with care, 
especially when extrapolating these data to patient samples.  
It is nevertheless interesting to note that this tendency of higher mutation frequency 
in cell lines compared to patient samples does not extend to all analyzed genes. The 
most evident example is TET1, showing novel variants in only 1/18 cell lines 
(KARPAS-45) versus 5/37 (13.5%) patients.  
 
In conclusion, we describe a method for fast re-sequencing of a moderate size gene 
set of 97 genes using 454 next generation sequencing equipment that would be 
suitable for implementation into the clinic. Our results show that this setting is 
useful to identify (i) known mutations in known driver genes; (ii) new mutations in 
known drivers; and (iii) oncogenes or tumor suppressors that had not previously 
been associated with a specific subtype of cancer based on a candidate gene 
approach. 
The optimized data analysis pipeline, which was assembled from publicly available 
tools, slightly exceeded the performance of the Roche gsMapper software with 95% 
sensitivity and 93% specificity for SNV detection, and subsequent analysis of the 
Roche/454 data from the T-ALL cell lines and patient samples confirmed previously 
known oncogenes and tumor suppressors in T-ALL and identified previously 
unrecognized rare somatic mutations in TET1 and SPRY4 in T-ALL patients. 
Screening a larger patient series should reveal the exact mutation frequency of these 
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genes in T-ALL and whether mutations in these tumor suppressors also play a role 
in other types of hematopoietic malignancies.  
 
MATERIALS AND METHODS 
 
Targeted genes 
97 genes were selected for sequencing in this study. The gene set consists of genes 
that are known to be involved in oncogenesis of T-ALL (and other cancer types), 
and a large set of kinases and phosphotases due to their potential therapeutic value. 
In total, 56 of the selected genes have been causally implicated in cancer according to 
Census 2 (extracted on 10th of November 2011) and 81 have somatic mutations in 
cancer according to COSMIC 16 (v48 release). According to the Molecular Signature 
Database 35 extracted on 10th of September 2010) there are 40 tumor suppressors 
and 32 oncogenes among the targeted 97 genes. Twenty of the 24 known cancer 
genes from the NCI-60 cell line set 36 are also included in the selected genes. 
Functional classification of the genes performed with DAVID 37 shows enrichment 
for GO terms related to cell proliferation and to signaling cascades, besides the 
expected enrichment for kinase and phosphotase activity (Figure S4; Table S8). 
 
Cell lines and patient samples 
All T-ALL cell lines originated from DSMZ (Braunschweig, Germany). Samples from 
patients with T-ALL (n = 93) , Acute myeloid leukemia (AML) (n = 54) and B-cell 
acute lymphoblastic leukemia (B-ALL) (n = 53), obtained at diagnosis and 
remission samples from T-ALL patients (n = 42) were collected at the University 
Hospital Leuven and VU Medical Center Amsterdam. Diagnosis of T-ALL, AML or 
B-ALL was based on morphology, cytogenetics and immunophenotyping according 
to the World Health Organization and European Group for the Immunological 
Characterization of Leukemias (EGIL) criteria. Informed consent was obtained from 
all subjects and experiments were approved by the ethical committee of the 
University Hospital Leuven.  
 
Sequence capture and pyrosequencing 
Preparation of a shot-gun DNA sequencing library and capture of the exons, with 
flanking intron junctions of 97 genes (Table S9) was performed on custom 
designed Nimblegen sequence capture 385K Version 2.0 Arrays (Roche Applied 
Science, Mannheim, Germany) according to the manufacturer’s instructions. The 
content of these arrays is described in (Table S9). Captured DNA was 
pyrosequenced on a GS FLX instrument (Roche).  
 
Evaluation of the alignment and variant calling algorithms 
The performance of the alignment and variant calling algorithms was evaluated to 
determine the optimal method for analyzing 454 reads. Eight analysis pipelines were 
constructed from long read aligners BWA-SW 1, SSAHA2 7, BLAT 8 and variant 
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callers SAMTools 9, VarScan 10, Atlas-SNP2 11. (We will use the term ‘pipeline’ to 
refer to a combination of an aligner and a variant caller in the remaining part of 
this manuscript.) In addition to these pipelines, gsMapper was also included in the 
evaluation. The aligners map the sequence reads to the human reference sequence 
(NCBI Build 36.1). To remove duplicate reads in the data, the alignments generated 
by SSAHA2 and BWA-SW were processed further using Picard 38 (BLAT 
alignments were not “dedupped” since Picard requires the alignments in BAM 
format, and format conversion was not possible). Reads mapping to multiple 
locations in the reference genome (possibly coming from the homologes and/or 
pseudogenes of the genes targeted in the capture) are marked with a mapping 
quality of 0.  
The pipelines were implemented and reviewed on 7 cell lines: P12ichikawa, KE-37, 
ALL-SIL, CCRF-CEM, KARPAS45, SUPT1, DND41.  
Initial SNV predictions were performed with following settings:  
• SAMTools: with pileup -c command, with total coverage threshold of 3 and 
SNP quality threshold of 20 
• VarScan: with pileup2snp –min_coverage 3 –min_reads2 2 min_avg_qual 15 
–min_var_freq 0.01 –p_value 0.99 
• Atlas-SNP2: with total coverage threshold of 3 
• gsMapper: with HCDiff (high confidence differences) strategy; requiring the 
following criteria:  
1. There must be at least 3 reads with the difference.  
2. There must be both forward and reverse reads showing the 
difference, unless there are at least 5 reads with quality scores over 20 (or 30 
if the difference involves a 5-mer or higher).  
3. If the difference is a single-base overcall or undercall, then the 
reads with the differences must form the consensus of the sequenced reads.  
The SNPs to be confirmed with capillary sequencing were selected from the 
predictions generated with these settings.  
Then, predictions from the pipelines were filtered with varying VAF and DoC 
thresholds. Two VAF thresholds (0.20 and 0.30) and two DoC thresholds (3 and 
10) were used. SAMTools pipelines were also processed with samtools varFilter 
command, which implements minimum RMS mapping quality of 25, minimum read 
depth of 3, maximum read depth of 100, SNP within 10 bp around a gap to be 
filtered, and maximum number of SNPs in a window of 10 bp to be 2. Atlas-SNP2 
pipelines were also filtered with posterior SNP-probability threshold P(SNP|Sj,cj).  
The performance of each pipeline was evaluated by Sanger resequencing of 210 
variants that were sampled from the pooled set of all predicted variants from all 
pipelines (Table S10) and the performance of each pipeline was quantified by 
calculating sensitivity, specificity and Matthews correlation coefficient (MCC) which 
ranges from 0, no correlation, to 1, perfect correlation 39.  
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Sanger sequencing  
Whole genome amplified DNA (REPLI-g system, Qiagen, Hildenberg, Germany) 
from primary leukemia or remission samples was used as template for PCR 
amplification of indicated genes. PCR products were Sanger sequenced and 
inspected for the presence of sequence variants using Mutation Surveyer software 
(Softgenetics, State College, PA) and CLC DNA Workbench 6 (CLC Bio, Aarhus, 
Denmark). All variants that were detected in whole genome amplified material were 
subsequently validated in non-amplified original patient material. Primer sequences 
are available upon request.  
 
Data availability 
Sequence data has been deposited at the European Genome-phenome Archive (EGA, 
http://www.ebi.ac.uk/ega/), which is hosted by the EBI, under accession number 
EGAS00001000268.  
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Table S1. Performance comparison of different analysis pipelines and parameter settings 
 
Pipeline 
Default 
parameter 
settings 
Default 
parameter 
settings after 
duplicate removal 
Optimized 
parameter 
settings after 
duplicate removal 
BWA-
SW+SAMTools MCC 0.68 0.75 0.86 
  parameter settings 
varFilter & 
SNP-quality ≥20 
varFilter & SNP 
quality ≥20 
DoC ≥3 & SNP 
quality ≥20 
SSAHA2+SAMTools MCC 0.67 0.74 0.87 
  parameter settings 
varFilter & 
SNP-quality ≥20 
varFilter & SNP 
quality≥20 
DoC ≥3 & SNP 
quality ≥20 
BWA-SW+VarScan MCC 0.56 0.66 0.79 
  parameter settings 
DoC ≥10 & VAF 
≥0.25 
DoC ≥10 & VAF 
≥0.25 
DoC ≥3 & VAF 
≥0.25 
SSAHA2+VarScan MCC 0.61 0.63 0.79 
  parameter settings 
DoC ≥10 & VAF 
≥0.25 
DoC ≥10 & VAF 
≥0.25 
DoC ≥3 & VAF 
≥0.25 
BLAT+VarScan MCC 0.64 0.639* 0.80 
  parameter settings 
DoC ≥10 & VAF 
≥0.25 
DoC ≥10 & VAF 
≥0.25 
DoC ≥3 & VAF 
≥0.30 
BWA-SW+Atlas-
SNP2 MCC 0.59 0.83 0.86 
  parameter settings 
DoC ≥3 & 
P(SNP|Sj,cj)± 
≥0.5 
DoC ≥3 & 
P(SNP|Sj,cj) ≥0.5 
DoC ≥3 & 
P(SNP|Sj,cj) ≥0.5 & 
VAF ≥0.20 
SSAHA2+Atlas-
SNP2 MCC 0.63 0.86 0.88 
  parameter settings 
DoC ≥3 & 
P(SNP|Sj,cj) 
≥0.5 
DoC ≥3 & 
P(SNP|Sj,cj) ≥0.5 
DoC≥3 & 
P(SNP|Sj,cj) ≥0.5 & 
VAF ≥0.20 
gsMapper MCC 0.82 0.82 § 0.82 § 
  parameter settings HCDiff HCDiff HCDiff 
MCC = Matthew's Correlation Coefficient 
* BLAT pipelines without duplicate removal  
§ gsMapper was not subjected to duplicate removal nor further filtering.  
± The posterior variant allele probability at locus j when signal is Sj at a specific variant read coverage, c 
as calculated by Atlas-SNP2. 
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Table S2. Performance of the pipelines under varying parameters 
The table is not included in the thesis due to space constrains and can be obtained through the published 
article.  
 
Table S3. 368 retained SNVs.  
The table is not included in the thesis due to space constrains and can be obtained through the published 
article.  
 
 
Table S4. Point mutations from the Cancer Cell Line project and their detection status by 
different analysis pipelines 
 
Chr 
Position 
(hg19) Sample Gene 
BWA-SW + 
SSAHA2 +Atlas-
SNP2 pipeline ROCHE 
chr17 7578442 BE-13 TP53 1 1 
chr9 139399344 BE-13 NOTCH1 1 1 
chr12 25398284 CCRF-CEM KRAS 1 1 
chr13 28608087 CCRF-CEM FLT3 1 1 
chr17 7578406 CCRF-CEM TP53 1 1 
chr17 7577538 CCRF-CEM TP53 1 1 
chr4 153249385 CCRF-CEM FBXW7 1 1 
chr13 28592653 CTV1 FLT3 1 1 
chr4 153247289 CTV1 FBXW7 1 1 
chr9 139390623 CTV1 NOTCH1 0 0 
chr10 89720852 KARPAS45 PTEN 1 1 
chr17 7578406 KARPAS45 TP53 1 1 
chr17 7577121 KARPAS45 TP53 1 1 
chr2 48027431 KARPAS45 MSH6 1 1 
chr2 48026605 KARPAS45 MSH6 1 1 
chr4 153247289 KARPAS45 FBXW7 1 1 
chr9 139397675 KARPAS45 NOTCH1 0 0 
chr1 115258747 KE37 NRAS 1 1 
chr9 139390816 KE37 NOTCH1 0 0 
chr17 7577124 LOUCY TP53 1 1 
chr17 7578457 MOTL16 TP53 1 1 
chr1 115258747 P12ichikawa NRAS 1 1 
chr10 89720670 P12ichikawa PTEN 1 1 
chr17 7577538 P12ichikawa TP53 1 1 
chr4 153247289 P12ichikawa FBXW7 1 1 
chr10 89692993 RPMI PTEN 1 1 
chr17 7577121 RPMI TP53 1 1 
chr4 153249384 RPMI FBXW7 1 1 
chr17 7577120 SUPT1 TP53 1 1 
chr17 7577138 SUPT1 TP53 1 1 
chr17 7577538 SUPT1 TP53 1 1 
chr3 178936093 SUPT1 PIK3CA 1 0 
chr1 115258747 TALL1 NRAS 1 1 
chr17 7577538 TALL1 TP53 0 0 
chr17 7577548 TALL1 TP53 1 1 
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Table S5. Sanger confirmed variants in JAK genes 
 
Sample 
JAK 
gene 
nucleotide 
change (cDNA) 
# 
reads 
% mutant 
reads 
AA 
change 
Protein 
domain SIFT Conserved Somatic COSMIC 
TLE46 (T-ALL) JAK2 A2681G 21 57% D894G Kinase 0,01 yes no - 
TLE64 (T-ALL) JAK2 A3323G N/A N/A N1108S Kinase 0,51 yes no 33708 
KARPAS45 JAK3 G751A 16 69% A251T FERM 1 no N/A - 
SUPT1 JAK3 G815A 18 44% R272H FERM 0,16 yes N/A - 
SUPT1 JAK3 G1208A 8 38% R403H SH2 0,13 yes N/A - 
TLE44 (T-ALL) JAK3 G1533A 9 44% M511I Pseudokinase 0,11 yes yes 51374 
TLE34 (T-ALL) JAK3 T2021C N/A N/A V674A Pseudokinase 0,01 yes yes - 
TLE44 (T-ALL) JAK3 G1714A N/A N/A A572T Pseudokinase 0 yes yes - 
CCRF-CEM TYK2 G3080A 22 55% R1027H Kinase  0 yes N/A - 
CCRF-CEM TYK2 C104T 20 60% A35V FERM 0,12 no N/A - 
KARPAS45 TYK2 C2488T 17 35% Q830* Pseudokinase 0,76 yes N/A - 
SUPT1 TYK2 C1124T 18 39% A375V FERM 0,2 no N/A - 
DND41 TYK2 C1480T 13 23% P494S SH2 0,86 no N/A - 
JURKAT TYK2 G575A 11 55% C192Y FERM 0,03 yes N/A - 
TALL1 TYK2 T2863C 11 36% Y955H Kinase 0,07 yes N/A - 
CTV1  TYK2 G2810C 52 25% G937A  kinase  0,04 no N/A - 
TLE10 (T-ALL) TYK2 T44C N/A N/A V15A - 0,73 no no - 
TLE90 (T-ALL) TYK2 G821A N/A N/A R274H FERM 0,13 no N/A - 
AML10 (AML) TYK2 C727T N/A N/A R243W FERM 0 no N/A - 
Variants for which no read # and % mutant reads are reported were identified by supplemental Sanger sequencing. Conservation was assessed by means of the region 
based conservation score across 46 species (mce46way 30). Somatic status was tested by Sanger sequencing of a sample of the patient at remission, if available. In case 
a variant has been described in COSMIC before, the COSMIC mutation identifier is reported. 
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Table S6. Sanger confirmed variants in TET genes 
 
Sample Gene 
Nucleotide change 
(cDNA) AA change # reads % mutant reads SIFT Conserved Somatic COSMIC 
KARPAS45 TET1 C4966T R1656C 11 36% 0 yes N/A - 
KARPAS45 TET1 G6358A V2120M N/A N/A 0,01 yes N/A - 
KARPAS45 TET1 C2924T T975I N/A N/A 0,19 no N/A - 
TLE36 (T-ALL) TET1 C2047G Q683E 18 44% 0,15 yes no - 
TLE43 (T-ALL) TET1 C3889T H1297Y 21 57% 0,01 yes yes - 
TLE50 (T-ALL) TET1 C5453T P1818L 37 49% 0,02 yes no - 
TLE48 (T-ALL) TET1 G382T V128F N/A N/A 0,04 yes N/A - 
TLE53 (T-ALL) TET1 G382T V128F N/A N/A 0,04 yes N/A - 
JURKAT TET2 G4759A D1587N 23 48% 0,02 yes N/A - 
KARPAS45 TET2 A3445G T1149A 15 47% 0 yes N/A - 
TLE58 TET2 T2598C Y867H N/A N/A 0,02 yes N/A - 
TLE44 TET2 G5152T V1718L N/A N/A 0,66 no no 41742 
CCRF-CEM TET3 A3239C K1080T 42 40% 0 yes N/A - 
TLE40 TET3 C1319A P440H 7 57% 0,01 yes no - 
Variants for which no read # and % mutant reads are reported were identified by supplemental Sanger sequencing. Conservation was assessed by means of the region 
based conservation score across 46 species (mce46way 30). Somatic status was tested by Sanger sequencing of a sample of the patient at remission, if available. In case 
a variant has been described in COSMIC before, the COSMIC mutation identifier is reported. 
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Table S7. Sanger confirmed mutations in SPRY genes 
Sample Gene 
nucleotide change 
(cDNA) 
# 
reads 
% mutant 
reads 
AA 
change SIFT Conserved 
Somatically 
acquired?  COSMIC 
TLE43 SPRY3 G785T 22 59 C262F 0 yes no - 
KARPAS45 SPRY4 T338A 20 50 I113N 0 yes N/A - 
TLE43 SPRY4 G349A 8 63 G117R 0 yes yes - 
SUPT1 SPRY4 C142T 7 57 R48W 0 yes N/A - 
Variants for which no read # and % mutant reads are reported were identified by supplemental Sanger sequencing. Conservation was assessed by means of the region 
based conservation score across 46 species (mce46way 30). Somatic status was tested by Sanger sequencing of a sample of the patient at remission, if available. In case 
a variant has been described in COSMIC before, the COSMIC mutation identifier is reported. 
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Table S8. Top 20 enriched (a) molecular function and (b) biological process GO terms from 97 
genes  
a) Top 20 biological processes enriched in target genes 
GO_BP 
Coun
t % P-Value 
Corrected 
p-value 
(BH) 
phosphorus metabolic process  51 52.6  1.3E-32  2.0E-29 
phosphate metabolic process  51 52.6  1.3E-32  2.0E-29 
enzyme linked receptor protein signaling pathway  31 32.0  2.4E-25  1.9E-22 
transmembrane receptor protein tyrosine kinase 
signaling pathway  27 27.8  4.4E-25  2.3E-22 
protein amino acid phosphorylation  36 37.1  3.3E-22  1.3E-19 
regulation of cell proliferation  38 39.2  6.5E-22  2.0E-19 
phosphorylation  38 39.2  1.1E-21  3.0E-19 
regulation of phosphorylation  28 28.9  4.5E-18  1.0E-15 
regulation of protein kinase activity  25 25.8  7.0E-18  1.4E-15 
regulation of phosphorus metabolic process  28 28.9  1.2E-17  2.2E-15 
regulation of phosphate metabolic process  28 28.9  1.2E-17  2.2E-15 
regulation of kinase activity  25 25.8  1.5E-17  2.4E-15 
protein kinase cascade  25 25.8  3.5E-17  4.9E-15 
regulation of transferase activity  25 25.8  3.9E-17  5.1E-15 
positive regulation of cell proliferation  23 23.7  5.8E-14  7.0E-12 
intracellular signaling cascade  36 37.1  1.6E-13  1.8E-11 
protein amino acid dephosphorylation  15 15.5  3.5E-13  3.7E-11 
regulation of MAP kinase activity  15 15.5  7.9E-13  7.8E-11 
cell surface receptor linked signal transduction  42 43.3  1.3E-12  1.2E-10 
dephosphorylation  15 15.5  2.7E-12  2.3E-10 
b) Top 20 molecular functions enriched in target genes 
protein tyrosine kinase activity  24 24.7  4.4E-24  1.0E-21 
transmembrane receptor protein tyrosine kinase activity  17 17.5  5.8E-21  6.9E-19 
protein kinase activity  30 30.9  2.7E-17  2.1E-15 
ATP binding  40 41.2  1.3E-14  7.8E-13 
adenyl ribonucleotide binding  40 41.2  2.1E-14  9.7E-13 
purine nucleoside binding  41 42.3  3.3E-14  1.3E-12 
nucleoside binding  41 42.3  4.1E-14  1.4E-12 
ribonucleotide binding  43 44.3  1.1E-13  3.2E-12 
purine ribonucleotide binding  43 44.3  1.1E-13  3.2E-12 
adenyl nucleotide binding  40 41.2  1.1E-13  3.0E-12 
protein tyrosine phosphatase activity  14 14.4  2.6E-13  6.0E-12 
phosphoprotein phosphatase activity  16 16.5  3.9E-13  8.2E-12 
purine nucleotide binding  43 44.3  5.0E-13  9.8E-12 
nucleotide binding  43 44.3  9.9E-11  1.8E-9 
phosphatase activity  16 16.5  1.5E-10  2.4E-9 
kinase binding  14 14.4  2.7E-10  4.3E-9 
enzyme binding  20 20.6  2.3E-9  3.3E-8 
insulin receptor substrate binding  6 6.2  6.4E-9  8.8E-8 
structure-specific DNA binding  11 11.3  5.9E-8  7.7E-7 
non-membrane spanning protein tyrosine kinase activity  7 7.2  3.5E-7  4.3E-6 
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Table S9. 97 selected genes for capture and their targeted exons.  
The table is not included in the thesis due to space constrains and can be obtained through the published 
article.  
 
 
Table S10. Selected positions for Sanger sequencing validation.  
The table is not included in the thesis due to space constrains and can be obtained through the published 
article.  
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Figure S1. Mis-alignment in SSAHA2 causes a false prediction in TET2.  
IGV (Integrative Genomic Viewer) software visualizes alignment of next generation sequencing reads to the 
reference sequence.15 In IGV, each sequence read is represented as a grey rectangle and the reference 
sequence is represented at the bottom. If there is base in a read that is different from the reference sequence, 
it is indicated with the corresponding letter. This figure shows the IGV output when anlayzing the same set 
of reads with the BWA-SW (top) and with the SSAHA2 (bottom) algorithms for sequence alignment. 
Looking at the alignments generated by these two algorithms revealed that SSAHA2 alignment was 
incorrectly positioning 3 reads (as indicated by colored read names on the plot), causing a false variant 
call on chr4:106384366 and resulting false prediction of a non-synonymous coding mutation in the TET2 
gene. 
 
 
 
Figure S2. Low coverage exons have significantly higher GC-content. 
Comparing the GC-content of the exons with low and high coverage revealed that the two groups have 
significantly different GC-content (p-value 2.2e-16), with low coverage exons having higher GC-content. 
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Figure S3: SNP clusters identified in (A) SUMF1 gene in ALLSIL cell line and (B) PTPRM gene 
in CCRF-CEM cell line 
 
 
Figure S4: Functional classification of the 97 selected genes based on molecular function terms. 
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ABSTRACT  
 
T-cell acute lymphoblastic leukemia (T-ALL) is caused by cooperation of multiple 
oncogenic lesions1,2. We used exome sequencing on 67 T-ALLs to gain insight in the 
mutational spectrum in these leukemias. We detected protein-altering mutations in 
508 genes, with an average of 8.2 mutations in pediatric and 21.0 in adult T-ALL. 
Using stringent filtering, we predict 7 novel oncogenic driver genes in T-ALL. We 
identify CNOT3 as a tumor suppressor mutated in 7/89 (7.9%) of adult T-ALL 
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and for which knock-down causes tumors in a sensitized drosophila model3. In 
addition, we identify mutations in the ribosomal proteins RPL5 and RPL10 in 
12/122 (9.8%) of pediatric T-ALL, with recurrent mutation of arginine 98 in 
RPL10. Yeast and lymphoid cells expressing the RPL10 p.Arg98Ser mutant showed 
a ribosome biogenesis defect. Our data provide insights in the mutational landscape 
of pediatric versus adult T-ALL and identify the ribosome as a potential oncogenic 
factor 
 
RESULTS AND DISCUSSION 
 
T-ALL is a genetically heterogeneous leukemia that is caused by accumulation of 
multiple oncogenic lesions, which have been identified through characterization of 
chromosomal aberrations or via candidate gene sequencing4-7. In addition, recent 
whole genome sequencing of 12 immature early T-cell precursor (ETP) ALLs 
revealed several new oncogenic drivers in this T-ALL subtype8. To discover novel 
disease driving genes in pediatric and adult T-ALL, we performed exome sequencing 
on 67 diagnostic T-ALL samples, 39 corresponding remission samples and 17 cell 
lines (Supplementary Tables 1-3).  
For discovering somatic mutations, we limited our initial analysis to the 39 paired 
diagnosis-remission samples. To assess the performance of variant calling, 185 
predicted single nucleotide variations (SNVs) were validated by Sanger sequencing. 
This set was used to detect the filtering strategy with the best sensitivity-specificity 
characteristics. Different parameters were tested as filters, including coverage of the 
variant nucleotide, variant allele frequency, variant quality, and presence in repeat 
regions. Finally, ranging thresholds of the “somatic score”, as calculated by 
SomaticSniper9 were used as filter (Supplementary Fig. 1). Removing variants 
with a somatic score below 70 resulted in 89% sensitivity and 96% specificity. Using 
this filter, a second batch of SNVs was selected for testing with capillary sequencing, 
which confirmed 80% (67 out of 84) of predicted SNVs. 
We identified 1810 somatic SNVs and 1248 insertion-deletions (INDELs) in the 39 
diagnostic-remission pairs. Excessively high numbers of somatic INDELs were 
present in 3 samples, possibly due to defective DNA repair. These INDELs were 
excluded for candidate gene detection. One fourth of the somatic mutations were 
protein-altering, with the majority being missense mutations (413), and the rest 
frame-shift INDEL (55), in-frame INDEL (30), nonsense coding (32) or splice site 
mutations (39). On average, each sample contained 14.7 somatic protein altering 
SNVs and INDELs (Supplementary Table 4). Remarkably, adults (age >15 
years) showed 2.5 times more somatic protein-altering mutations than children (21.0 
versus 8.2; p<0.0001) and there was a clear correlation between patient age and 
mutation number (Fig. 1a-b, Supplementary Fig. 2). However, outcome was 
not linked to mutation number (Supplementary Fig. 3). Interestingly, a larger 
fraction of somatic SNVs in adults were C>T transitions and adults had a lower 
fraction of A>G transitions than children (Fig. 1c-d). 
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Figure 1. Correlation between patient age and mutation number and type. 
(a) Plot showing the number of protein-altering somatic mutations in pediatric (≤ 15 years) and in adult (≥ 
16) T-ALL patients. Average and s.e.m. is indicated on the plots. The p-value tests whether there is a 
significantly different mutation number in adults versus children and was calculated using a 2-tailed 
Wilcoxon signed rank test. Group size pediatric: n=19; adult: n=20. (b) Dot plot representing the number 
of protein-altering somatic mutations versus patient age. (c, d) Plot showing the fraction of somatic SNVs 
that were C>T/G>A transitions (c) or A>G/T>C transitions (d) in pediatric and in adult T-ALL 
patients. Average and s.e.m. is indicated on the plots. Samples with less than 10 somatic SNVs were 
excluded for this analysis. The reported p-value tests whether there is a significant difference between 
adults and children and was calculated using a 2-tailed Wilcoxon signed rank test. Group size pediatric: 
n=16; adult: n=19. 
  
 
 
Protein-altering mutations occurred across 508 genes (Supplementary table 5). 
To distinguish driver from passenger mutations, we only considered genes that were 
mutated in at least 2 samples and that were significantly more mutated than the 
local background mutation rate as calculated by Genome MuSiC10 
(Supplementary table 6). We identified 15 candidate drivers meeting these two 
criteria (Table 1, Fig. 2), and 11 additional genes that were recurrently but not 
significantly mutated (Supplementary Fig. 4). Of the 15 candidate drivers, 8 
were known drivers in T-ALL and 7 were novel. Reassuringly, we found additional 
mutations in many of the 15 candidate drivers across the 28 additional diagnosis 
samples and 17 cell lines that were sequenced (Fig. 2, Supplementary Fig. 5, 
Supplementary table 7). 
Adult samples showed 2.7 times more mutations in candidate drivers than children 
(1.9 versus 0.7; p=0.0034) (Supplementary Fig. 2). Moreover, mutations in 
FBXW7, CNOT3, PHF6, KDM6A and MAGEC3 were mainly in adults whereas 
RPL10 mutations were almost exclusively found in children (Fig. 2+3, Table 1, 
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Supplementary tables 8-10). Notably, our candidate driver list included RPL5 
and RPL10, two genes encoding ribosomal proteins that occupy neighboring 
positions in the 60S ribosomal complex (Supplementary Fig. 6), with 5 exome 
samples carrying the same somatic p.Arg98Ser mutation in RPL10. Also the 
CNOT3 gene showed a mutational hotspot, with 3 patients carrying a p.Arg57 
substitution (Fig. 3a). Mutation screening of these 3 genes in an independent 
confirmation cohort of 144 T-ALLs identified additional mutations in each of these 
genes (Fig. 3a, Supplementary table 8-9), resulting in total mutation 
frequencies of 8/211 (3.8%) for CNOT3 and 15/211 (7.1%) for RPL5 and RPL10. 
Adding the results from the confirmation cohort consolidated the association 
between CNOT3 mutations and adult age (p= 0.01) and CNOT3 was mutated in 
7/89 (7.9%) of adult T-ALLs. In contrast, RPL10 mutations were associated with 
young age (p= 0.03) and 10/122 (8.2%) pediatric cases showed RPL10 mutations 
(Fig. 3b). Mutations in CNOT3, RPL10 or RPL5 were not associated with any of 
the major molecular subgroups in T-ALL, nor with NOTCH1 mutations 
(Supplementary Table 8-10). 
Ribosomal defects have been identified in inherited hematopoietic disorders 
(‘ribosomopathies’) that result in anemia and a propensity to develop leukemia11. 
Mutations in RPL5 have previously been associated with Diamond Blackfan anemia 
and were studied in much detail in that context11, but mutation of RPL10 has not 
been described in any disease. Interestingly, also loss of RPL22, another 60S 
ribosomal protein, was recently identified in T-ALL12, and also in our exome cohort 
we detected 1 patient with an RPL22 frameshift mutation (Supplementary 
Table 5). RPL10 is located on the X chromosome, and 7/11 mutant cases were 
males carrying the mutation in nearly all leukemia cells. Moreover, the single RPL10 
mutated female from whom we had RNA available expressed only the mutant allele 
in the tumor cells (Supplementary Figure 7). To confirm that these RPL10 
mutations were not random passenger mutations but alter RPL10 function, we 
engineered yeast cells to express Rpl10 wild type, Rpl10 p.Arg98Ser, Rpl10 
p.Arg98Cys or Rpl10 p.His123Pro as sole copy. Rpl10 has been intensively studied13 
and is highly conserved in yeast, with Arg98 being unchanged from yeast to human 
(Supplementary Fig. 8a). Interestingly, residues Arg98 and His123 are closely 
apposed in a beta-hairpin near the peptidyltransferase center, the catalytic core of 
the ribosome (Supplementary Fig. 8b-c). 
 
Figure 2. Overview of mutations in 15 identified candidate T-ALL driver genes in 67 patient 
samples. (next page) 
Mutations in 15 candidate T-ALL driver genes across the patient set. For clarity, only patients harboring 
mutations in any of these 15 genes are shown. Each type of mutation is indicated with a different color as 
indicated in the legend and symbols for homozygous, hemizygous, and compound heterozygous mutations 
are explained. Mutations with no indication are heterozygous. All mutations in this figure were validated 
by Sanger sequencing. Relevant patient characteristics (identified by Sanger sequencing, karyotyping, or 
gene expression) are included at the bottom of the figure. Mutations in NOTCH1 were hard to identify by 
exome sequencing due to low capture efficiency and resulting low sequence coverage of NOTCH1. NOTCH1 
mutations detected by Sanger sequencing are indicated in the section patient characteristics of the figure. 
Detailed description of the mutations shown in this figure is in supplementary tables 5, 7, 8 and 9.  
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Table 1. Significantly and recurrently mutated genes 
Gene 
# 
mutant 
patients Gene function 
Associated 
age group 
Associated 
pathologies with 
genomic alterations 
NOTCH1 29/67 (43.3%)* 
transmembrane receptor, 
releases intracellular 
NOTCH1 transcriptional 
enhancer upon acitvation 
none 
T-ALL25; CLL26-27; lung 
cancer28; head and neck 
cancer29-30; breast 
cancer31-32 
FBXW7 8/67 (11.9%) 
Part of ubiquitin-ligase 
complex targeting cyclin E, 
MYC and NOTCH1 
none T-ALL
33; various cancer 
types34 
WT1 7/67 (10.4%) 
zinc finger transcription 
factor none 
T-ALL35; AML36; Wilms 
tumor 
BCL11B 5/67 (7.5%) 
zinc finger transcription 
factor none T-ALL
37 
CNOT3 8/211 (3.8%) 
part of the CCR4-NOT 
complex that regulates gene 
expression 
adult  
RPL10 
11/211 
(5.2%) 
 
ribosomal protein of the 
60S ribosomal subunit 
 
pediatric autism38-39 
RPL5 
4/211 
(1.9%) 
 
ribosomal protein of the 
60S ribosomal subunit 
 
none Diamond Blackfan anemia11 
JAK3 
7/67 
(10.4%) 
 
kinase involved in cytokine 
receptor signaling 
 
none 
T-ALL8,40; various 
myeloid and lymphoid 
malignancies 
PTEN 4/67 (6.0%) 
phosphatase antagonizing 
PI3K function none 
T-ALL18; various cancer 
types 
DNM2 4/67 (6.0%) 
microtubule associated 
GTPase none 
T-ALL8; Charcot Marie 
Tooth disease41; 
centronuclear 
myopathy41 
ODZ2 2/67 (3.0%) 
may function as a cellular 
signal transducer none  
PHF6 12/67 (17.9%) 
plant homeodomain-like 
finger (PHF) family 
protein that may regulate 
transcription 
adult 
T-ALL42; AML43; 
Borjeson-Forssman-
Lehmann syndrome44 
TET1 4/67 epigenetic regulator none t(10;11)(q22;23) (MLL-
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(6.0%) converting methylcytosine 
(5mC) to 5-
hydroxymethylcytosine 
(hmC) 
TET1 fusion) in AML 
and B-ALL45,46,47 
KDM6A 3/67 (4.5%) 
histone demethylase for 
'Lys-27' of histone H3 none 
various cancer types48-49; 
Kabuki syndrome50 
MAGEC
3 
2/67 
(3.0%) 
Gene function unknown. 
Only expressed in normal 
testis and in various tumor 
types. 
none Diffuse large B-cell lymphoma51 
*Note: Mutations in NOTCH1 were hard to identify by exome sequencing due to poor capture efficiency and 
resulting low sequence coverage of NOTCH1. The reported mutation number in this table reflects NOTCH1 
mutations detected by complementary Sanger sequencing.  
 
In yeast, expression of the Rpl10 mutants impaired proliferation and caused a 
ribosome biogenesis defect, evidenced by the altered ratio of mature 80S and free 
subunits and reduced presence of polysomes (Fig. 4a-b, Supplementary Figure 
9). In addition, Nmd3 and Tif6 showed aberrant accumulation in the cytoplasm in 
cells expressing Rpl10 p.Arg98Ser (Fig. 4c, Supplementary Figure 9), 
demonstrating that this mutation impaired release of the 60S export adapter Nmd3 
as well as the subunit anti-association factor Tif6. 
 
Figure 3. Overview of mutations in RPL10, RPL5 and CNOT3. 
(a) Schematic representation of RPL10, RPL5 and CNOT3 protein structure with indication of the 
mutations detected in 211 T-ALL samples. Somatic status of the mutations is indicated as explained in the 
figure legend. Supplementary tables 8 and 9 report on the characteristics of the patients with RPL10, 
RPL5 or CNOT3 mutations. (b) Pie diagrams reporting mutation frequencies detected in adult versus 
pediatric patients. All reported p-values test whether there is a significant difference between mutation 
frequency in adults versus children and were calculated using the unpaired t-test.  
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The deleterious effects of the Rpl10 mutants were partially suppressed by Nmd3 
p.Leu291Phe (Fig. 4d), a mutant with weakened affinity for the ribosome14 and by 
increased gene dosage for Nmd3 ( Supplementary Figure 9).These data indicate 
that these Rpl10 mutants affect release of Nmd3 from the ribosome. Retention of 
Nmd3 and Tif6 on pre-60S subunits blocks ribosome assembly and the resulting 
depletion of Nmd3 from the nucleus reduces export of new ribosome subunits15. We 
also tested the effect of expression of human RPL10 p.Arg98Ser, the most frequent 
RPL10 mutation, in lymphoid cells. Also in these cells, expression of RPL10 
p.Arg98Ser resulted in a proliferation and ribosome biogenesis defect (Fig. 4e-f). 
 
 
Figure 4. Cellular effects of RPL10 p.Arg98Ser mutation.  
The growth of yeast cells expressing wild type (WT) Rpl10 or Rpl10 p.Arg98Ser was compared by plating 
ten-fold serial dilutions (a), and polysome profiles were obtained (b). Fluorescence of Nmd3-GFP and Tif6-
GFP was examined in WT and Rpl10 p.Arg98Ser-expressing cells. Scale bars: 5 µm. (c). In the case of 
Nmd3, cells also contained a leptomycin B (LMB)-sensitive Crm1 and Nmd3-GFP localization was examined 
after treatment with LMB to trap Nmd3 in the nucleus. (d) Rpl10 WT or p.Arg98Ser yeast cells were 
transformed with vector or vector expressing Nmd3 p.Leu291Phe. Ten-fold serial dilutions were grown. (e) 
Proliferation curve of mouse lymphoid B-cells (Ba/F3) expressing RPL10 wt or p.Arg98Ser. Error bars 
represent standard deviations of measurements in triplicate. (f) Polysome profiling on Ba/F3 cells 
expressing RPL10 wt or p.Arg98Ser. 
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In the context of CNOT3, part of the mutations we identified were clearly 
truncating mutations, while another group of mutations seemed to present missense 
mutations at residue Arg57. Analysis of mRNA expression, however, revealed that 
also in the cases with Arg57 mutations, the mutant transcripts are not or weakly 
expressed (Supplementary Figure 7). This is most likely caused by splicing 
defects as the mutations are located at the splice donor site of exon 5. The 
mutations in CNOT3 thus suggest that this gene acts as a tumor suppressor in T-
ALL. CNOT3 is part of the CCR4-NOT complex that regulates gene expression 
transcriptionally and post-transcriptionally16. CNOT3 also mediates self-renewal in 
mouse embryonic stem cells, where CNOT3 shares many target genes with MYC17, a 
known oncogene in T-ALL. To investigate the effect of loss of CNOT3 in tumor 
formation, we utilized an established Drosophila melanogaster eye cancer model. We 
used the “sensitized” model in which the Notch ligand Delta is overexpressed in the 
developing eyes. These flies have larger eyes, but by themselves do not develop 
tumors3,7,18,19, and this model is relevant for T-ALL given the central role of 
NOTCH1 signaling in this disease1. Reduction of Not3 expression in this genetic 
background resulted in a dramatic increase in tumor incidence from 8% of the eyes 
with the control RNAi to 46% up to 90% with 3 different Not3 RNAi lines and one 
line with a P-element insertion in Not3 (Fig. 5). These data support that a 
reduction of Not3 expression is sufficient to transform sensitized cells. Using whole 
exome sequencing, we describe clear differences between pediatric and adult T-ALL 
and identify a spectrum of driver mutations that function in various cellular 
processes. One remarkable observation is that a subset of T-ALL cases have 
accumulated mutations that affect the function of the ribosome, and it is currently 
unclear what advantage this may provide to the cancer cells. This is, however, very 
similar to recent findings of deregulated splicing in myelodysplasia and chronic 
lymphocytic leukemia20,21,22,23, and may indicate that cancer cells have mechanisms to 
overcome defects in these basic processes. Indeed, cancer cells may compensate for 
the deleterious effect of ribosome mutations by acquiring additional mutations, 
similar to the suppressive effect of the Nmd3 p.Leu291Phe mutation that we 
describe in the yeast model (Fig. 4d). Alternatively, the ribosome mutations may 
downregulate the hyperactive translation machinery in cancer cells24, which may be 
beneficial for the fitness of cancer cells. Our data shed light on the diversity of 
mutations that are implicated in T-ALL development and on the differences 
between adult and pediatric T-ALL. 
 
Figure 5. Reduced Not3 expression promotes tumor development in a Drosophila melanogaster 
sensitized background (next page). 
(a,b) Sensitized flies overexpressing the Notch ligand Delta in the eye were crossed to one of three different 
Drosophila melanogaster Not3 RNAi fly lines (v105990, v37545, v37547), to the 15271 line with a P-
element insertion in Not3 or to control RNAi flies (RNAi construct against white gene). The figure shows 
quantitative (a) and qualitative (b) representation of the eye tumor burden in different genotypes. Triple 
asterisks (***) in (a) indicates that tumor incidence in this cross is significantly different from the control 
cross (p<0.001) as analyzed by the 2-tailed Fisher’s exact test. Group sizes per cross are indicated in the 
figure (n). Scale bars in (b): 200 µm. 
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Accession codes 
Sequence and variant data are available via EGA (http://www.ebi.ac.uk/ega/) 
under accession number EGAS00001000296, and somatic variants are available 
through a BioMart interface http://lcbmart.aertslab.org/  
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METHODS  
 
Cell lines 
The Ba/F3 murine pro B cell line and all human T-ALL cell lines were obtained 
from Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ). 
 
Sequencing 
Genomic DNA samples from patients and cell lines were sonicated to fragment size 
250 bp on a Bioruptor UCD-300 TM instrument (Diagenode) followed by library 
preparation using the Truseq DNA sample prep kit (Illumina) and capture with 
CHAPTER III: RESULTS 
74 
 
C
HAPTER III: R
ESULTS 
SeqCapEZ Exome v2.0 (Nimblegen) or Agilent SureSelect 38 Mb (Agilent) capture 
reagents. Captured samples were sequenced on a Hiseq 2000 (Illumina) operated in 
paired-end 2 x 100 bp mode. Reads from each sample were aligned to the reference 
genome version hg19 using BWA52. Alignment files were processed further with 
Genome Analysis ToolKit (GATK) before variant calling. Duplicate removal, local 
realignment around known INDELs, and base quality recalibration has been done as 
described in DePristo et al53. Variants were called with the Variant Quality Score 
Recalibration (VQSR) routine of GATK. Variant calling was performed for each 
sample separately, and somatic variants were identified by selecting the variants 
observed in diagnosis that were absent in remission. The somatic score for each 
variant was calculated with the Somatic Sniper54 algorithm using the processed 
alignment files for diagnosis and remission samples. INDEL calling was performed 
with DINDEL55 using the calibrated bam files for each sample separately. Somatic 
INDEL detection was performed by identifying the high quality INDELs in the 
diagnosis sample (minimum read depth of 15 in the variant site, and 15% of the 
reads supporting the variant allele) and then filtering out the ones observed in the 
corresponding remission sample (minimum read depth of 1).  
 
Sanger validation of results 
All predicted somatic variants shown in Figure 2 were tested and confirmed by 
conventional Sanger sequencing. These and additional Sanger validated SNVs and 
INDELs are reported in Supplementary tables 5 and 7. Overall, we performed 
Sanger validation for 219 SNVs, of which 202 were confirmed (92.2% validation 
rate) and of 78 INDELs of which 61 were confirmed (78% validation rate). Analysis 
of Sanger chromatograms was performed using CLC Main Workbench 6 (CLC Bio). 
Predicted somatic variants that were not confirmed by Sanger sequencing are not 
shown in Figure 2, but are reported in Supplementary Table 5 and are indicated as 
false positives. The entire coding sequence of RPL5, RPL10 and CNOT3 genes was 
PCR amplified and Sanger sequenced on whole genome amplified DNA from an 
independent set of 144 T-ALL patients. Primer sequences are provided in 
Supplementary table 11. Mutation detection was performed using Mutation 
Surveyor v4.0.4 (Softgenetics) software. Detected variants were confirmed on 
original, non-amplified material and were tested for their somatic origin on remission 
DNA if available.  
 
Statistical testing 
Throughout this entire work, statistical significance was defined as p<0.05. Used 
statistical testing methods are mentioned in figures and tables.  
 
Drosophila melanogaster experiments 
The fly line 15271 (y1; P{SUPor-P}l(2)NC136KG10496/CyO; ry506) with a P-element 
insertion in the Not3 gene was obtained from the Bloomington Stock Center56. Not3 
RNAi Fly lines v37547 (w1118;; P{GD4068}v37547), v37545 (w1118;; 
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P{GD4068}v37545) and v105990 (;P{KK102144}VIE-260B;) were purchased from 
the Vienna Drosophila RNAi Center (VDRC)57. Control RNAi flies (w; Sp/CyO; 
UAS-w dsRNA) and the Cy8 ‘‘sensitized” fly (w; eyeless-Gal4, UAS-Dl/ CyO;) were 
described previously3. All fly strains were crossed to Cy8 virgin females. From the 
performed crosses, the following F1 progeny was selected as positive:  
Cy8 x 15271: ;eyeless-Gal4, UAS-Dl/P{SUPor-P}l(2)NC136KG10496; ry506/+ 
Cy8 x v37547: ;eyeless-Gal4, UAS-Dl/+; P{GD4068}v37547/+ 
Cy8 x v37545: ;eyeless-Gal4, UAS-Dl/+; P{GD4068}v37545/+ 
Cy8 x v105990: ;eyeless-Gal4, UAS-Dl, P{KK102144}VIE-260B); 
Cy8 x control: ;eyeless-Gal4, UAS-Dl/CyO; UAS-w dsRNA/+ 
All flies were raised at 25°C on standard fly food. To analyze the tumor burden, 
each eye was scored separately in the selected F1 progeny. Eyes were counted as 
hyperplastic when the eye showed at least one fold. 
 
Yeast experiments 
Codon 98 of yeast (Saccharomyces cerevisiae) RPL10 in the centromeric LEU2 
vector pAJ2522 was changed from AGA to either TCT or TGT, and codon 123 was 
changed from CAC to CCA by site-specific mutagenesis. Wild type and mutants 
were introduced into the Rpl10 deletion strain AJY1437 (MATα rpl10::KanMX 
lys2Δ0 met15Δ0 his3Δ1 leu2Δ0 ura3Δ0 pAJ392 - Rpl10 URA3 CEN) by plasmid 
shuffle or the conditional glucose-repressible Rpl10 strain AJY3373 (MATα KanMX-
GAL1-RPL10 his3Δ1 leu2Δ0 ura3Δ0) and assayed for growth by plating ten-fold 
serial dilutions onto selective medium. To test suppression of Rpl10 mutants by 
mutations in Nmd3, empty vector or vector expressing Nmd3 or Nmd3 p.Leu291Phe 
was introduced into the indicated strains. 
 
Polysome profiles were analyzed as described2. Wild type and Rpl10 mutants were 
introduced into AJY1837, containing a glucose repressible Rpl10 gene (GAL-Rpl10), 
the leptomycin-B (LMB) sensitive allele of Crm1 p.Thr539Cys and Nmd3-GFP, and 
AJY2766, containing GAL-Rpl10 and Tif6-GFP. Cultures were grown in selective 
medium containing galactose. Glucose was added to repress expression of wild type 
genomic Rpl10 for 2 hours and LMB was added to a final concentration of 0.1 
µg/ml for 30 min to block Nmd3 shuttling. Images were captured using a Nikon 
E800 microscope fitted with a 100X Plan Apo objective and a Photometrics 
CoolSNAP ES camera controlled by NIS-Elements AR 2.10 software. Images were 
prepared using Adobe Photoshop 7.0. 
 
Experiments in mammalian cells 
Wild type RPL10 cDNA (ENST00000344746) was PCR amplified from human 
thymus cDNA and was cloned into the BglII and EcoRI sites of pMSCV-GFP. The 
p.Arg98Ser mutation was introduced by mutagenesis of the RPL10 wild type 
construct. Mouse lymphoid Pro-B-cells (Ba/F3) were transduced with pMSCV-
RPL10 wild type or p.Arg98Ser retroviral constructs according to standard 
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methods. To mimic the situation in T-ALL patients which only express mutant and 
not wild type RPL10 in their leukemia cells (Supplementary Figure 7), Ba/F3 cell 
experiments were performed with concurrent knock-down of endogenous Rpl10 
protein. Delivery of siRNAs into the cells was performed by electoporation on a Gene 
Pulser Xcell machine (Bio-Rad, Hercules, CA) using exponential decay, 250V, 950 
µF. siRNAs against mouse Rpl10 (MMC.RNAI.N052835.12.2; 
CCAACAAAUACAUGGUAAAGAGUTG) were used at a concentration of 400 nM 
during electroporation and were obtained from Integrated DNA Technologies (IDT). 
Cell proliferation was measured on a Guava flow cytometer (Millipore) at the 
indicated time points after electroporation. 
For polysome profiling, Ba/F3 cells were homogenized in 100mM Tris-HCl pH 7.5, 
100mM NaCl, 100mM MgCl2, 1% DOC/Triton-X100, 1mM dithiothreitol, 10ul/ml 
Protease Inhibitor Cocktail (Sigma), 10ul/ml Phosphatase Inhibitor Cocktail I 
(Sigma), 10ul/ml Phosphatase Inhibitor Cocktail II (Sigma), 30u/mL RNasin 
supplemented with 100 ug/ml cycloheximide. After 5 min of incubation on ice, the 
extract was centrifuged for 5 min at 12,000 g at 4°C. The supernatant was loaded 
onto a 10-60% (w/v) sucrose gradient and sedimented by centrifugation at 4°C for 
150 min at 37,000 rpm in a Beckman SW41 rotor.  
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SUPPLEMENTARY INFORMATION FOR:  
 
“Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and 
RPL10 in T-cell acute lymphoblastic leukemia” 
 
Supplementary Note: Leukemia samples 
Supplementary Figure 1: Comparison of somatic SNV filtering strategies 
Supplementary Figure 2: The number of somatic mutations increases with age 
Supplementary Figure 3: The number of mutations does not correlate with 
outcome 
Supplementary Figure 4: Overview of mutations in recurrently but not 
significantly mutated genes in T-ALL samples 
Supplementary Figure 5: Mutations in 15 identified candidate T-ALL driver 
genes in 17 T-ALL cell lines 
Supplementary Figure 6: Localization of Rpl10 and Rpl5 proteins in the 60S 
ribosomal subunit 
Supplementary Figure 7: DNA and RNA Sanger results RPL10 and CNOT3 
mutations 
Supplementary Figure 8: RPL10 mutated residues are close to the catalytic 
center of the  ribosome 
Supplementary Figure 9: T-ALL associated RPL10 mutants impair proliferation 
and ribosome biogenesis in yeast cells 
 
Supplementary Table 1: Description patient set exome sequencing 
Supplementary Table 2: Average alignment results over 123 samples 
Supplementary Table 3: Sequencing and mapping statistics of the 123 samples 
Supplementary Table 4: Detected SNV and INDEL numbers 
Supplementary Table 5: Protein-altering (A) somatic SNVs and (B) somatic 
INDELs in 39 diagnosis-remission pairs 
Supplementary Table 6: 20 significantly mutated genes 
Supplementary Table 7: Protein-altering SNVs and INDELs in 15 candidate 
genes in (A) diagnosis-only samples and (B) cell lines 
Supplementary Table 8: Patient characteristics CNOT3 (NM_014516.3) 
mutated cases 
Supplementary Table 9: Patient characteristics RPL mutated cases 
Supplementary Table 10: Association between candidate driver mutations and 
clinico-biological features 
Supplementary Table 11: RPL10, RPL5 and CNOT3 PCR and sequencing 
primers  
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SUPPLEMENTARY NOTE  
 
Leukemia samples  
T-ALL patient samples were collected at various institutions. All patients have 
given their informed consent and all samples were obtained according to the 
guidelines of the local ethical committees. This study was approved by the ethical 
committee of the University Hospital Leuven. Diagnosis of T-ALL was based on 
morphology, cytochemistry and immunophenotyping according to the World Health 
Organization and European Group for the Immunological Characterization of 
Leukemias criteria. A detailed description of the clinico-biological characteristics of 
the analyzed patient samples is provided in Supplementary table 1. 
 
Supplemental Figure 1. Comparison of somatic SNV filtering strategies. 
Variant quality filtering is denoted as ‘PASS’ (referring to the quality tag for high quality variants 
predicted by VQSR). Coverage filtering is defined as depth of coverage ≥ 10 reads in diagnosis and 
remission, and variant allele frequency ≥ 20% in diagnosis and ≤ 5% in remission. For repeat region 
filtering (‘segdup’ in the legend), all variants in segmental duplication regions are removed. The final 
filtering strategy used in the rest of this work is indicated with a red square. 
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Supplemental Figure 2. The number of somatic mutations increases with age. 
 (a) Box plot showing the number of somatic mutations in pediatric (age ≤ 15 years) and in adult (age ≥ 
16) T-ALL samples. Average and s.e.m. is indicated on the plots. The reported p-value tests whether there 
is a significant difference between mutation number in adults versus children and was calculated using a 2-
tailed Wilcoxon signed rank test. Group size pediatric: n=19; adult: n=20. (b) Dot plot representing the 
number of somatic mutations versus patient age. (c) Box plot showing the number of somatic mutations in 
candidate driver genes in pediatric and in adult T-ALL patients. Average and s.e.m. is indicated on the 
plots. The reported p-value tests whether there is a significant difference between mutation number in 
adults versus children and was calculated using a 2-tailed Wilcoxon signed rank test. Group size pediatric: 
n=19; adult: n=20. (d) Dot plot representing the number of somatic mutations in candidate driver genes 
versus patient age. 
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Supplemental Figure 3. The number of mutations does not correlate with outcome.  
(a-c) Box plots showing number of somatic mutations (a), number of protein-altering somatic mutations 
(b) and number of somatic mutations in candidate driver genes (c) in patients that did not undergo an 
event versus patient that relapsed and/or died due to T-ALL. Average and s.e.m. is indicated on the plots. 
All reported p-values test whether there is a significant difference between mutation number in event free 
versus relapsed and/or leukemia induced dead patiens and were calculated using a 2-tailed Wilcoxon singed 
rank test. Group size event free: n=28; relapse and/or dead: n=10. 
CHAPTER III: RESULTS 
85 
 
C
HAPTER III: R
ESULTS 
Supplemental Figure 4. Overview of mutations in recurrent but not significantly mutated genes in 
T-ALL samples. 
Mutations observed in 11 genes that were recurrently mutated in at least 2 of the diagnosis-remission pairs 
but that were not significantly mutated as determined by Genome MuSiC. For clarity, only samples 
harboring mutations in any of these 11 genes are shown in the figure. Each type of mutation is indicated 
with a different color as indicated in the legend and symbols for homozygous and compound heterozygous 
mutations are explained. Mutations with no indication are heterozygous. All mutations shown in this figure 
were validated by conventional Sanger sequencing. Relevant patient characteristics (identified by Sanger 
sequencing, karyotyping, or gene expression) are included at the bottom of the heatmap. Mutations in 
NOTCH1 were hard to identify by exome sequencing due to the low coverage of NOTCH1 exons. NOTCH1 
mutations detected by Sanger sequencing are indicated at the bottom of the heatmap under patient 
characteristics. 
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Supplemental Figure 5. Overview of mutations in 15 identified candidate T-ALL driver.  
Mutations observed in the 15 selected candidate T-ALL driver genes in 17 sequenced T-ALL cell lines. Each 
type of mutation is indicated with a different color as indicated in the legend and symbols for homozygous 
and compound heterozygous mutations are explained. Mutations with no indication are heterozygous. All 
mutations shown in this figure were validated by conventional Sanger sequencing. Relevant cell line 
characteristics (identified by Sanger sequencing, karyotyping, or gene expression) are included at the 
bottom of the heatmap. Mutations in NOTCH1 were hard to identify by exome sequencing due to the low 
coverage of NOTCH1 exons. NOTCH1 mutations detected by Sanger sequencing are indicated at the bottom 
of the heatmap under cell line characteristics. 
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Supplemental Figure 6. Localization of Rpl10 and Rpl5 proteins in the 60S ribosomal subunit. 
The figure shows the ‘crown view’ of the rRNA and proteins of the yeast 60S ribosomal subunit with 
indication of Rpl10 and Rpl5 proteins. PTC: peptidyltransferase center; CP: central protuberance. This 
model is based on the yeast 3Å crystal structure (PDB entries 3U5E and 3U5D). 
 
 
 
 
Supplemental Figure 7. DNA and RNA Sanger results RPL10 and CNOT3 mutations. 
Representative chromatograms illustrating presence or absence of indicated RPL10 or CNOT3 mutations in 
diagnostic or remission genomic DNA or diagnostic RNA. 
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Supplemental Figure 8. RPL10 mutated residues are close to the catalytic center of the ribosome.  
(a) Alignment of Rpl10 protein sequence from yeast (S cer), Drosophila (D mel), nematodes (C ele) and 
human (H sap). Amino acid positions are given and Arg98 and Gln123 (or His123 in yeast) are indicated 
(▼). β-sheets in the secondary structure of Rpl10 are indicated under the alignment. (b) 3D representation 
of the region of yeast Rpl10 containing Arg98 and His123 and surrounding rRNA helices H38, H38 and 
H89. The figure shows that Rpl10 residues Arg98 and His123 are opposing residues in a beta-hairpin loop 
of Rpl10. (c) Model showing the position of Rpl10 and its residues Arg98 and His123 into the 60S yeast 
ribosomal subunit ('crown view'). The figure illustrates that Rpl10, and particularly residues Arg98 and 
His123, are close to the peptidyltransferase center (PTC) in the ribosome. For Reference, rRNA helices H38 
and H89 that are also shown in panel (b) are indicated. CP: Central Protuberance. Modeling in panels (b) 
and (c) is based on the yeast 3Å crystal structure (PDB entries 3U5E and 3U5D). 
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Supplemental Figure 9. T-ALL associated RPL10 mutants impair proliferation and ribosome 
biogenesis in yeast cells.  
(a) Growth of conditional glucose-repressible Rpl10 yeast cells expressing wild-type (WT) Rpl10, or the T-
ALL associated Rpl10 p.Arg98Ser, Rpl10 p.Arg98Cys and Rpl10 p.His123Pro mutants was compared by 
plating ten-fold serial dilutions. (b) Polysome profiles for Rpl10 WT, Rpl10 p.Arg98Ser, Rpl10 
p.Arg98Cys and Rpl10 p.His123Pro yeast cells were carried out as described for Fig 4b with the exception 
that the Rpl10 alleles were expressed in a glucose-repressible Rpl10 strain shifted to glucose for six hours. 
(c) Fluorescence microscopy of Tif6-GFP or Nmd3-GFP for the indicated yeast cells was done as described 
in the legend to Fig 4c. Scale bars: 5 µm. (d) Rpl10 WT, Rpl10 p.Arg98Ser, Rpl10 p.Arg98Cys and Rpl10 
p.His123Pro yeast cells were transformed with empty vector or vector WT Nmd3. Ten-fold serial dilutions 
were grown. 
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Supplementary Table 1. Description patient set exome sequencing. 
The table is not included in the thesis due to space constrains and can be obtained through the published 
article.  
 
Supplementary Table 2. Average alignment results over 123 samples 
  Average ± St. Dev. Range 
Number of high-quality aligned bases (Gbp) 7.1 ± 2.5 3.9 – 17.2 
Mean target coverage 109.12 ± 31.8 51.3 - 239 
Percentage of bases covered by at least 2 reads (%) 95.7 ± 0.8 92.5 – 97.3 
Percentage of bases covered by at least 10 reads (%) 91.0 ± 2.0 81.5 – 95.7 
Percentage of bases covered by at least 20 reads (%) 84.9 ± 3.8 68.7 – 94.1 
 
 
Supplementary Table 3. Sequencing and mapping statistics of the 123 samples. 
The table is not included in the thesis due to space constrains and can be obtained through the published 
article.  
 
Supplementary Table 4. Detected SNV and INDEL numbers. 
 
Supplementary Table 4A. Number of somatic SNVs and INDELs observed in 39 samples 
Sample 
# 
somatic 
SNVs 
# 
somatic 
INDELs 
Total # of 
somatic 
variations 
#of 
protein 
altering 
somatic 
SNVs 
#of 
protein 
altering 
somatic 
INDELs 
Total # of 
protein 
altering 
somatic 
variations  
TLE02 28 7 35 6 0 6  
TLE03 35 4 39 13 1 14  
TLE07 4 27 31 0 5 5  
TLE09 5 7 12 0 1 1  
TLE10 51 17 68 14 4 18  
TLE29 24 9 33 1 0 1  
TLE31 37 2 39 4 0 4  
TLE32 9 84 93 0 9 9  
TLE33 40 7 47 17 1 18  
TLE34 66 153 66 19 61 19 * 
TLE36 27 32 59 6 4 10  
TLE38 33 12 45 17 5 22  
TLE39 53 5 58 20 1 21  
TLE40 38 63 101 0 14 14  
TLE41 53 6 59 11 1 12  
TLE42 64 253 64 14 27 14 * 
TLE43 250 16 266 76 5 81  
TLE44 46 25 71 12 2 14  
TLE45 37 7 44 10 2 12  
TLE50 30 9 39 13 0 13  
TLE51 40 13 53 10 4 14  
TLE54 61 5 66 13 1 14  
TLE55 35 2 37 8 0 8  
TLE57 35 316 35 13 103 13 * 
TLE60 30 28 58 6 6 12  
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TLE61 74 3 77 15 0 15  
TLE63 44 5 49 4 3 7  
TLE64 44 2 46 11 0 11  
TLE65 35 19 54 6 1 7  
TLE66 34 14 48 2 3 5  
TLE67 47 3 50 7 0 7  
TLE68 23 8 31 3 1 4  
TLE109 69 14 83 20 4 24  
TLE110 0 7 7 0 0 0  
TBR01 63 4 67 26 2 28  
TBR03 52 5 57 17 0 17  
TBR05 86 11 97 37 3 40  
TBR06 45 30 75 11 7 18  
TBR08 63 14 77 20 3 23  
* the INDEL calls from these samples are excluded from further analysis 
 
Supplementary Table 4B. Number of SNVs and INDELs observed in 28 diagnosis-only samples 
Sample 
# of 
SNVs 
# of 
INDELs 
Total # of 
variation 
# of protein 
altering 
SNVs 
# of protein 
altering 
INDELs 
Total # of 
protein altering 
variations 
TLE01 3683 58 3741 274 7 281 
TLE04 3433 44 3477 179 6 185 
TLE05 3959 45 4004 193 8 201 
TLE06 3602 66 3668 201 12 213 
TLE08 3791 42 3833 198 4 202 
TLE35 12118 132 12250 280 11 291 
TLE37 5704 32 5736 256 6 262 
TLE47 5983 40 6023 263 7 270 
TLE48 9229 50 9279 298 5 303 
TLE53 6040 40 6080 271 2 273 
TLE56 6306 49 6355 303 6 309 
TLE58 14013 114 14127 401 18 419 
TLE59 8323 33 8356 333 8 341 
TLE62 5326 47 5373 232 6 238 
TLE76 16973 64 17037 262 5 267 
TLE78 14446 124 14570 251 12 263 
TLE79 9487 108 9595 194 16 210 
TLE80 5052 80 5132 211 8 219 
TLE82 5922 86 6008 221 8 229 
TLE83 6097 117 6214 212 15 227 
TLE84 8393 123 8516 236 18 254 
TLE85 8717 113 8830 219 11 230 
TLE87 4769 77 4846 188 8 196 
TLE89 8113 110 8223 236 15 251 
TLE90 25753 494 26247 996 117 1113 
TLE91 8047 102 8149 217 10 227 
TLE92 5400 90 5490 212 10 222 
TBR09 5489 100 5589 307 8 315 
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Supplementary Table 4C. Number of SNVs and INDELs observed in 17 T-ALL cell lines 
Sample 
# of 
SNVs 
# of 
INDELs 
Total # of 
variation 
# of 
protein 
altering 
SNVs 
# of 
protein 
altering 
INDELs 
Total # of 
protein 
altering 
variations 
BE13 7127 58 7185 553 17 570 
HSB2 10400 281 10681 1522 162 1684 
KARPAS45 23897 110 24007 6094 43 6137 
SUPT1 18056 371 18427 3481 211 3692 
ALLSIL 6099 52 6151 424 11 435 
DND41 13220 230 13450 2295 122 2417 
HPBALL 4772 49 4821 519 13 532 
JURKAT 21269 517 21786 4627 309 4936 
KE37 5863 50 5913 296 8 304 
MOLT4 9195 123 9318 1190 47 1237 
P12ICHIKAWA 5475 54 5529 405 11 416 
PEER 6342 38 6380 420 7 427 
SUPT13 4932 50 4982 268 11 279 
TALL1 6343 38 6381 347 12 359 
PF382 9640 63 9703 1705 18 1723 
CCRFCEM 12838 544 13382 2735 234 2969 
LOUCY 4185 63 4248 292 9 301 
 
 
 
Supplementary Table 5. Protein-altering (A) somatic SNVs and (B) somatic INDELs in 39 
diagnosis-remission pairs. 
The table is not included in the thesis due to space constrains and can be obtained through the published 
article.  
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Supplementary Table 6. 20 significantly mutated genes. 
Gene SNVs INDELs 
p-value 
FCPT 
p-value 
LRT 
p-value 
CT 
FDR 
FCPT 
FDR 
LRT 
FDR 
CT 
PHF6 6 3 0 0 0 0 0 0 
FBXW7 5 0 3E-07 4E-12 6E-12 2E-03 4E-08 6E-08 
WT1 1 2 7E-04 9E-08 1E-07 1E+00 6E-04 4E-04 
JAK3 3 1 2E-04 2E-07 7E-08 1E+00 1E-03 4E-04 
DNM2 3 1 3E-04 3E-07 1E-07 1E+00 1E-03 4E-04 
PTEN 2 1 7E-04 8E-07 1E-07 1E+00 2E-03 4E-04 
CNOT3 3 1 6E-04 9E-07 2E-07 1E+00 2E-03 6E-04 
NOTCH1 4 0 4E-04 3E-06 2E-07 1E+00 5E-03 6E-04 
BCL11B 3 0 2E-03 4E-07 6E-07 1E+00 1E-03 1E-03 
TET1 2 2 1E-03 2E-06 6E-07 1E+00 3E-03 1E-03 
KDM6A 1 2 3E-03 6E-07 1E-06 1E+00 2E-03 2E-03 
PPP1R15A * 0 2 3E-02 2E-06 2E-05 1E+00 4E-03 3E-02 
ODZ2 3 0 2E-02 1E-05 2E-05 1E+00 1E-02 3E-02 
TLR1 1 1 4E-02 3E-05 3E-05 1E+00 4E-02 4E-02 
RPL10 2 0 4E-02 3E-06 4E-05 1E+00 5E-03 5E-02 
ST8SIA2 * 2 0 7E-02 8E-06 1E-04 1E+00 1E-02 1E-01 
RPL5 2 0 7E-02 1E-04 1E-04 1E+00 9E-02 1E-01 
FAM55A * 1 0 3E-01 1E-04 2E-04 1E+00 9E-02 2E-01 
MAGEC3 2 0 1E-01 2E-05 2E-04 1E+00 2E-02 2E-01 
MTMR8 * 2 0 1E-01 2E-04 2E-04 1E+00 1E-01 2E-01 
* the gene is not recurrently mutated across different samples (the gene has either one mutation, or several 
mutations in the same sample).  
 
 
Supplementary Table 7. Protein-altering SNVs and INDELs in 15 candidate genes in (A) 
diagnosis-only samples and (B) cell lines. 
The table is not included in the thesis due to space constrains and can be obtained through the published 
article.  
 
Supplementary Table 8. Patient characteristics CNOT3 (NM_014516.3) mutated cases. 
The table is not included in the thesis due to space constrains and can be obtained through the published 
article.  
 
Supplementary Table 9. Patient characteristics RPL mutated cases. 
The table is not included in the thesis due to space constrains and can be obtained through the published 
article.  
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Supplementary Table 10. Association between candidate driver mutations and clinicobiological 
features  
 
 
# adult (≥16 
y) 
# pediatric 
(≤15) p-value 
AGE  patients patients 2-tailed Fisher's test 
mutant 15 14 NOTCH1 
n=67 wild type 22 16 p=0.6300 
mutant 7 1 FBXW7 
n=67 wild type 30 29 
p=0.0657 
mutant 2 5 WT1 
n=67 wild type 35 25 p=0.4334 
mutant 4 1 BCL11B 
n=67 wild type 33 29 p=0.3700 
mutant 7 1 CNOT3 
n=211 wild type 82 121 p=0.0107 
mutant 1 10 RPL10 
n=211 wild type 88 112 
p=0.0268 
mutant 2 2 RPL5 
n=211 wild type 87 120 p=1.0000 
mutant 4 3 JAK3 
n=67 wild type 33 27 p=1.0000 
mutant 3 1 PTEN 
n=67 wild type 34 29 p=0.6220 
mutant 1 3 DNM2 
n=67 wild type 36 27 
p=0.3179 
mutant 1 1 ODZ2 
n=67 wild type 36 29 p=1.0000 
mutant 11 1 PHF6 
n=67 wild type 26 29 p=0.0083 
mutant 3 1 TET1 
n=67 wild type 34 29 p=0.6220 
mutant 3 0 KDM6A 
n=67 wild type 34 30 
p=0.2469 
mutant 2 0 MAGEC3 
n=67 wild type 35 30 p=0.4980 
 
 # NOTCH1 wt # NOTCH1 mut p-value NOTCH1 status 
 patients patients 2-tailed Fisher's test 
mutant 5 3 FBXW7 
n=67 wild type 33 26 p=1.0000 
mutant 4 3 WT1 
n=67 wild type 34 26 p=1.0000 
mutant 0 5 BCL11B 
n=67 wild type 38 24 p=0.0123 
mutant 2 6 CNOT3 
n=84 wild type 43 33 
p=0.1369 
RPL10 mutant 3 6 P=0.2918 
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n=84 wild type 42 33  
mutant 1 2 RPL5 
n=84 wild type 44 37 
p=0.5948 
mutant 5 2 JAK3 
n=67 wild type 33 27 p=0.6899 
mutant 4 0 PTEN 
n=67 wild type 34 29 p=0.1273 
mutant 2 2 DNM2 
n=67 wild type 36 27 p=1.0000 
mutant 0 2 ODZ2 
n=67 wild type 38 27 
p=0.1836 
mutant 4 8 PHF6 
n=67 wild type 34 21 p=0.1078 
mutant 2 2 TET1 
n=67 wild type 36 27 p=1.0000 
mutant 1 2 KDM6A 
n=67 wild type 37 27 p=0.5744 
mutant 2 0 MAGEC3 
n=67 wild type 36 29 
p=0.5016 
 
 
 
 
Supplementary Table 11. RPL10, RPL5 and CNOT3 PCR and sequencing primers  
The table is not included in the thesis due to space constrains and can be obtained through the published 
article
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ABSTRACT 
RNA-seq is a promising technology to re-sequence protein coding genes for the 
identification of single nucleotide variants (SNV), while simultaneously obtaining 
information on structural variations and gene expression perturbations. We asked 
whether RNA-seq is suitable for the detection of driver mutations in T-cell acute 
lymphoblastic leukemia (T-ALL). These leukemias are caused by a combination of 
gene fusions, over-expression of transcription factors and cooperative point 
mutations in oncogenes and tumor suppressor genes. We analyzed 31 T-ALL 
patient samples and 18 T-ALL cell lines by high-coverage paired-end RNA-seq. 
First, we optimized the detection of SNVs in RNA-seq data by comparing the 
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results with exome re-sequencing data. We identified known driver genes with 
recurrent protein altering variations, as well as several new candidates including 
H3F3A, PTK2B, and STAT5B. Next, we determined accurate gene expression levels 
from the RNA-seq data through normalizations and batch effect removal, and used 
these to classify patients into T-ALL subtypes. Finally, we detected gene fusions, of 
which several can explain the over-expression of key driver genes such as TLX1, 
PLAG1, LMO1, or NKX2-1; and others result in novel fusion transcripts encoding 
activated kinases (SSBP2-FER and TPM3-JAK2) or involving MLLT10. In 
conclusion, we present novel analysis pipelines for variant calling, variant filtering, 
and expression normalization on RNA-seq data, and successfully applied these for 
the detection of translocations, point mutations, INDELs, exon-skipping events, and 
expression perturbations in T-ALL. 
 
AUTHOR SUMMARY 
The quest for somatic mutations underlying oncogenic processes is a central theme 
in today’s cancer research. High-throughput genomics approaches including 
amplicon re-sequencing, exome re-sequencing, full genome re-sequencing, and SNP 
arrays have contributed to cataloguing driver genes across cancer types. Thus far 
transcriptome sequencing by RNA-seq has been mainly used for the detection of 
fusion genes, while few studies have assessed its value for the combined detection of 
SNPs, INDELs, fusions, gene expression changes, and alternative transcript events. 
Here we apply RNA-seq to 49 T-ALL samples and perform a critical assessment of 
the bioinformatics pipelines and filters to identify each type of aberration. By 
comparing to exome re-sequencing, and by exploiting the catalogues of known cancer 
drivers, we identified many known and several novel driver genes in T-ALL. We also 
determined an optimal normalization strategy to obtain accurate gene expression 
levels and used these to identify over-expressed transcription factors that 
characterize different T-ALL subtypes. Finally, by PCR, cloning, and in vitro 
cellular assays we uncover new fusion genes that have consequences at the level of 
gene expression, oncogenic chimaeras, and tumor suppressor inactivation. In 
conclusion, we present the first RNA-seq data set across T-ALL patients and 
identify new driver events. 
 
INTRODUCTION  
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy that 
accounts for approximately 15% of pediatric and 25% of adult ALL cases. Despite 
improved outcome over the years, about 25% of children and 50% of adults still fail 
to respond to intensive chemotherapy protocols or relapse 1. Improved 
understanding of T-ALL biology through the identification and characterization of 
oncogenic lesions is expected to lead to a better prognostic classification and the 
development of new targeted therapeutic strategies. 
T-ALL is caused by the accumulation of multiple oncogenic mutations that have 
been identified through characterization of chromosomal aberrations and candidate 
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gene sequencing 2. Chromosomal translocations in T-ALL frequently involve the T-
cell receptor (TCR) loci, whereby TCR regulatory elements become juxtaposed to 
genes that are normally not expressed in T-cells 3,4. In this way, a specific set of 
recurrently over-expressed TFs have been documented, including TLX1, TLX3, 
TAL1, LMO1, HOXA, and NKX family members 5. T-ALL samples expressing each 
of these transcription factors show a distinctive gene expression signature and as 
such these transcription factors define distinct molecular subtypes in T-ALL 6. 
Chromosomal rearrangements can also lead to large chromosomal deletions and 
amplifications; to focal gene deletions or amplifications, such as CDKN2A deletion 
and MYB duplication 7,8; and to in-frame fusion genes encoding chimeric proteins 
with oncogenic properties such as the constitutively active NUP214-ABL1 fusion 
kinase 9. In addition, point mutations and small INDELs have also been described 
leading to oncogenic events, such as mutations activating NOTCH1 that occur in 
more than 60% of T-ALL cases 10, or mutations in cytokine receptors and tyrosine 
kinases such as IL7R and JAK3 11-17. The latter may lead to new opportunities for 
molecularly tailored therapies with kinase inhibitors 12,16,18,19.  
With the advent of next generation sequencing (NGS) technologies, our sequencing 
capacity has significantly improved in the past five years. It is now possible to apply 
targeted re-sequencing, exome sequencing (Exome-seq), whole genome sequencing 
(WGS), whole transcriptome sequencing (RNA-seq) or a combination of these, to 
investigate individual genomes, especially those related to disease 20. Also for T-ALL, 
these NGS approaches have recently proven their value in the discovery of novel 
driver genes 13,14,17,21. We previously identified a spectrum of new oncogenic driver 
genes using Exome-seq on 67 T-ALLs, and described clear differences between 
pediatric and adult patients 17. In particular, we identified CNOT3 as a tumor 
suppressor mutated in 8% of adult T-ALL cases and mutations affecting the 
ribosomal proteins RPL5 and RPL10 in 10% of pediatric T-ALLs 17. Similarly, 
whole genome sequencing of early T-cell precursor ALL cases led to the identification 
of mutations in several new oncogenes and tumor suppressor genes affecting 
cytokine signaling, T-cell development and histone-modifying genes 2,13. However, the 
potential of RNA-seq for the discovery of driver genes in T-ALL remains 
unexplored.  
In the present study, we applied paired-end RNA-seq on 49 T-ALL samples (31 
patients, 18 cell lines) to gain insights in the transcriptome landscape of T-ALL. 
First, we show that identification of somatic single nucleotide variants (SNV) and 
recurrently mutated driver genes is feasible on RNA-seq data, even without matched 
normal samples (e.g., germline or remission DNA). We identify STAT5B, H3F3A, 
and PTK2B as candidate cancer genes in T-ALL. This becomes possible when (1) 
optimal read mapping and SNV calling procedures are applied; and (2) functional 
annotation, gene expression, or additional sequencing data from other cohorts is 
used to prioritize the true driver genes. Next, we optimized gene expression 
measurements using multiple normalization strategies, and showed that classical 
gene expression studies (e.g., clustering) are feasible on normalized RNA-seq data. 
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We also detected new fusion genes (SSBP2-FER and TPM3-JAK2) and used gene 
expression data to determine the consequence of observed chromosomal 
rearrangements on the over-expression of key driver genes. Finally, we searched for 
significant alternative transcript events (ATE) but besides one coherent exon-
skipping event in SUZ12, we found relatively few candidate ATEs in T-ALL. In 
conclusion, through a combination of the analysis of gene expression levels, fusion 
transcripts, SNVs, and INDELs, we could identify known and new driver alterations 
in T-ALLs and novel potential targets for therapy. 
 
RESULTS 
 
Correct SNV and INDEL calling on RNA-seq data depends on accurate 
read mapping 
 
We performed paired-end RNA-seq on 31 T-ALL patients, 18 T-ALL cell lines, and 
1 normal thymus sample. We obtained on average ~110 million reads per sample, 
leading to an average coverage of ~88X (Table S1.A). To assess the quality of 
detecting SNVs from the RNA-seq data, we compared the RNA-seq to Exome-seq 
data. For 16/18 of the cell lines and for 20/31 patient samples we had exome data 
available (previously generated 17 or obtained for this study, Table S2). For the 
exome data analysis, we followed the pipeline of mapping, SNV and somatic 
mutation detection that we validated previously 17 (using BWA, GATK, 
SomaticSniper, and Variant Effect Predictor (VEP)) 22-25. For the RNA-seq data we 
used TopHat2 1,26 for mapping, SAMTools 2,27 for SNV detection, and VEP 3,4,25 for 
variant annotation (Figure 1.A).  
 
By comparing positions that had a coverage of at least 20x in both RNA-seq and 
Exome-seq, combined with Sanger re-sequencing of a subset of positions, we found 
that the accuracy of SNV calling in RNA-seq strongly depends on the read mapping, 
corroborating earlier observations 5,28,29 (Figure S1). We found that mapping 
RNA-seq reads to the genome (as used by TopHat version 1.3.3) is prone to errors 
when dealing with paralogous genes, as observed by the prediction of false positive 
SNVs in KIF4A and GLUD1 due to erroneous mapping to KIF4B and GLUD2 
(both pseudogenes with no introns) (Figure S1). However, these errors were 
resolved by mapping to the transcriptome. In the case of the RPMI8402 cell line, 877 
SNVs were found by mapping to the genome, while this number was reduced to 283 
SNVs when mapping to the transcriptome. Mapping to the transcriptome did not 
only reduce the number of RNA-seq exclusive calls but also increased the overlap 
with the Exome-seq calls (Figure 2, Figure S2).  
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Figure 1. RNA-seq data analysis pipelines for (A) variant calling and filtering to detect point mutations, (B) fusion detection and annotation, (C) gene 
expression analysis. 
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However, transcriptome mapping also has limitations as it relies on current gene and 
isoform annotation. We observed that a combination of transcriptome and genome 
mapping provides the best solution. It is important that all reads are mapped twice 
to the genome, independently of each other; once as entire read and once as split 
read. This has become possible in TopHat2 by setting the option "read-realign-edit-
dist" to zero. Our analysis reveals that this mapping approach results in the best 
overlap of SNVs compared to exomes (Figure 2, Figure S3). This mapping 
strategy not only improves the alignment accuracy by preventing misalignment to 
pseudogenes, but also leads to identification of the most likely isoform structure of a 
gene by mapping the reads independently both to the transcriptome and to the 
genome and then selecting the best possible alignment.  
 
Figure 2. Comparison between RNA-seq and exome-seq.  
Variant Allele Frequency plots for evaluating two RNA-seq mapping strategies for two example samples, 
namely the RPMI8402 cell line (A, B) and the TLE79 patient sample (C, D). On the left are the results of 
mapping with TopHat 1.3.3. (A,C), while on the right are the results of mapping with TopHat 2.0.5 with 
forced re-mapping of all reads to the genome. The SNVs that have at least 20 reads in exome-seq and RNA-
seq are plotted. Red and green dots represent the SNVs that are detected only in RNA-seq and only in 
exome-seq, respectively, while black dots represent the SNVs that are called in both. Venn diagrams are 
produced from the points represented in the graphs.  
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Using the optimized mapping and filtering strategy we identified 436974 SNVs 
across 49 samples. By using samples for which both the exome and the 
transcriptome were sequenced several aspects of SNV detection in RNA-seq data can 
be evaluated, such as sensitivity, specificity, and allelic imbalance. Regarding 
sensitivity, we found that on average, 32% of the SNVs that are called in Exome-seq 
were also called by the RNA-seq (Table S3). Similar ratios were observed when 
comparing validated somatic SNVs from Exome-seq/WGS to RNA-seq SNVs: 36% in 
a triple negative breast cancer study 6,30, and 41% in a lymphoma study 7,8,31. We 
observed that the sensitivity varies considerably between samples, and strongly 
correlates with the average depth of coverage of the sample (Figure S4).  
 
Regarding specificity, we found that the remaining RNA-seq-only and exome-only 
SNVs (for positions where both have at least 20x coverage) are found mainly with a 
low variant allele frequency (VAF) and are therefore likely due to arbitrary VAF 
and coverage thresholds. For example, on the RPMI8402 and TLE79 samples, many 
RNA-seq-only SNVs (9/18 and 61/88 respectively) have a VAF below 40%. 
Regarding allelic imbalance, we found that of all heterozygous Exome SNVs with 
more than 20X coverage, the majority (2914/4043 or 72%) were also heterozygous 
SNVs in RNA-seq. Of the remaining SNVs, many (988/4043) are homozygous 
reference in the RNA-seq (i.e., not detected). A small fraction we can almost 
certainly attribute to allelic imbalance, namely the 141/4043 SNVs (3.5%) that are 
homozygous variant in the RNA-seq, indicating that for those only the variant allele 
is expressed (or the gene is only expressed in cancer cells that harbor the variant).  
Next we asked whether small insertions and deletions (INDELs) can be detected 
from RNA-seq data. As with the SNVs, we used the Exome-seq data for assessing 
the quality of our INDEL detection strategy. On average, 47.5% of the INDELs that 
were detected by RNA-seq were also found in the Exome-seq (unfiltered) INDEL 
calls. However, only 4% of the Exome-seq INDELs (for which the region containing 
INDEL is covered by at least 3 reads in RNAseq data) were found back in the RNA-
seq calls (Table S3). To investigate this sensitivity issue, we evaluated ten 
validated INDELs that we previously identified with Exome-Seq 9,17(Table S4). 
Three of the ten INDELs were also identified in the RNA-seq data using the default 
SAMTools parameters (see Materials and Methods). Of the seven missed INDELS, 
two are found in a gene that is not expressed; another two are clearly present in the 
RNA-seq data when inspected manually with IGV, but did not reach the default 
threshold (see Materials and Methods); and the last three are effectively discordant 
between RNA-seq and Exome-seq, as they show only reads with reference sequence 
(Figure S5). Re-mapping of the reads with BWA 10,22 on the transcriptome 
followed by BLAT 11-17,32 on the genome improved the INDEL identification, now 
revealing the KDM6A INDEL in TLE87 and PTEN INDEL in TLE92, which were 
previously missed (Figure S6.A-B). It is notable that the combination of TopHat2 
(to transcriptome only) and BLAT does not correctly detect these two INDELS 
(Figure S6.C-D). We conclude that INDEL detection on RNA-seq data is feasible, 
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yet technically challenging, and that the fraction of INDELs compared to SNVs is 
moderate (see also the next Section and Figure 3 below).  
 
Leveraging diagnosis-only RNA-seq data with the T-ALL body of 
knowledge to identify mutated cancer genes  
Our next aim was to select candidate driver genes using the collected SNVs and 
INDELS. To remove germline variants we initially removed all SNPs present in 
dbSNP 12,16,18,19,33, 1000genomes 20,34, the Complete Genomics genomes 13,14,17,21,35, and 
those detected in our own exome data from normal samples (39 from our earlier 
work 17 and 6 from this study). We, however, retained those variants also present in 
the COSMIC 17,36 database, since SNP databases are know to contain also some 
disease-specific SNVs. Some examples of SNVs that are likely driver mutations, but 
that are also present in polymorphism databases are: JAK3 A572V in R7, and 
FBXW7 R425C in TUG1. With this filtering, we obtained a final list of 10403 
protein-altering SNVs and 430 protein-altering INDELs, with a median of 63 SNVs 
and 4 INDELS per sample (Table S1.B). Cell lines harbored significantly more 
mutations than patient samples (Mann-Whitney test p-value=1.095e-05), as 
previously also observed by exome-seq 2,13,17. 
 
As a first approach to identify candidate T-ALL driver genes, we selected all genes 
that contained a protein-altering mutation in at least two of the 31 patient samples 
(for recurrence we did not take cell lines into account). This process resulted in the 
selection of 213 genes (Table S5). We found that this list is strongly enriched for 
genes related to T-ALL and to cancer in general, with "precursor T-cell 
lymphoblastic leukemia-lymphoma" as the most highly enriched function (p-value 
1.35E-11 by Ingenuity Pathway Analysis) (Table S6). The list of 213 candidates 
contained many known T-ALL driver genes (Figure 3), such as NOTCH1, 
BCL11B, FBXW7, IL7R, JAK1 and JAK3; and it also contained the drivers 
CNOT3 and RPL10, recently identified in our exome re-sequencing study 17; and 
CTCF, which was recently reported to be recurrently mutated in ETP-ALL 13,17. In 
addition, the candidate list contained two established cancer driver genes involved in 
other cancer types, but not yet reported to be mutated in T-ALL, namely H3F3A 
and CIC. These genes were reported recently by Vogelstein 22-25,37 to be true cancer 
drivers.  
 
Figure 3. Point mutations and gene fusions organized into functional categories (next-page).  
Protein altering mutations and INDELs, alternative splicing events and validated fusions are shown. Red 
boxes indicate protein-altering mutations (i.e. nonsense, missense and splice site mutations), purple boxes 
indicate frameshift INDELs whereas blue, green and orange boxes represent fusion events resulting in over-
expression of the partner gene, inactivation of the partner gene or generation of a chimeric protein, 
respectively, and finally black boxes indicating alternative splicing events.  
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We identified two patient samples (TLE76 and TUG6) with H3F3A mutations both 
on the K28 residue that is a mutational hotspot in glioblastoma 38. This mutation 
was confirmed somatic in the TUG6 sample. Sequencing of this hotspot in 
additional T-ALL samples indicated a low frequency of H3F3A K28 mutation in T-
ALL (detected in 3 of 102 cases). 
Next we asked if we could identify additional genes in the candidate list that could 
be linked to T-ALL. We wanted to utilize the genes that are known to be involved 
in T-ALL as a guide for identifying additional candidates. To this end we used our 
gene prioritization approach ENDEAVOUR 39, which scores candidate genes based 
on a set of training genes. It builds a profile based on the training genes (integrating 
information on protein-protein interactions, genetic interactions, gene expression, 
text-mining, sequence homology, Gene Ontology, and protein domains) and then 
prioritizes the candidate genes for their similarity to the derived profile. As training 
set we used all known drivers, and as test set we used all the 213 candidates with at 
least two patient mutations (excluding the genes that are in the training set). We 
reasoned that this would reveal the genes with strong similarity to the known 
drivers and such genes would be good candidate drivers. We found 45 significantly 
ranked genes with two interesting genes at the top of the ranking, namely PTK2B 
and STAT5B that are involved in JAK/STAT signaling (Table S7). Furthermore, 
the list contained genes for which we had identified single T-ALL cases with a 
somatic mutation in our previous exome study: ANKRD11, CTCF, DOCK2, 
H3F3A, and HADHA. We did not select these genes before in our Exome-seq cohort 
17 because they were only mutated in one of the 39 samples we analyzed. Now, with 
the RNA-seq cohort, we thus found additional samples with mutations in these 
genes.  
 
Optimized gene expression measurements and batch effect removal from 
RNA-seq data identify co-expression modules and T-ALL subtypes  
T-ALL is characterized by the overexpression of transcription factors (TFs), such as 
TLX1, TLX3, TAL1, and the HOXA family members 6. Therefore, identifying and 
analyzing expression perturbations in a T-ALL cohort is highly relevant. To obtain 
accurate gene expression levels from the mapped RNA-seq reads, we followed the 
procedure outlined in Figure 1.B, including read aggregation, GC-normalization, 
length normalization, and between-sample normalization (see Materials and 
Methods). In addition, we removed a batch effect that was clearly present in the 
data set using a Generalized Linear Model (GLM, see Materials and Methods) 
(Figure S7). It is notable that transcript-based expression analysis conducted with 
cufflinks revealed the same batch effect linked to the origin of the sample, thereby 
confirming a technical bias in the data set (Figure S7.B, see Materials and 
Methods).  
We next looked at the expression values of TLX1, TLX3, TAL1, and other 
important TFs in T-ALL. Clustering of TLX1, TLX3, and TAL1 expressing 
samples confirmed that the correct samples (based on karyotyping and molecular 
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analysis) showed over-expression of the respective TF (Figure 4.A). Indeed, 8 
samples that harbored a STIL-TAL1 rearrangement showed high TAL1 expression 
(Figure 4.D). Note that also other samples with high TAL1 expression were 
detected. This fits with a previously reported observation of TAL1 over-expression 
in the absence of a translocation in T-ALL 6,40. 
To assess the accuracy of our expression values obtained after normalization, batch 
effect removal and clustering, we tested whether previously published gene 
signatures associated with TAL1, TLX (TLX1 and TLX3) and LYL1 can be 
detected also in our data set 41. We used 13 gene signatures obtained by Soulier et al 
using a microarray study on 92 primary T-ALL samples 41. Gene set enrichment 
analysis shows that our TAL1 expressing cases are significantly associated with 
TAL1 signatures, whereas our TLX over-expressing cases are associated with the 
TLX signature (7, 8) and the LYL1 cases with the LYL1 signature (10, 11). This 
analysis confirms that the obtained expression data represent meaningful values and 
sample clustering produces gene lists that are biologically meaningful (Figure 
4.B).We next used the gene expression information as a guide to assist in the 
detection of relevant mutations. We found that the expression profile of PTK2B, a 
candidate driver identified above by ENDEAVOUR, significantly correlated with the 
JAK3 expression profile (PTM, with p-value threshold at 1E-5, see Materials and 
Methods) (Figure 4.C). Indeed, PTK2B was previously implicated in IL-2 
mediated signaling and JAK/STAT signaling, and was shown to physically interact 
with JAK3 42. These data warrant further investigation of PTK2B as an important 
tyrosine kinase in T-ALL case with activated JAK/STAT signaling. 
 
 
Figure 4. Validation and discovery using gene expression data, and SUZ12 ATE (next page).  
(A) Classification of the samples using the TFs that are known to be overexpressed in T-ALL. Using the 
expression patterns of TAL1, TLX1, TLX3, NKX2-5, LYL1 and LMO2 we could discriminate the samples in 
to six distinct clusters. The heatmap is plotted with the normalized log2(count) values. Gene set 
enrichment analysis curves are displayed for (B) enrichment of TAL1 associated clusters 2, 6 and 3 in 
TAL1 based ranking, (C) enrichment of TLX associated clusters 7 and 8 in TLX based ranking, and (D) 
enrichment of LYL1 associated clusters 10 and 11 in LYL1 based ranking of the genes. (E) Expression of 
JAK3 and PTK2B across samples is significantly correlated (with PTM p-value 1E-5). (F) Normalized 
expression values of TAL1 and TLX1 with translocations affecting these genes indicated. The samples with 
a translocation have elevated expression of the affected gene, showing the driver potential of the fusion 
event. There are additional samples with high expression of TLX1 and TAL1 without the indicated fusions, 
pointing to other mechanisms of activating these genes. (G) Predicted SUZ12 transcript aligned with the 
known SUZ12 isoforms. Dotted red box indicates the location of the exon-skipping event. (H) The sashimi 
plot below shows the junction (in black) supporting the exon-skipping event in patient sample R5 with 
respect to Thymus.(I) Agarose gel electrophoresis of the RT-PCR products for validation of SUZ12 exon 
skipping event. The two isoforms are clearly detected in R5 and to a minor extent in the other T-ALL 
samples while Thymus shows only the canonical transcript. 
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T-ALL presents robust transcript isoform usage 
To our knowledge, only very few cancer specific alternative transcript events (ATE) 
have been described for any cancer type 43-45, and no ATE is reported for T-ALL. In 
contrast to SNVs, INDELS, CNAs, and fusions, which are all curated and present 
in large numbers in public cancer mutation databases (e.g., COSMIC 36 , CENSUS 
46 ), we could not find driver ATEs in those databases (although splice sites 
represent an important class of cancer mutations). If ATEs represent an important, 
yet underestimated, type of somatic variation in cancer, we would expect at least 
some of the known cancer driver genes to present a significant ATE. We thus asked 
whether novel variations could be found in these genes in the form of ATEs.  
To this end, we applied cufflinks and cuffdiff (see Materials and Methods) and 
found significant ATEs in 12 of the 47 known driver genes (BCL11B, FLT3, IL7R, 
LCK, MYB, NKX2-1, SFTA3, RPL10, RUNX1, SETD2, SUZ12, and TAL1) 
(Table S8). However, when we manually inspected these events in IGV, we found 
only two interesting cases. One case represents an unambiguous skipping of exon 7 
in SUZ12, occurring in several patient samples, but most significant (Cuffdiff p-
value 5.10-5) in the R5 patient sample, and absent in thymus (Figure 4.E). and a 
potential, but less clear, skipping of exon 8 in LCK in three samples (Figure S8). 
Exon 7 of SUZ12 is a canonical exon (present in all known isoforms) according to 
RefSeq, Ensembl, and UCSC annotation. The ATE we observe is a heterozygous 
event with the wild-type junction supported by 90 reads and the novel junction 
supported by 71 reads. RT-PCR clearly confirmed the exon-skipping event in R5 
and to a minor extent in other samples, while being absent in the thymus (Fig 4.F). 
The functional consequences of these splice variants remain to be determined, but 
the fact that these variants are both in-frame suggests that these proteins could be 
functional protein isoforms (Figure S8 and S9). Overall, relatively few significant 
ATEs are detected, and no obvious ATEs are found with consequences on the 
protein structure, therefore T-ALL presents robust isoform usage at the current 
resolution of sequencing and analysis.  
 
Detection and validation of known and novel fusion transcripts 
Most of the T-ALL cases harbor chromosomal rearrangements that lead to the 
generation of fusion genes or ectopic expression of genes due to juxtaposition to 
strong promoters or regulatory sequences. Chromosomal translocations involving the 
TCR genes are largely underestimated by karyotyping and the TCR partner genes 
remained unidentified in several cases 4,47. On the other hand, a multitude of 
mechanisms other than translocations could cause ectopic expression of oncogenes 48. 
To detect fusion transcripts, we used the defuse algorithm on our entire dataset 49. 
Briefly, this method identifies candidate gene fusions by discordant alignments 
produced by spanning reads (each read in the read pair aligns to a different gene) 
and by split reads (reads that harbor a fusion boundary). The total number of 
predicted fusions initially was 1,160 and 1,265 in patient and cell line samples, 
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respectively. Also in normal thymus RNA, 60 fusion transcripts were detected. Next, 
we implemented additional filters, considering only predictions supported by 8 or 
more spanning reads and 5 or more split reads. Furthermore, we removed fusions 
involving ribosomal genes, mitochondrial genes and fusions between adjacent genes, 
as these could be caused by read-through or trans-splicing 50,51 (Figure 1.C).  
After applying these filters, we obtained an average of 5.5 fusion events per patient 
sample and 11.1 per cell line (Table S1.C). In total, 397 candidate genes are 
involved as potential partner in a gene fusion (Table S9). Details on the fusion 
breakpoints and validation of the novel candidate fusion transcripts are reported in 
Tables S9 and S12 (see also Materials and Methods: RT-PCR and Sanger 
Sequencing).  
 
First, to determine the relevance of these predicted fusion transcripts we looked at 
functional enrichment of these genes. 278 of 397 genes correspond to functionally 
annotated protein-coding genes according to DAVID functional enrichment 52,53. 
Furthermore, this set is strongly enriched for cancer-related genes, and more 
specifically for genes involved in AML (p value 4.48E-10) and T-ALL (p value 4.47E-
5), including TP53, STAT5B, NOTCH1, IL7R, IKZF1, CDKN2A, MLLT10, 
ETV6, and ABL1.  
 
Second, we specifically analyzed the 27 in-frame fusions, predicted to encode chimeric 
proteins (Table S10). This list contained known oncogenic fusion genes, including 
NUP214-ABL1 (n=2), MLL-FOXO4 (n=1), PICALM-MLLT10 (n=1), ETV6-
NCOA2 (n=1) and SET-NUP214 (n=1). In addition, we identified 3 novel chimeric 
transcripts in T-ALL, namely NUP98-PSIP1 (n=1), TPM3-JAK2 (n=1) and 
SSBP2-FER (n=1) and a novel DDX3X-MLLT10 fusion transcript (n=1) recently 
described in a pediatric T-ALL patient 54.  
 
Figure 5. SSBP2-FER and TPM3-JAK2 fusions transform lymphoid cells and show constitutive 
activity (next page).  
(A) Schematic representations of the predicted SSBP2-FER and TPM3-JAK2 fusion joining the 
dimerization units of SSBP2 (LisH domain) or TPM3 (coiled-coil domains) to the TK domain of FER or 
JAK2, respectively. (B) Proliferation curve of mouse Ba/F3 cells in the absence of the cytokine interleukin 
3 (IL3) (upper graph) and in the presence of ruxolitinib (lower graph). In the absence of IL3, cells 
expressing empty vector died whereas cells expressing the SSBP2-FER or TPM3-JAK2 fusion protein were 
transformed and could proliferate. Ba/F3 cells expressing the oncogenic JAK1 A634D mutant were used as 
positive control for transformation 18. The graph shows mean +/- st. dev. The lower graph illustrates the 
effects of the JAK kinase inhibitor ruxolitinib on Ba/F3 cell proliferation after 24 hours of treatment. The 
graph represents mean +/- st. dev. of triplicate measurements. (C) Western blot analysis of Ba/F3 cells 
transformed by the indicated kinases. The 2 upper panels show phosphorylation of the JAK and FER 
kinases, the panels below illustrate phosphorylation of downstream targets STAT5, STAT3, SRC and 
ERK1/2. (D) TCR gene fusions result in overexpression of a flanking gene in RIC3-TRBC2 and SFTA3-
TRDC fusions. The barplot is drawn for relative (to Thymus) expression values for the upstream and 
downstream flanking genes around RIC3 and SFTA3 for R4 and TLE90 samples, respectively. In both cases, 
the nearest downstream neighbor shows increased expression. (E) The heatmap illustrates the expression 
patterns of RIC3 and SFTA3, together with their immediately upstream and downstream flanking genes in 
the genome, showing strong over-expression (red) of LMO1 near the RIC3 fusion, and of NKX2-1 near the 
SFTA3 fusion. 
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Conventional cytogenetic analysis confirmed the presence of a t(X;10) in the case 
with the DDX3X-MLLT10 fusion, whereas it failed to detect the chromosomal 
rearrangements for the TPM3-JAK2, NUP98-PSIP1 and SSBP2-FER fusions, 
demonstrating the power of RNA-seq to identify cryptic fusion genes and to provide 
genetic information even in patients with uninformative cytogenetics. Reassuringly, 
RT-PCR and Sanger sequencing confirmed the presence of these fusion transcripts 
(Table S12). 
The TPM3-JAK2 and SSBP2-FER fusions encode typical tyrosine-kinase fusions 
that join the tyrosine-kinase domain of JAK2 or FER to the dimerization units of 
TPM3 or SSBP2, respectively (Figure 5.A). To assess whether the TPM3-JAK2 
and SSBP2-FER fusions encode oncogenic proteins, we tested their transforming 
properties in the IL-3–dependent Ba/F3 cell line 55. Both TPM3-JAK2 and SSBP2-
FER transformed Ba/F3 cells to IL-3–independent growth, with even faster kinetics 
than the JAK1 A634D mutant, which is a known transforming kinase 18 (Figure 
5.B). Western blot analysis confirmed the constitutive autophosphorylation of the 
JAK2 and FER fusion proteins, as well as the downstream STAT proteins (Figure 
5.C). Ba/F3 cells transformed by the TPM3-JAK2 fusion were sensitive to a JAK 
kinase inhibitor, documenting the potential application of JAK2 kinase inhibitors for 
the treatment of T-ALL cases with JAK2 fusion genes. No specific FER inhibitors 
were available to test their activity. Both TPM3-JAK2 and SSBP2-FER fusion were 
screened in 50 additional T-ALL samples, but no additional case with these fusions 
was found.  
 
Third, we also analyzed the identified fusions that did not seem to encode chimeric 
proteins (out-of-frame fusions), and which were the majority of fusions detected in 
T-ALL. These fusion events can be used as surrogate markers for the identification 
of chromosomal rearrangements, providing accurate information on the precise 
chromosomal breakpoints. In combination with the gene expression data obtained 
by RNA-seq, these data can identify genes that are located close to such potential 
breakpoints and for which the expression is significantly up- or downregulated. As 
expected, we identified the STIL-TAL1 fusion in several T-ALL cases (n=8). We 
also identified and validated 6 fusion events involving TCR genes. In 4 of these 
cases, the TCR gene was found to be fused to the potential oncogene (NOTCH1, 
IL7R, PLAG1, TLX1). In the two other cases (R4, TLE90), the TCR gene was 
fused to RIC3 or SFTA3, resulting in the ectopic expression of LMO1 and NKX2-1, 
respectively, as indicated by RNA-seq gene expression data (Figure 5.D and E). 
Similarly, we could better characterize the t(10;14) in ALL-SIL cell line that 
expresses TLX1 at high level.  
 
In addition to the TCR gene rearrangements, also other fusions were associated 
with overexpression. We detected out-of-frame fusion transcripts that joined exon 4 
of CDK6 to exon 2 of HOXA11-AS and exon 5 of CDK6 to sequences downstream 
of EVX1. In the same patient we also detected a fusion joining DPY19L1 on 
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chromosome 7p14 to HOXA11 on chromosome 7p15. The gene expression analysis 
documented high expression of genes of the HOXA cluster (i.e. HOXA9, -A5, -A13, -
A10, -A11). Moreover, other fusions identified in this study, such as CLINT1-
MEF2C, HNRP-ZNF219 (n=2), ZEB1-BMI1 and AHI1-MYB (n=2) were also 
associated with transcriptional activation of MEF2C, ZNF219, BMI1 and MYB as 
confirmed by the expression data (Table S9 and S12 and Figure S10). 
Increased MYB expression in T-ALL was previously observed as a consequence of 
MYB duplication (including in the BE-13 cell line), which may also explain the 
detected AHI1-MYB fusion 8,56.  
 
Finally, we also found out-of-frame fusion transcripts leading to the potential 
inactivation of tumor suppressor genes, such as TP53-TBC1D3F (ALLSIL cell line), 
PTEN-RNLS (LOUCY cell line), IKZF1-ABCA13 and CDKN2A-miR31HG (R6 
case), indicating a third class of fusion events (Figure S10). FISH analysis 
performed in the R6 case confirmed the p15/p16 deletion. As the genes are in close 
proximity, the IKZF1-ABCA13 was presumably generated by deletion although no 
material was available to confirm this hypothesis. 
 
DISCUSSION 
 
The landscape of genomic variation underlying T-ALL has recently been 
investigated by sequencing candidate genes 14,21, whole exomes 17 and whole genomes 
13. The results of these studies, combined with a large body of gene-by-gene evidence 
collected over the last decade, provide a growing comprehension of the T-ALL 
genome. The T-ALL genome is mainly characterized by the over-expression of TF, 
such as TLX1/3 and TAL1, in combination with gain-of-function NOTCH1 
mutations, and with additional mutations in chromatin modifiers, cellular signaling 
factors such as those involved in the JAK-STAT signaling pathway 57, tumor 
suppressor genes (TP53, PTEN, WT1), or in other genes such as ribosomal genes 17. 
Since the majority of observed mutations are point mutations and gene fusions 
(much more than copy number aberrations 13) we reasoned that RNA-seq would be 
effective to identify many of these mutations, certainly those associated with (over-
)expressed oncogenes. Indeed, exome sequencing allows identifying point mutations 
but not gene fusions; and low coverage whole-genome sequencing allows identifying 
structural variation (gene fusions) but not point mutations. In this study we 
present RNA-seq analyses on a heterogeneous group of 31 T-ALL samples and 18 
T-ALL cell-lines and demonstrate that RNA-Seq is indeed a very powerful approach 
to detect gene mutations and fusions as well as expression perturbations.  
 
Our first challenge with regards to the accurate identification of point mutations 
was finding the optimal analysis pipeline – from read mapping to SNV calling and 
filtering – to avoid too many false positive SNVs. By exploiting whole-exome 
sequencing data for a subset of our samples we obtained a recovery ratio of 32% 
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when compared to the exome derived SNVs; a ratio that is comparable with 
previous RNA-seq studies 30,31. However, this concordance could only be achieved by 
using the optimal read mapping methods and parameters: (1) use of a recent 
version of TopHat2 (v. 2.0.5. or higher) and (2) forcing this aligner to map all reads 
twice to the genome (once directly and once using split reads) and once to the 
transcriptome. Indeed, the computational task of sequence read mapping is more 
challenging for RNA-seq data because a large fraction of the obtained reads need to 
be split to allow reads that overlap exon-exon boundaries in the cDNA to be 
mapped to the genome. In this way, RNA-seq is more prone to the identification of 
false SNVs due to the erroneous mapping of reads, for example to highly similar 
non-spliced pseudogenes. For example, in the RPMI8402 cell line, 603 RNA-seq 
exclusive SNVs were found with the genome mapping strategy, while only 35 when 
using combined mapping strategy.  
Among the previously published large scale RNA-seq cancer studies, only a handful 
performed variant calling on the RNA-seq data 30,31,58,59. A combined mapping 
strategy was followed in all cases either by mapping the reads to a customized 
genome reference file (by the addition of exon junction segments) or mapping the 
reads twice (once to the genome and once to the transcriptome). Variant calling 
pipelines also showed diversity: Morin et al and Shah et al used SNVMix 60 for 
variant calling, while Seo et al and Berger et al implemented filters based on 
alignment on the non-reference bases. To our knowledge there is no extensive 
benchmarking study evaluating aligners and variant callers for RNA-seq data, but a 
review paper by Quinn et al compared the performance of two variant callers 
(GATK 23 and SAMTools27) with the optional duplicate removal step (pre and post 
alignment), and concluded that post-alignment duplicate removal and variant calling 
with SAMTools achieved the best performance in terms of sensitivity and specificity 
61. We have also followed the same strategy in our study and we could achieve a 
comparable recovery ratio of 32% when compared to Exome-seq calls.  
A second challenge in identifying point mutations was the prioritization of candidate 
driver mutations versus passenger mutations. Due to the lack of matched germline 
RNA for each patient as control, we used a large cohort of local normal exome 
datasets, in combination with the commonly used variants from dbSNP and 
1000genomes, to distinguish SNPs from candidate somatic mutations. This strategy 
has been successfully used before on transcriptome sequencing studies 62. Identifying 
candidate cancer genes by gene mutation frequency is a frequently used approach 
13,30,58. Remarkably, by simply selecting all genes having a candidate somatic 
mutation in at least two samples (213 genes in total), we already achieved a highly 
significant enrichment for T-ALL related genes, such as NOTCH1, BCL11B, 
FBXW7, DNM2, JAK3, JAK1, and IL7R. Among the remaining candidates we 
searched for additional evidence and we propose seven additional candidate drivers 
because they are either “functionally similar” to the previously known drivers, or 
because they were mutated somatically at least once in another T-ALL cohort 17, or 
both. Six of these genes, namely CIC, H3F3A, PTK2B, STAT5B, ANKRD1 and 
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HADHA have already been implicated in other cancers 63-70 while DOCK2 has no 
association with cancer yet.  
 
We found a remarkable clustering of molecular functions among the identified T-
ALL driver genes, with enrichment for functions related to the regulation of gene 
expression. TFs and their co-factors play a central role in transcriptional regulation 
and these proteins are often mutated in T-ALL. Also, many of these play important 
roles in the normal T-cell developmental gene regulatory network 71, such as 
NOTCH1, TLX1, TLX3, TAL1, BCL11B, CTCF, FOXO4, MYB, and others. 
Upstream of these activated TFs, multiple kinases and other signaling factors 
control their activity, and these regulators are also often mutated in T-ALL (for 
example, JAK1, JAK3, and IL7R). Finally, chromatin modifiers and methylation 
factors are recurrently mutated and these can have both generally pervasive but also 
specific effects on the expression of oncogenes, such as MYC 72. When multiple 
driver mutations are serially acquired, their combined effect will result in oncogenic 
expression profiles, whereby genes supporting a growth advantage increase and 
genes negatively affecting growth advantage (e.g., apoptosis, senescense) decrease in 
expression. It will be an interesting future challenge to draw the connections 
between the observed DNA mutations, the oncogenic program, and the final gene 
expression changes that we and others observe in T-ALL samples. Finally, it is likely 
that non-coding mutations, such as those in promoters, enhancers, microRNAs, and 
lncRNAs, add to the cancer-related gene regulatory network changes underlying 
leukemogenesis. 
 
As mentioned above, only mutations in genes that are actively transcribed are 
detected, and this likely adds to the specificity of driver gene detection. On the other 
hand, this could also present a limitation of RNA-seq, because loss-of-function 
mutations in tumor suppressor genes may lead to nonsense-mediated decay, and as 
consequence low sequence coverage to call mutations. Based on our data however, 
this is not the case because we could detect PHF6 mutations in up to 4/31 patient 
cases (13%), where exome sequencing identified PHF6 mutations in 9/67 cases (13%) 
17 and Zhang et al identified PHF6 mutations in 24/106 cases by means of whole 
genome sequencing and capillary sequencing 13.  
Interestingly, the gene expression information used above (i.e., read coverage to 
identify point mutations) can be further exploited at the quantitative level, similar 
to gene expression studies performed with microarray technology over the last 15 
years. As many leukemia driver genes are characterized by changes in gene 
expression, this level of information is invaluable, both in research and diagnostic 
settings. We investigated how accurate gene expression levels can be achieved and we 
found that multiple normalization steps are required, both within-sample (gene 
length and gene GC content) and across samples (library size), and that batch 
effects can be effectively removed using a previously published Generalized Linear 
Model (GLM) 73. The gene expression levels of the known drivers (e.g., TLX1/3, 
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TAL1, NOTCH1) are highly representative as driving events and as subtype 
identifiers. However, to discover driver genes de novo, using only gene expression 
values, is to our opinion not feasible (data not shown). Alternatively, we attempted 
to select candidate drivers based on the expression similarity (i.e., co-expression 
across the cohort) with known drivers. This led to the identification of PTK2B, 
whose expression strongly correlated with JAK3 and which is known to be 
implicated in JAK-STAT signaling. The next level of gene expression analysis would 
preferably be a network-level analysis 74, but this requires a larger sample cohort.  
 
Another kind of information that can be extracted from RNA-seq data, besides 
point mutations and gene expression changes, are alternative transcript events 
(ATE) and gene fusions 75. We found only few significant ATEs but could confirm 
two exon-skipping events in the known T-ALL oncogenes SUZ12 and LCK. More 
importantly, we identified (i) known and novel in-frame fusions encoding chimeric 
proteins, (ii) TCR gene arrangements resulting in over-expression of oncogenes, and 
(iii) fusions not involving TCR genes but also resulting in over-expression of 
oncogenic transcription factors. The most recurrent fusion event, observed in 8/31 
samples, was the STIL-TAL1 fusion resulting in the ectopic over-expression of the 
TAL1 gene. We also identified novel gene fusions, including two in-frame fusions, 
TPM3-JAK2 and SSBP2-FER, producing chimeric oncoproteins; and other fusions 
resulting in the ectopic expression of transcription factors such as PLAG1, MEF2C, 
ZNF219, and BMI1. The ectopic expression of these genes is associated with a fusion 
event and with changed expression, which can both be detected by RNA-seq, 
making this technology extremely powerful to accurately detect such oncogenic 
events. Each of these novel events appears to be rare in T-ALL, as we identified at 
most 2 cases of each fusion. However the evidence of transcriptional activation of the 
partner genes suggests that further studies are required to establish the recurrence 
of these lesions and their functional meaning. It is notable that the normal thymus 
sample also shows four fusion events. However, as these genes are located in close 
proximity to each other, they may represent unannotated isoforms in the human 
transcriptome. Despite RNA-seq has offered a deeper insight into the complexity of 
the transcriptome, several studies have highlighted that the catalogue of all 
expressed transcripts is still far from complete and it is increasing the number of 
novel splice junctions connecting novel exon, non-exon regions, or linking 
independent transcripts 76.  
 
Today, high-quality catalogues of driver genes across cancer types are available, and 
this influences how and why cancer genomes need to be sequenced. For T-ALL, and 
for many common cancer types, the objectives of sequencing are shifting from the 
discovery of cancer genes, to a diagnostic setting in which a list of driver events are 
a priori known. Targeted re-sequencing provides an interesting route, although this 
poses technical challenges of amplification or capturing, and perhaps more 
importantly, is focused on a limited number of genes and on one particular 
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mutation type, namely point mutations and small indels. We have shown in this 
study that, with a list of interesting cancer drivers at hand, and with other datasets 
being available (e.g., rare variants from local exome studies, 1000 genomes, TCGA 
data, etc), RNA-sequencing of only the cancer sample provides a technically 
straightforward approach and delivers at once the point mutations, gene fusions 
and gene expression changes across the entire transcriptome. And as a corollary, the 
data analysis strategies provided here would be beneficial for any cancer type as long 
as a body of knowledge is available for selecting and prioritizing candidate events.  
 
MATERIALS AND METHODS 
  
Patient samples and cell lines 
Diagnostic total RNAs from 31 T-ALL patients (20 adults and 11 children) were 
collected at various institutions. All patients have given their informed consent and 
all samples were obtained according to the guidelines of the local ethical committees. 
This study was approved by the ethical committee of the University Hospital 
Leuven. Diagnosis of T-ALL was based on morphology, cytochemistry and 
immunophenotyping according to the World Health Organization and European 
Group for the Immunological Characterization of Leukemia criteria 77. The clinical 
and hematologic features of the 31 patients at the diagnosis are summarized in 
Table S11 Total RNAs from 18 T-ALL cell lines (DSMZ, Braunschweig, Germany) 
were extracted using QIAGEN RNeasy Mini Kit. A pool of total RNAs from 5 
normal human thymuses was purchased from Capital Biosciences. 
All the RNA samples showed a high quality RNA Integrative Number (RIN>/=7) 
score on the Bioanalyzer (Agilent Technologies).  
Fifty additional RNA samples were used for TPM3-JAK2 and SSBP2-FER analysis. 
Genomic DNA from of 71 adult T-ALL patients were used for H3F3A K28 
screening.  
 
RNA-seq 
Next generation sequencing libraries were constructed from 500 ng of total RNA 
using the Truseq RNA sample prep kit (Illumina). RNA-seq libraries were subjected 
to 2 x 100bp paired-end sequencing on a HiSeq2000 instrument (Illumina). Sequence 
reads were processed to identify gene fusion transcripts, single nucleotide variants 
(SNVs) and gene expression levels. For the read mapping, variant calling and 
transcriptome assembly, we used the infrastructure of the VSC - Flemish 
Supercomputer Center, funded by the Hercules foundation and the Flemish 
Government - department EWI. 
 
Fusion transcript discovery 
Fusion transcript discovery was performed using defuse v.0.5.0 49 with default 
parameters. The resulting list was filtered as described in 78. Briefly, fusion 
transcripts with less than 8 spanning reads and less than 5 split reads were filtered 
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out. In addition, we removed fusion events observed in adjacent genes and fusion 
events involving ribosomal genes (ribosomal genes were downloaded from Biomart 
on 24-05-2011 using GO:0005840) and the genes located on chrM. Fusion events 
were annotated using Pegasus (http://sourceforge.net/projects/pegasus-fus/).  
 
Gene expression analysis 
For Gene Expression Profiling analysis, reads were mapped to the human reference 
genome (assembly GRCh37.68) using TopHat v.2.0.5 26 with the following 
parameters: transcriptome-only. Read counts per gene were obtained with the 
HTSeq package (htseq-count) (http://www-huber.embl.de/users/anders/HTSeq). 
The aggregated read counts were normalized with EDASeq v1.4.0 79 and generalized 
linear model was fitted with edgeR v3.0.4 73 to remove batch effect originating from 
the sample collection center. The pathways, and upstream regulators were generated 
through the use of IPA (Ingenuity® Systems, www.ingenuity.com). Expression 
neighbors were detected with Pavlidis Template Matching (PTM) analysis 80. 
Transcript based gene expression values were obtained using Cufflinks suite 81,82. 
Transcript assembly was performed with cufflinks v2.1.1 with –g option using 
assembly GRCh37.68.  
Gene set enrichment analysis (GSEA) was performed for TAL1, TLX and LYL1 
clusters 83. We have obtained whole genome rankings for TAL1, TLX (TLX1 and 
TLX3), and LYL1 simply by calculating the log fold changes between samples 
expressing the respective gene versus the remaining samples. The gene signatures 
from Soulier et al were obtained from Table S2 41.  
 
Alternative Transcript Event Discovery 
Tumor patient samples and Thymus RNA-Seq samples were mapped to the 
Ensembl GRCh37.68 reference genome by Tophat2 26. Mapped reads were realigned, 
and transcript abundance were estimated using cufflinks v2.1.1 81,82. Transcript 
assembly was reconstructed using the cuffmerge program of the cufflinks package 
from the realigned transfrags for each of patient RNA-seq samples, merged with the 
Thymus sample (control), followed by differential expression analysis performed 
using cuffdiff2 program. The significant events were extracted from the list of 
differentially expressed genes, isoforms, primary transcripts and coding sequence and 
assessed manually with IGV 84. The mRNA sequences for novel SUZ12 and LCK 
transcripts were extracted using gffread command of cufflinks, and these sequences 
were translated using the translate tool of the ExPASy Bioinformatics Resource 
Portal 85. The longest ORF sequence was used to verify the domain architecture of 
the resulting proteins using SMART 86,87. 
 
Prediction of Single Nucleotide Variation  
The sequence reads were mapped to the human reference genome (assembly 
GRCh37.68) using TopHat2 setting the option "read-realign-edit-dist" to zero 26. 
Duplicate removal process was performed on the aligned reads using Picard v1.74 
CHAPTER III: RESULTS 
119 
 
C
HAPTER III: R
ESULTS 
(http://picard.sourceforge.net). Then SAMTools package v0.1.19+ (pulled from the 
git repository on 29-07-2013) 27 was used for single nucleotide variant (SNV) and 
small insertion and deletion (INDEL) detection with minimum mapping quality 
threshold of 1 and minimum base quality threshold of 13 (-q 1 -Q 13) 27. The 
variant calling was done on the coding regions of the genome only (extracted from 
the transcript definitions in the assembly GRCh37.68). The variant predictions that 
were supported exclusively by variants located in the beginning or the end of the 
read were filtered out. Then the SNVs were further filtered with depth of coverage 
threshold of 20 and minimum variant allele frequency threshold of 0.20. INDELs 
predictions were filtered with the SAMTools recommended parameters (varFilter -10 
-20 -30 -40 -a4 -G90 -S30) and additionally INDELs located in homopolymer 
stretches longer than 5 bps were filtered. The high quality list of variants was 
filtered for common population variants using the calls from 1000 genomes, dbSNP, 
HapMap, and Complete Genomics. Note that, the list of common population 
variants was cleaned from oncogenic variants using COSMIC listed variants (v66) 36. 
Moreover, the variants located in the repeat regions (simple repeat and 
RepeatMasker) were filtered out. Finally, the variants that are observed in the 
exomes of remission (i.e. healthy) samples (including the previously published 39 
exome remissions 17 and the 6 additional exome remission sequenced) and the 
variants that are observed in Thymus were also filtered out. The final filtered list of 
variants was annotated with the Variant Effect Predictor version 2.7 25 and the 
protein-altering mutations were selected. The following terms were used for selecting 
protein-altering SNV: splice_donor_variant, splice_acceptor_variant, stop_gained, 
initiator_codon_variant, missense_variant, splice_region_variant. The same terms 
were used for filtering the INDELs with the addition of the following terms: 
inframe_insertion, inframe_deletion, frameshift_variant.  
The list of candidate genes was created by intersecting the genes with recurrent 
mutations (SNVs and INDELs) in RNA-seq patient cohort with the somatic 
mutations in Exome-seq patient cohort 17. The list of genes that have recurrent 
mutations in the RNA-seq patient cohort was filtered for mutations observed in 
chrM.  
The list of T-ALL driver genes were curated using the Census database 46 and T-
ALL literature and includes the following genes: TLX1, TLX3, PHF6, MYC, 
BCL11B, HOXA1, SET, MLL, MLLT1, PICALM, MLLT10, WT1, MYB, LEF1, 
LMO2, LMO1, TAL1, NUP98, NOTCH1, FBXW7, CCND2, PTEN, PTPN2, NF1, 
FLT3, JAK1, NRAS, LCK, NUP214, ABL1, EZH2, SETD2, SUZ12, JAK3, 
MEF2C, NKX2-1, NKX2-2, CDKN2A, CDKN2B, RUNX1, KRAS, EED, ETV6, 
RPL10, DNM2, IL7R, CNOT3.  
 
Exome-seq analysis  
Somatic mutations from the exome pairs were obtained as described previously 17. 
Briefly, the alignment was performed with BWA 22 and post-alignment modifications 
(duplicate removal, realignment around indels and calibration of the quality scores) 
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were done with the Genome Analysis Toolkit (GATK) 23. Variant calling was 
performed with GATK using Variant Quality Score Recalibration (VQSR) method. 
Putative somatic variants were identified by subtracting the mutations observed in 
the primary samples from the mutations observed in the corresponding remission 
samples. SomaticSniper score above 70 was used to identify the final list of somatic 
events 24.  
Variant allele frequency (VAF) plots were drawn for the positions that are novel 
SNVs in either of the RNA-seq or Exome-seq data and covered by at least 20 reads 
in both datasets.  
 
RT-PCR and Sanger Sequencing 
Novel candidate fusion transcripts were validated by Reverse-Transcription 
Polymerase-Chain-Reaction (RT-PCR) and Sanger sequencing. In all cases thymus 
was used as negative control. cDNA synthesis and PCR amplification were 
performed using standard protocols that come with Superscript III Reverse 
Transcriptase (Invitrogen) and GoTaq (Promega). PCR primers were designed to 
amplify 200-400 bp fragments containing the fusion boundary detected by RNA-seq. 
The PCR products were analyzed using a QIAxcel automated multicapillary 
electrophoresis system (QIAGEN). The results were processed and visualized using 
the BioCalculator Software. PCR products were analyzed by Sanger Sequencing. In 
cases where multiple PCR products were detected, we performed conventional 
agarose gel electrophoresis and extraction of specific bands using the gel DNA 
Recovery Kit (Zymo). Analysis of Sanger chromatograms was performed using CLC 
Main Workbench 6 (CLC Bio, Aarhus, Denmark). Fusion detection was performed 
using NCBI Blast alignment. Analysis of the breakpoint was done on the longest 
isoform reported on the Ensembl genome browser. The tested fusions predictions 
and the primers used for validations are reported in Table S12.  
Validation of SUZ12 exon skipping was performed by RT-PCR, gel extraction and 
sequencing of the two PCR products (Figure 4.I). The following primers were used 
for RT-PCR and Sanger sequencing: SUZ12_EX1F 
(CTGACCACGAGCTTTTCCTC) and SUZ12_EX9R 
(CCATTTCCTGCATGGCTACT).  
 
Cloning 
The plasmid TPM3-JAK2 pMSCV-GFP was obtained as follows: a DNA fragment 
containing TPM3 coding region till exon 7 was PCR amplified from thymus cDNA 
using Phusion High Fidelity DNA Polymerase (Finzyme) and primers containing 
BglII and XhoI restriction sites. Primers containing XhoI and EcoRI restriction sites 
were used to amplify JAK2 coding exons 17-25. PCR products were cloned into the 
BglII and EcoRI sites of the pMSCV-GFP vector after subcloning into the pJET1.2 
CloneJET vector (Fermentas). As a final control, plasmid DNA was sequenced by 
Sanger sequencing. 
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SSBP2-FER fusion was synthesized by Genscript (Piscataway, NJ, USA) and cloned 
into pMSCV-GFP by using the unique restriction sites XhoI and EcoRI. The 
plasmid contained the full length SSBP2-FER fusion including the first 16 coding 
exons of SSBP2 and the coding exons 14-20 of FER.  
 
Cell culture 
Viral supernatants were produced in HEK293T cells using an EcoPack packaging 
plasmid and TurboFect transfection reagent (Fermentas). Viruses were harvested 
48 hours after transfection followed by transduction of the Ba/F3 murine pro-B 
cells (DSMZ, Braunschweig, Germany) as described previously 88. 
 
Transformation experiments 
Ba/F3 cells were washed twice in PBS to remove all traces of cytokines and were 
seeded in triplicate in 24-well dishes at 100 000 cells/mL. GFP expression and cell 
number were measure on a Guava flow cytometer (Millipore). All experiments were 
terminated at day 8 after cytokine removal and cell lines showing no sign of cell 
proliferation at that timepoint were declared to be non-transforming. 
 
Western blotting 
Total cell lysates were analyzed by standard electrophoresis and western blotting 
procedures using the following antibodies: anti-phospho-JAK1 (Tyr1022/1023), anti-
phospho-STAT1, anti–phospho-STAT5 (Tyr694), anti–phospho-STAT3 (Tyr705), 
anti-phosphoERK1-2, anti-phospho-SRC families (Tyr416) (from Cell Signaling 
Technology). 
 
Inhibitor experiments 
TPM3-JAK2 and SSBP2-FER IL3-independent Ba/F3 cells were seeded in triplicate 
in 96-well plates at a density of 0.03 X 106 cells in the presence of JAK inhibitor 
Ruxolitinib (INCB018424, Azon Medchem). Cell proliferation and viability were 
assessed on a Guava flow cytometer after 24 hours to determine the IC50, the 
concentration of inhibitor that gave a 50% inhibition. 
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Figure S1. Suboptimal mapping strategies result in incorrect read alignment.  
Alignment of the Exome-seq and RNA-seq reads on GLUD2 and GLUD1 genes for the RPMI8402 cell line. 
Two alignment strategies are visualized in these figures for RNA-seq: genome-only mapping and combined 
mapping strategy. Panel (A) shows the alignment for GLUD2 gene. With exome-seq a very high coverage 
was achieved (the coverage track scale is 0-1000). Aligning the RNA-seq reads with ‘genome-only’ option 
yields high coverage as well however with a lot of mismatches in the alignment (colored lines indicate the 
presence of a nucleotide different than the reference base). However, when combined mapping strategy is 
applied the coverage drops drastically. Panel (B) shows the alignment of GLUD1 gene. When mapping with 
genome only option, the coverage is not high (the coverage track scale is 0-900) since the reads are forced 
to map to the pseudogene (GLUD2) with a lot of mismatched. When the combined mapping strategy 
implemented, the reads align to GLUD1 gene correctly with less mismatches. 
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Figure S2. Variant allele frequency plots for assessing transcriptome-only mapping strategy.  
The variant allele frequencines of the SNVs that have at least 20X reads in exome-seq and RNA-seq are 
plotted. The RNA-seq SNVs were obtained with the transcriptome-only alignment option. Red and green 
dots represent the SNVs that are detected only in RNA-seq and only in exome-seq, respectively, while black 
dots represent the SNVs that are called in both. Venn diagrams are produced from the points represented in 
the graphs. The plots are generated for (A) RPMI8402 cell line and (B) TLE79 patient sample. 
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Figure S3. Variant Allele Frequency (VAF) plots for 16 cell lines and 20 patient samples.  
RNA-seq calls are made with combined mapping strategy. The venn diagrams and VAF plots are drawn for 
variants that have sequence coverage of at least 20X.  
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Figure S4. Scatter plot of average coverage versus recall ratio per sample.  
Recall ratio per sample is calculated as the percentage of Exome-seq SNVs that are called in the RNA-seq 
as well. Recall ratio 0.3 is assumed as the indicator of a ‘good sample’ in terms of variant detection. 
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Figure S5. Visualization of the alignments with Exome-seq and RNA-seq for the 5 INDELs that are 
validated in the DNA of the samples but absent in the RNA-seq alignments.  
The Exome-seq and RNA-seq alignment files are visualized using IGV for A. KDM6A in TLE87, B. PTEN 
in TLE92, C. WT1 in TLE76, D. USP9X in SUPT1, and E. UNC5D in MOLT4. The exome-seq alignment 
files (below) have the reads containing the INDEL, whereas RNA-seq alignment files (above) either contain 
reads with reference only (A, B, and E) or a small portion of reads with INDEL (C and D).  
 
CHAPTER III: RESULTS 
138 
 
C
HAPTER III: R
ESULTS 
 
CHAPTER III: RESULTS 
139 
 
C
HAPTER III: R
ESULTS 
 
CHAPTER III: RESULTS 
140 
 
C
HAPTER III: R
ESULTS 
Figure S6. INDELs in TLE92 and TLE87 are detected after mapping with a different aligner.  
The screenshots from UCSC genome browser shows A. the 4 bp deletion in PTEN (note that only a part of 
the alignment was shown) and B. 1bp deletion in KDM6A. In both cases BWA transcriptome-only mapping 
was coupled to BLAT genome mapping. In C and D, TopHat2 transcriptome-only mapping coupled with 
BLAT genome mapping was displayed for PTEN and KMD6A INDELs, respectively. 
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Figure S7. Batch effect removal for gene expression profiling.  
Multidimensional scaling (MDS) plots before and after batch effect removal. A batch effect was observed 
whereby samples originating from the same collection center clustered together based on the edgeR 
normalized gene-by-gene counts (A). A similar clustering was observed when the FPKM values per 
transcript was used (B). After fitting a Generalized Linear Model (on the edgeR normalized gene-by-gene 
counts) accounting for sample collection center, the aberrant clustering of the samples is corrected (C).  
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Figure S8. Overview of exon skipping event in LCK.  
(A) Predicted novel transcript of LCK aligned with known LCK isoforms. Dotted red box indicates the 
exon-skipping event in the 8th exon (B) Sashimi plot detailing the junction supporting the exon skipping 
event in patient samples R5, R5 and TLE93 with respect to Thymus. (C) Schematic representation of the 
predicted alternative splicing event of LCK. The exon skipping ratio (C/A+B+C) of exon 8 of LCK in R5, 
R4, TLE93 are 0.40, 0.47 and 0.20, respectively. (D) Schematic overview of LCK protein illustrating the 
spliced out portion without affecting the functional domains. 
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Figure S9. Schematic overview of the SUZ12 exon-skipping event.  
(A) Schematic representation of the predicted alternative splicing event of SUZ12. The exon skipping ratio 
(C/A+B+C) of exon 7 of SUZ12 in R5 is 0.35. (B) Schematic overview of SUZ12 protein illustrating the 
spliced out portion without affecting the functional domains. 
 
 
Figure S10. Out-of-frame fusions can have various consequences.  
The over or under expression caused by out-of-frame gene fusions are illustrated in the normalized 
expression heatmap. CLINT1-MEF2C, HNRP-ZNF219, ZEB1-BMI1 and AHI1-MYB fusion are associated 
with overexpression of MEF2C, ZNF219, BMI1 and MYB; whereas as TP53-TBC1D3F, PTEN-RNLS, 
IKZF1-ABCA13 and CDKN2A-miR31HG fusions are responsible for the underexpression of TP53, PTEN, 
IKZF1 and CDKN2A. 
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Table S1. (A) Sequencing and mapping statistics, (B) Variant statistics, (C) Fusion statistics  
Table S1.A. Sequencing and mapping statistics 
 
 Sample 
Total 
Number 
of Reads 
Mean 
Target 
Coverage 
2X 
Coverage 
(%) 
10X 
Coverage 
(%) 
20X 
Coverage 
(%) 
30X 
Coverage 
(%) 
ALLSIL 58424415 90,2 0,49 0,39 0,35 0,32 
CCRFCEM 62730572 61,86 0,48 0,4 0,34 0,3 
DND41 88001825 179,51 0,52 0,43 0,4 0,38 
HPBALL 88897354 135,8 0,58 0,45 0,4 0,37 
HSB2 40873291 74,47 0,53 0,42 0,37 0,33 
JURKAT 88221222 172,95 0,56 0,46 0,42 0,4 
KARPAS45 65822553 89,9 0,94 0,71 0,53 0,43 
KE37 58459669 79,79 0,92 0,66 0,48 0,39 
LOUCY 69422887 82,5 0,94 0,73 0,56 0,45 
MOLT4 94708631 128,03 0,95 0,78 0,61 0,5 
MOLT14 87567592 145,97 0,57 0,45 0,41 0,38 
P12ICHIKAWA 53998577 76,42 0,91 0,64 0,46 0,37 
PEER 45406860 77,23 0,5 0,36 0,28 0,24 
PF382 83334490 140,04 0,6 0,46 0,41 0,38 
RPMI8402 79017501 125,56 0,59 0,46 0,41 0,38 
SUPT1 49895390 48,42 0,48 0,37 0,3 0,24 
SUPT13 58387261 75,04 0,91 0,61 0,44 0,36 
Ce
ll 
Li
ne
s 
TALL1 42768080 80,32 0,48 0,39 0,34 0,3 
R1 60261677 73,24 0,57 0,45 0,38 0,34 
R3 4360841 7,35 0,19 0,04 0,02 0,01 
R4 53008343 69,74 0,57 0,42 0,34 0,29 
R5 25383022 46,34 0,49 0,36 0,29 0,23 
R6 28409604 48,88 0,51 0,38 0,29 0,23 
R7 85277047 102,01 0,97 0,83 0,67 0,55 
R8 73952998 101,1 0,96 0,79 0,61 0,49 
R9 93048786 82,08 0,96 0,78 0,59 0,48 
R10 101832247 93,62 0,96 0,79 0,62 0,5 
RM2 64790950 90,46 0,57 0,44 0,37 0,33 
TLE76 31257065 46,14 0,84 0,47 0,3 0,23 
TLE77 52836140 66,49 0,8 0,42 0,3 0,24 
TLE79 29413263 33,74 0,91 0,59 0,32 0,19 
TLE80 93907574 128,33 0,85 0,52 0,41 0,36 
TLE81 62090742 76,04 0,95 0,76 0,57 0,44 
TLE85 36800184 50,94 0,93 0,65 0,4 0,26 
TLE86 58813818 84,6 0,94 0,71 0,51 0,4 
TLE87 64363651 91,98 0,93 0,7 0,52 0,41 
TLE89 79024483 117,57 0,93 0,7 0,51 0,42 
TLE90 54605273 83,09 0,94 0,7 0,49 0,37 
Pa
tie
nt
s 
TLE91 56011156 82,98 0,91 0,62 0,44 0,35 
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TLE92 69228913 103,11 0,9 0,59 0,42 0,34 
TLE93 50392641 73,76 0,9 0,58 0,39 0,3 
TUG1 63614364 96,91 0,56 0,43 0,37 0,32 
TUG2 36014631 53,19 0,52 0,36 0,27 0,21 
TUG3 90673798 112,33 0,6 0,46 0,4 0,36 
TUG4 62401567 83,91 0,59 0,45 0,38 0,33 
TUG5 83629512 114,37 0,59 0,46 0,41 0,37 
TUG6 62199073 79,55 0,57 0,44 0,38 0,33 
TUG7 85454478 99,56 0,61 0,47 0,41 0,37 
 
TUG8 61922165 68,23 0,63 0,47 0,39 0,34 
 Thymus 127342408 128,77 0,97418 0,85528 0,712207 0,60432 
 Average 64365211.68 89,09     
 Min 4360841 7,35     
 Max 127342408 179,51     
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Table S1.B. Variant Statistics  
Initial Variant Calling Custom Variant Filtering 
 
Sample SNVs INDELs SNVs INDELs 
ALLSIL 10464 63 555 25 
CCRFCEM 10464 120 1201 56 
DND41 9980 136 766 26 
HPBALL 8505 57 19 8 
HSB2 7033 78 471 23 
JURKAT 11725 169 1836 59 
KARPAS45 14392 84 1532 6 
KE37 9883 103 62 4 
LOUCY 12761 121 65 12 
MOLT4 14612 126 256 18 
MOLT14 8086 50 73 3 
P12ICHIKAWA 9853 76 101 4 
PEER 5161 70 64 3 
PF382 8856 44 511 4 
RPMI8402 7572 42 116 4 
SUPT1 7589 92 979 5 
SUPT13 8916 92 67 42 
Ce
ll 
lin
es
 
TALL1 5873 46 75 3 
R1 7072 69 63 3 
R3 291 7 2 0 
R4 5710 81 49 2 
R5 4420 54 46 5 
R6 4485 61 43 4 
R7 14592 107 109 9 
R8 13022 102 75 8 
R9 13550 117 91 4 
R10 14760 123 74 5 
RM2 7505 51 83 4 
TLE76 4797 54 36 1 
TLE77 5753 65 35 0 
TLE79 7743 85 23 0 
TLE80 8905 103 42 8 
TLE81 14038 117 47 2 
TLE85 9909 87 27 5 
TLE86 12546 101 64 7 
TLE87 12715 109 52 7 
TLE89 12108 95 64 7 
TLE90 10190 85 54 1 
TLE91 8921 85 45 5 
TLE92 8469 87 44 4 
Pa
tie
nt
 sa
m
pl
e 
TLE93 7922 91 34 6 
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TUG1 7143 36 5 3 
TUG2 5013 26 42 2 
TUG3 7983 46 9 2 
TUG4 8217 52 11 3 
TUG5 8493 54 9 0 
TUG6 7765 43 15 3 
TUG7 8355 53 12 4 
 
TUG8 8847 62 349 11 
      
Sum 442964 3877 10403 430 
Average 9040,1 79,1 212,3 8,8 
Median 8505 81 63 4 
Max 14760 169 1836 59 
To
ta
l 
Min 291 7 2 0 
      
      
Sum 271239 2308 1654 125 
Average 8749,6 74,5 53,4 4,0 
Median 8355 81 44 4 
Max 14760 123 349 11 
Pa
tie
nt
s o
nl
y 
Min 291 7 2 0 
 
CHAPTER III: RESULTS 
149 
 
C
HAPTER III: R
ESULTS 
Table S1.C. Fusions statistics 
 Sample 
# of fusions 
before 
filtering 
# of fusions 
after defuse 
filtering 
# of fusions 
after custom 
filtering 
ALLSIL 585 80 17 
CCRFCEM 512 40 5 
DND41 796 37 3 
HPBALL 1963 113 19 
HSB2 1136 99 10 
JURKAT 1263 68 10 
KARPAS45 833 71 10 
KE37 685 44 6 
LOUCY 820 91 10 
MOLT4 704 19 0 
MOLT14 1381 104 15 
P12ICHIKAWA 690 37 6 
PEER 563 19 4 
PF382 1378 80 11 
RPMI8402 2919 239 42 
SUPT1 485 84 24 
SUPT13 576 19 4 
Ce
ll 
Li
ne
s 
TALL1 466 21 4 
R1 770 59 7 
R3 209 4 0 
R4 632 43 8 
R5 316 21 2 
R6 431 21 7 
R7 972 44 9 
R8 824 33 4 
R9 1283 71 5 
R10 1686 74 4 
RM2 710 37 4 
TLE76 692 43 9 
TLE77 724 26 4 
TLE79 1101 17 4 
TLE80 1255 53 11 
TLE81 669 38 5 
TLE85 517 17 3 
TLE86 580 15 5 
TLE87 675 14 5 
TLE89 1052 46 12 
Pa
tie
nt
s 
TLE90 1269 72 13 
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TLE91 792 37 7 
TLE92 1202 69 10 
TLE93 829 35 2 
TUG1 552 33 3 
TUG2 341 12 1 
TUG3 1014 38 8 
TUG4 653 18 3 
TUG5 1019 55 6 
TUG6 565 24 6 
TUG7 852 56 4 
 
TUG8 627 35 0 
 Thymus 1633 60 4 
     
Sum 42568 2425 371 
Average 868.73 49.49 7.57 
Median 724 38 6 
Max 2919 239 42 
To
ta
l 
Min 209 4 0 
     
     
Sum 24813 1160 171 
Average 800.42 37.42 5.52 
Median 724 37 5 
Max 1686 74 13 
Pa
tie
nt
s o
nl
y 
Min 209 4 0 
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Table S2. Samples analyzed in this study  
 Sample RNAseq Diagnosis exome Remission exome 
ALLSIL yes yes (*) NA 
CCRFCEM yes yes (*) NA 
DND41 yes yes (*) NA 
HPBALL yes no NA 
HSB2 yes yes (*) NA 
JURKAT yes yes (*) NA 
KARPAS45 yes yes (*) NA 
KE37 yes yes (*) NA 
LOUCY yes yes (*) NA 
MOLT4 yes yes (*) NA 
MOLT14 yes no NA 
P12ICHIKAWA yes yes (*) NA 
PEER yes yes (*) NA 
PF382 yes yes (*) NA 
RPMI8402 yes yes (*) NA 
SUPT1 yes yes (*) NA 
SUPT13 yes yes (*) NA 
Ce
ll 
Li
ne
s 
TALL1 yes yes (*) NA 
R1 yes no no 
R3 yes no no 
R4 yes no no 
R5 yes no no 
R6 yes no no 
R7 yes no no 
R8 yes no no 
R9 yes no no 
R10 yes no no 
RM2 yes no no 
TLE76 yes yes (*) no 
TLE77 yes yes no 
TLE79 yes yes (*) no 
TLE80 yes yes (*) no 
TLE81 yes yes no 
TLE85 yes yes (*) no 
TLE86 yes yes no 
TLE87 yes yes (*) no 
TLE89 yes yes (*) no 
TLE90 yes yes (*) no 
TLE91 yes yes (*) no 
TLE92 yes yes (*) no 
TLE93 yes yes no 
Pa
tie
nt
 S
am
pl
es
 
TUG1 yes yes yes 
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TUG2 yes yes no 
TUG3 yes yes yes 
TUG4 yes yes yes 
TUG5 yes yes yes 
TUG6 yes yes yes 
TUG7 yes yes yes 
 
TUG8 yes no no 
 THYMUS yes no no 
* published previously in De Keersmaecker K, Atak ZK, Li N, Vicente C, Patchett S, et al. (2013) Exome 
sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute 
lymphoblastic leukemia. Nat Genet 45: 186–190. doi:10.1038/ng.2508 
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Table S3. Comparison of the number of novel SNV and INDELs between RNAseq and Exome-seq 
RNA-seq Exome-seq Overlap 
Sample SNVs 
INDE
Ls SNVs
a SNVsb INDELsc INDELsd SNVs INDELse INDELsf 
ALLSIL 3017 29 652 190 52 19 165 2 2 
CCRFCEM 3921 49 2923 997 544 148 861 6 11 
DND41 1725 24 2543 1328 230 103 1161 5 6 
HSB2 961 18 1906 719 281 112 680 7 8 
JURKAT 3222 46 4717 2532 517 246 2300 18 19 
KARPAS45 3678 19 5795 3345 110 89 2278 2 8 
KE37 407 22 647 303 50 41 230 1 5 
LOUCY 515 20 530 313 63 50 254 3 7 
MOLT4 1025 22 1358 807 123 108 424 1 5 
P12ICHIKAWA 469 17 746 352 54 43 256 0 4 
PEER 244 5 667 160 38 10 138 2 2 
PF382 1082 9 1891 844 63 22 732 1 3 
RPMI8402 376 9 794 270 49 19 224 1 1 
SUPT13 376 18 651 275 50 36 239 1 5 
SUPT1 3055 40 3717 829 371 127 767 6 9 
TALL1 257 8 688 182 38 8 158 2 2 
TLE76 197 9 714 157 64 37 130 0 8 
TLE77 232 8 678 160 77 44 123 0 4 
TLE79 327 13 662 223 108 92 153 0 9 
TLE80 377 23 712 268 80 54 227 1 8 
TLE81 542 22 640 403 70 67 296 0 11 
TLE85 394 18 681 251 113 92 184 1 10 
TLE86 512 20 691 389 80 68 276 1 12 
TLE87 504 22 658 368 77 70 284 1 9 
TLE89 464 21 706 369 110 88 270 3 13 
TLE90 431 15 738 307 494 471 210 1 8 
TLE91 366 15 693 268 102 78 212 2 10 
TLE92 344 18 683 262 90 68 217 1 8 
TLE93 324 21 638 247 59 46 174 0 10 
TUG1 219 10 589 190 78 17 144 0 7 
TUG2 196 9 718 159 131 26 145 1 5 
TUG3 277 11 593 214 69 23 164 0 9 
TUG4 312 9 637 212 139 39 180 1 8 
TUG5 287 8 604 217 109 34 188 0 7 
TUG6 293 10 646 214 124 34 179 4 8 
TUG7 296 14 629 243 122 35 216 4 11 
a: SAMTools - default parameters ; b: SAMTools - default parameters & RNA-seq coverage >20; c: 
DINDEL - minimum depth:15 & minimum variant allele frequency:0.15; d: DINDEL - minimum depth:15 & 
minimum variant allele frequency:0.15 & RNA-seq coverage > 3 ; e: Overlap of RNA-seq INDELs with 
Exome-seq INDELs (d); f: Overlap of RNA-seq INDELs with unfiltered Exome-seq INDELs 
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Table S4. Validated INDELs from the Exome-seq 
Sample Gene Position Reference/Variant Notes 
TLE87 KDM6A chrX: 44942756 C/CAT 
No variant reads, BWA+BLAT 
predicts a deletion in the 
adjacent base 
TLE92 PTEN chr10: 89717678 ACGGG/A No variant reads, BWA+BLAT mapping predicts the indel 
TLE76 WT1 chr11: 32417942 A/AG 
There are variant reads in 
RNAseq, however the INDEL falls 
below the detection limit in 
variant calling step 
TLE80 PHF6 chrX: 133551317 TC/T Detected in RNA-seq 
ALLSIL NOTCH1 chr9: 139390772 G/GCC Detected in RNA-seq 
SUPT1 USP9X chrX:41075721 A/AT 
There are variant reads in 
RNAseq, however the INDEL falls 
below the detection limit in 
variant calling step 
DND41 PHF6 chrX: 133511668 G/GA Detected in RNA-seq 
DND41 HMCN1 chr1:186017944 G/GA There are no reads in RNAseq for this gene 
MOLT4 UNC5D chr8:35541077 AA/A No variant reads 
CCRFCEM CT47B1 chrX:120008754 GG/G There are no reads in RNAseq for this gene 
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Table S5. Mutations detected in 213 genes.  
The table is not included in the thesis due to space constrains and can be obtained through the published 
article.  
 
 
Table S6. IPA on 213 candidate genes. Note that this enrichment was obtained using all "expressed 
genes" from the RNA-seq as background gene set to avoid any bias to expressed genes, because mutations 
can only be detected in expressed genes when using RNA-seq.  
The table is not included in the thesis due to space constrains and can be obtained through the published 
article.  
  
 
 
Table S7. ENDEAVOUR results on 213 genes 
The table is not included in the thesis due to space constrains and can be obtained through the published 
article.  
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Table S8. ATEs identified in known T-ALL drivers 
 
Gene Name Locus Sample1 Sample2 FPKMx FPKMy 
log2(FPKMy/ 
FPKMx) p-value q-value Test source 
SUZ12 chr17:30264036-30328064 R3 Thymus 0 439979 inf 5.00E-050 0.00994538 cds_exp.diff 
MYB chr6:135502452-135540311 TUG8 Thymus 0 137848 inf 0.00005 0.0413568 cds_exp.diff 
RPL10 chrX:153618314-153650065 TUG2 Thymus 0.245318 0 -inf 0.0001 0.025637 cds_exp.diff 
TAL1 chr1:47681922-47697892 TLE92 Thymus 577172 0.390812 -720638 0.0003 0.0454118 gene_exp.diff 
FLT3 chr13:28577410-28674729 TLE91 Thymus 282925 202236 -712824 0.00005 0.0109118 gene_exp.diff 
NKX2-1,SFTA3 chr14:36942411-36992221 R5 Thymus 0 0.715826 inf 0.00005 0.00573353 gene_exp.diff 
NKX2-1,SFTA3 chr14:36942411-36992221 TLE90 Thymus 138368 0.803834 -74274 0.00005 0.0155353 gene_exp.diff 
NKX2-1,SFTA3 chr14:36942411-36992221 TLE85 Thymus 100.34 0.847136 -688808 0.00005 0.0151664 gene_exp.diff 
NKX2-1,SFTA3 chr14:36942411-36992221 R6 Thymus 0 0.777489 inf 0.00005 0.00444771 gene_exp.diff 
NKX2-1,SFTA3 chr14:36942411-36992221 R4 Thymus 0 0.651055 inf 0.00005 0.00691144 gene_exp.diff 
NKX2-1,SFTA3 chr14:36942411-36992221 TUG6 Thymus 0 0.754103 inf 0.0001 0.0103673 gene_exp.diff 
NKX2-1,SFTA3 chr14:36942411-36992221 R1 Thymus 0 0.814263 inf 0.00005 0.0114146 gene_exp.diff 
NKX2-1,SFTA3 chr14:36942411-36992221 TUG5 Thymus 0 0.754974 inf 0.00005 0.00669218 gene_exp.diff 
NKX2-1,SFTA3 chr14:36942411-36992221 TUG8 Thymus 0 0.72586 inf 0.00005 0.0132969 gene_exp.diff 
NKX2-1,SFTA3 chr14:36942411-36992221 TUG7 Thymus 0 0.835087 inf 0.00015 0.0175297 gene_exp.diff 
BCL11B chr14:99635185-99737861 R3 Thymus 0.286987 205988 616543 0.00185 0.0375529 gene_exp.diff 
BCL11B chr14:99635185-99737861 TLE89 Thymus 0.815174 581135 615562 0.0002 0.0349239 gene_exp.diff 
NKX2-1,SFTA3 chr14:36942411-36992221 TUG4 Thymus 0 0.855147 inf 0.00025 0.0367317 gene_exp.diff 
NKX2-1,SFTA3 chr14:36942411-36992221 TUG1 Thymus 197343 0.785448 -797297 0.00005 0.0118491 gene_exp.diff 
IL7R chr5:35852796-35879705 R3 Thymus 0.971655 255157 47148 0.00175 0.0360998 gene_exp.diff 
LCK chr1:32716839-32751766 R4 Thymus 191491 0 -inf 0.00005 0.0496942 isoform_exp.diff 
LCK chr1:32716839-32751766 TLE93 Thymus 197045 0 -inf 0.00005 0.0341198 isoform_exp.diff 
LCK chr1:32716839-32751766 R5 Thymus 844094 0 -inf 0.00005 0.0439184 isoform_exp.diff 
SUZ12 chr17:30264036-30328064 R3 Thymus 0 439979 inf 0.00005 0.0185729 isoform_exp.diff 
SUZ12 chr17:30264036-30328064 R5 Thymus 276409 0 -inf 0.00005 0.0439184 isoform_exp.diff 
RUNX1 chr21:36160097-37357047 R5 Thymus 0 135643 inf 0.00005 0.0439184 isoform_exp.diff 
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RUNX1 chr21:36160097-37357047 TLE93 Thymus 0 127977 inf 0.00005 0.0341198 isoform_exp.diff 
SETD2 chr3:47057918-47205457 TUG5 Thymus 685273 0 -inf 0.00005 0.0395056 isoform_exp.diff 
SETD2 chr3:47057918-47205457 TUG7 Thymus 495803 0 -inf 0.00005 0.0399164 isoform_exp.diff 
RPL10 chrX:153618314-153650065 TLE76 Thymus 0.254194 0.0484117 -23925 0.00005 0.0304595 isoform_exp.diff 
RPL10 chrX:153618314-153650065 TLE90 Thymus 0.871304 0 -inf 0.00005 0.0456243 isoform_exp.diff 
RPL10 chrX:153618314-153650065 TLE76 Thymus 0.254194 0.0484117 -23925 0.00005 0.0225747 tss_group_exp.diff 
FLT3 chr13:28577410-28674729 TLE91 Thymus 282767 197891 -715876 0.00005 0.0249612 tss_group_exp.diff 
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Table S9. Fusions detected in 49 samples and the Thymus 
The table is not included in the thesis due to space constrains and can be obtained through the published 
article.  
 
 
Table S10. Annotation of fusions with Pegasus 
 Sample FrameShift Inframe Unannotated Total 
ALLSIL 7 2 8 17 
CCRFCEM 3 0 2 5 
DND41 1 0 2 3 
HPBALL 7 2 10 19 
HSB2 4 0 6 10 
JURKAT 5 0 5 10 
KARPAS45 3 1 6 10 
KE37 1 1 4 6 
LOUCY 2 0 8 10 
MOLT14 7 0 8 15 
MOLT4 0 0 0 0 
P12ICHIKAWA 2 0 4 6 
PEER 1 0 3 4 
PF382 7 0 4 11 
RPMI8402 12 4 26 42 
SUPT1 9 4 11 24 
SUPT13 1 0 3 4 
Ce
ll 
lin
es
 
TALL1 1 1 2 4 
R1 3 0 4 7 
R3 0 0 0 0 
R4 3 1 4 8 
R5 0 2 0 2 
R6 3 0 4 7 
R7 2 2 5 9 
R8 1 0 3 4 
R9 3 0 4 7 
R10 1 0 3 4 
RM2 1 0 3 4 
TLE76 4 0 5 9 
TLE77 2 1 1 4 
TLE79 2 1 1 4 
TLE80 3 0 8 11 
TLE81 1 0 4 5 
TLE85 0 0 3 3 
TLE86 1 0 4 5 
TLE87 3 0 2 5 
TLE89 6 0 6 12 
pa
tie
nt
 sa
m
pl
es
 
TLE90 3 1 9 13 
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TLE91 3 0 4 7 
TLE92 4 2 4 10 
TLE93 0 0 3 3 
TUG1 0 0 3 3 
TUG2 0 0 1 1 
TUG3 2 1 5 8 
TUG4 0 1 2 3 
TUG5 1 0 5 6 
TUG6 1 0 5 6 
TUG7 0 0 5 5 
 
TUG8 0 0 0 0 
 Thymus 1 1 2 4 
 
 
 
 
Table S11. Patient characteristics  
The table is not included in the thesis due to space constrains and can be obtained through the published 
article.  
 
Table S12. Novel Fusion Transcript validated by RT-PCR and Sanger sequencing 
The table is not included in the thesis due to space constrains and can be obtained through the published 
article.
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CHAPTER IV: DISCUSSION 
The cancer genomics field gained unprecedented traction with the introduction of 
next generation sequencing technologies. These sequencing technologies have enabled 
the inquiry of every base pair in a cancer genome, making it possible to obtain a 
comprehensive list of genomic changes that occurred during the transformation from 
a normal to a cancerous cell. Large-scale whole genome and exome sequencing based 
studies across a variety of cancer types broadened our knowledge on genes that are 
associated with cancer via genomic aberrations. With every sequenced cancer genome, 
we are getting one step closer to understand the mechanisms that govern these 
malignancies.  
 
In this thesis we have demonstrated the use of next generation sequencing 
technology for driver genomic aberration discovery in T-cell acute lymphoblastic 
leukemia (T-ALL) by using different sequencing techniques. In-depth analysis of 
targeted sequencing, exome sequencing and transcriptome sequencing studies have 
yielded several insights into underlying mechanisms of this cancer. In each project, 
bioinformatics pipelines were constructed, optimized and validated for obtaining the 
most accurate set of predictions. Each prediction set was evaluated for 
recapitulating the current body of knowledge on T-ALL; and the novel biological 
findings were assessed and further validated experimentally.  
 
In Paper I, we have analyzed the targeted sequencing that involved sequencing of 58 
cancer genes and 39 candidate genes in 15 T-ALL patient samples and 18 cell lines. 
We have performed a comparative analysis on the aligners and variant callers, 
including the companion software gsMapper, in the context of cancer mutation 
discovery. We have demonstrated that gsMapper, which is often the preferred 
method of analysis due to ease of use, is among the top performers in terms of 
sensitivity and specificity of SNV predictions. Moreover, we have showed that better 
accuracies can be achieved with the combination of other aligners and variant callers, 
and eventually we could identify SNVs with 95% sensitivity and 93% specificity with 
the pipeline consisting of two aligners BWA-SW and SSAHA2, and the variant caller 
Atlas-SNP2.  
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The sequencing experiment resulted in identification of known mutations in known 
cancer genes, as 58 out of 97 targeted genes were implicated cancer. On the other 
hand, we had the opportunity to discover novel driver events in the 38 genes that 
are included in the screen due to their potential role as tumor suppressors and 
oncogenes. We selected the candidate event based on their frequency across the 
patient and cell line cohort, and Sanger sequencing was performed to validate the 
mutations, and to assess their somatic status and recurrence across larger patient 
cohorts. Eventually, we observed rare somatic mutations in SPRY3, JAK3 and 
TET1. 
The initial motivation behind this study was to assess the feasibility of such a 
targeted approach for the discovery of novel drivers in large patient cohorts. 
However, the pace of advancement in the NGS field obviated the use of targeted 
approaches for discovery due to dropping costs of exome and whole genome 
sequencing. Instead, targeted sequencing is now widely used for the validation step 
of large scale sequencing projects. The mutations identified with exome or whole 
genome sequencing are re-sequenced for validation 46,99,103,218-221; or in another cohort 
of samples to assess the mutation frequencies 218,222,223. Thus we believe this study 
still holds its significance since the pipelines described here would be applicable to 
other re-sequencing studies using the Roche/454 platform or other platforms 
producing long sequence reads. Furthermore, when catalogues of mutations reach 
saturation, mainly targeted sequencing will be used in a clinical setting for 
diagnostics.  
 
In Paper II, we have explored the mutational landscape of the coding genome via 
exome sequencing of 67 T-ALL patient samples with 39 matched remissions and 17 
cell lines. The availability of the matched remission samples allowed us to find true 
somatic mutations and to analyze the recurrence on the additional diagnosis-only 
samples (28) and cell lines. After an iterative step of pipeline optimization and 
validation, we have identified high quality somatic mutations from the matched 
diagnosis-remission samples and high quality variations from the remaining 
diagnosis-only cases and cell lines. We observed marked differences between the 
pediatric and adult cases both in the number of mutations and in the mutation 
spectra. Adult T-ALLs harbored 2.7 fold more protein-altering somatic mutations 
compared to the pediatric cases, consistent with the observations in other tumors 5. 
Overall, the average number of somatic protein altering mutations per sample was 
12.2, similar to other liquid tumors 5. However there were vast differences between 
samples with six having less than 5 somatic protein altering mutations, and three 
samples having more than 25 somatic protein altering INDELs. 5/6 samples with 
low mutational load had normal karyotypes resembling other hematopoietic cancers 
with stable genomes and normal mutation rates 6. On the other hand, samples with 
excessive number of INDELs and mutations indicate an elevated mutations rate. 
Thus the results from our exome-seq data remain inconclusive whether genomic 
instability is an essential enabling characteristic for T-ALL tumorigenesis. Various 
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bioinformatics tools and databases were employed to annotate and filter the 
predicted variants based on the functional consequence on the protein, mutation 
significance and frequency across the sample cohort. The final candidate driver list 
contained 15 genes that included key players consistent with the T-ALL literature 
and novel genes highlighting novel processes that are disrupted in the T-ALL 
pathogenesis. One of the key findings was the implication of ribosome mutations in 
tumorigenesis via mutations in RPL10 and RPL5, which encode for parts of the 60S 
ribosomal complex. The observed mutations in RPL10, which occurred on a 
mutational hotspot on 14/15 of cases, were shown to cause defects in the ribosome 
in yeast and lymphoid cells using the functional validation studies conducted by the 
Laboratory of Molecular Biology of Leukemia and our collaborator Arlen Johnson. 
Another key finding were mutations observed in CNOT3, which is involved in 
transcriptional and post-transcriptional control of gene expression. Recurrent loss of 
function mutations in CNOT3 have led to further investigation of this gene in the 
context of cancer, and functional studies in the Drosophila eye cancer model 
proposed a tumor-suppressors role for this gene.  
Neither of these genes had been associated with T-ALL or any other human cancer 
previously. By following a large-scale sequencing approach in the coding genome, and 
implementing optimized analysis strategies we have identified mutations not only in 
known T-ALL drivers but also in genes and processes not involved with any other 
cancer. Moreover, the analysis pipelines we have assembled are being used in 
subsequent sequencing projects and an interface (http://lcbmart.aertslab.org/) we 
have constructed on the BioMart 224 software facilitated easy access to the analysis 
results and is being updated with the addition of new sequencing data.  
 
In Paper III, transcriptomic landscapes of T-ALLs were explored with the analysis 
of 31 T-ALL patient samples and 18 cell lines that were sequenced with RNA-seq. 
This study proved to be the most computationally challenging among the three 
projects, owing to the diverse range of aberrations that could be discovered. We 
have measured gene expression levels and identified mutations (SNV and INDEL), 
intragenic fusions and alternative transcript events after addressing key issues in the 
analysis. First, we have addressed the normalization and batch effect problem to 
obtain accurate levels of gene expression data, and validated our results against 
microarray data. We then successfully used the gene expression data for subtype 
analysis using known marker genes. Next, we addressed a mapping problem in the 
RNA-seq data for mutation calling, made use of matched exome data in a subset of 
the cases to assess different mapping strategies, and optimized our mapping and 
variant calling strategy accordingly. The final mapping strategy resulted in high 
quality SNV predictions, recovering 32% of the SNVs in matched exomes. Third, we 
identified fusion events in the RNA-seq data, implemented additional filters and 
annotations to better characterize these events. And lastly, we detected alternative 
transcript events. We have used the T-ALL literature to assess the validity of the 
predictions and obtained driver genes and events. Reassuringly, we found known 
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driver events in these samples such as STIL-TAL1 fusion, which results in TAL1 
overexpression and associated with the TAL/LMO subgroup, or NOTCH1 
mutations. For the identification of novel drivers, we have performed a gene 
prioritization technique on the mutated genes to select genes that are ‘functionally 
similar’ to known T-ALL drivers. And in the case of fusion events and ATEs, we 
have evaluated the events observed in known driver genes and mined for novel driver 
events in those. Eventually, we identified candidate drivers genes affected by 
mutations including CIC, H3F3A, PTK2B, STAT5B, ANKRD1, HADHA and 
DOCK2; and we identified and validated two novel oncogenic fusions SSBP2-FER 
and TPM3-JAK2. ATE discovery resulted in the identification of exon skipping 
events in SUZ12 and LCK, with the former being validated by PCR.  
Our transcriptome sequencing study marks one of the few published studies 
embarking on complete characterization of variations identifiable from RNA-seq 
data. We have demonstrated the power of this approach for novel driver detection, 
however there are still limitations and challenges to address. A first issue concerns 
the mapping of RNA-seq data for mutation detection. Although we could obtain 
high quality SNV predictions with our combined mapping strategy, INDEL 
detection was not as successful. A more refined mapping strategy might be necessary 
for INDEL detection in RNA-seq data. Second is the lack of systematic ways of 
assessing gene fusion predictions. Although fusions are identified accurately with 
existing methods, mathematical models predicting the functional consequences of 
fusion predictions is lacking and predictions require individual assessment to 
evaluate their potential effect. A similar problem exists for ATE predictions also, as 
current methods are limited to prediction algorithms. However, this issue is further 
complicated by the fact that ATEs have not been causally implicated in cancer 
although a number of events are associated with specific cancer types 116.  
 
In this thesis, we identified novel driver genes and events in T-ALL with the use of 
three different NGS approaches.  
One general drawback of our sequencing studies, or any sequencing in that matter, is 
that the driver prediction methods are biased towards specificity because very 
stringent thresholds are applied to eliminate false positive calls. Lowering these 
thresholds would indeed increase the sensitivity but it will be in the expense of 
specificity, thus there is a trade off between these two important aspects of analysis. 
A sensible way to overcome this conundrum would be to sequence more samples. In 
these projects, we partially addressed this problem by sequencing different patient 
cohorts with exome and transcriptome sequencing. And by incorporating the 
somatic mutation predictions from the exome sequencing project, we could identify 
additional mutations in genes that were not selected previously due to high 
stringency filtering. For instance, genes ANKRD11, CTCF, DOCK2, H3F3A and 
HADHA had somatic mutations in one patient sample in the exome sequencing 
study, and had not been identified as driver genes, but with RNA-seq we found 
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additional cases with mutations in those genes, permitting us to put forward these 
genes as novel candidates.  
 
We have identified novel drivers fitting into classical cancer genes such as ODZ2, 
PTK2B and STAT5B. But we also identified genes with broad functions such as 
RPL10, RPL5 and CNOT3. Putting the latter mutations in the context of cancer 
hallmark processes is hard, which was also pointed out by Imielinski et al in their 
analysis of lung cancer genomes 106. The authors suggested the addition of a new 
hallmark encompassing epigenetic and RNA regulators. However, changing the 
perspective from processes to functions can accommodate these mutations. As 
pointed out in Chapter I, putting these mutations in the context of gene regulation, 
which actually mediates most of the cancer processes, is revealing since these 
mutations fit well into the components of this machinery. A similar view has been 
proposed by Aerts et al for the mutational profile of Acute Myeloid Leukemias 
(AML) 96,225. Figure 6 depicts the mutations found in our three sequencing projected 
onto the components of transcriptional machinery as it was done for AML. This 
points to exciting opportunities for understanding cancer mutations by studying 
gene regulation.  
 
Figure 6. Frequent mutations in T-ALL can be linked to the regulation of gene expression. 
Adapted from 225 by somersault18:24 (www.somersault1824.com) Genes in blue represent the 
known drivers while genes in purple represent the ones that are identified in our three sequencing 
projects. 
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OUTLOOK  
Cancer driver discovery using NGS technologies will likely remain a central theme 
until we can identify the full range of genomic aberrations across different cancers. 
Here I will mention the emerging trends towards achieving this ambitious goal.  
The current focus of cancer genomics is the identification of driver oncogenic 
variants in the coding genome while the variation in the non-coding genome is 
largely ignored. Almost all the genes that are implicated in cancer are affected by 
protein-coding mutations, while there is only one gene affected by non-coding 
mutations in cancer: TERT gene with recurrent mutations in the promoter region 
117,118. The reason for this extremely biased focus is purely practical: the effect of a 
coding mutation can be estimated from the encoded protein, while for a non-coding 
variant the effect is difficult to estimate if not impossible. However, this trend is 
deemed to change, as large-scale projects, which are also NGS-based, are effectively 
improving our understanding of the non-coding genome. The ENCODE project, 
which aims at cataloging functional elements in the non-coding genome, has already 
associated 80% of the genome to a biochemical functional, and identified more than 
70,000 and 400,000 promoter and enhancer regions in the human genome, 
respectively 226. Incorporating this knowledge would finally shift the discovery scale 
to the whole genome as we will not only identify non-coding mutations but also 
interpret them.  
Another shift of paradigm is on the level of analysis conducted. Current research on 
cancer genomics is very detailed within the tumor type but very broad across tumor 
types. In other words, in-depth analysis is performed for each tumor type 
specifically, but integration of genomic aberrations across different cancers is lacking. 
A recent initiative is launched for addressing this issue in the Pan-cancer project 227. 
This project was initiated by the TCGA consortium and started with the 
integrative analysis across 12 cancer types. The analysis results from this initiative 
and the framework laid out by this project is expected to further improve the 
knowledge base in cancer genomics. 
It is undoubtedly clear that NGS will continue to be a driving force for genomic 
inquiry in the biomedical research and this ultimately will lead to better diagnostic, 
prognostic and therapeutic strategies in the clinic. 
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